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Uveal melanoma (UM) is the most common primary intraocular disease of adults 
and has a high mortality rate compared to other melanomas. Non-random 
chromosomal aberrations have been associated with UM, such as monosomy 3, 
gain of chromosome 8q, loss of chromosome 1p and gain of chromosome 6p and 
loss of 6q (isochromosome 6p). Monosomy 3 and gain of chromosome 8q have 
the strongest association with poor prognosis for UM. That said, although 
structural aberrations of chromosome 6 have been detected in some studies of 
UM, the alterations in this chromosome have been underestimated, possibly 
because of the focus on other chromosomes or the use of classical technologies 
such as karyotyping and comparative genomic hybridisation (CGH).   
This thesis, therefore, will look to identify candidate genes on altered 
chromosome 6 that may contribute to the development, prognosis and 
metastasis of UM.  
This thesis aims to associate different alterations of chromosome 6 with the 
known genetic mutations in UM. In order to achieve this, the aberrations within 
chromosome 6 will be analysed in detail using a specifically designed high-
resolution array-CGH for UM in order to determine candidate genes that have an 
association with UM. Ultimately, these candidate genes will be explored using 










Table of contents 
CHAPTER 1: INTRODUCTION ........................................................................................................... 13 
1.1 INTRODUCTION .......................................................................................................... 14 
1.1.1 Historical aspect of cancer as a genetic disease.......................................................................14 
1.1.2 Aetiology of cancer development .............................................................................................16 
1.1.3 Genetic changes associated with cancer ..................................................................................17 
1.2 OVERVIEW OF MELANOMA .......................................................................................... 19 
1.3 UVEAL MELANOMA (UM) ........................................................................................... 19 
1.3.1 Risk factors of UM.....................................................................................................................20 
1.3.2 Diagnosis of UM........................................................................................................................21 
1.3.3 Metastasis of UM .....................................................................................................................22 
1.3.4 Treatment of UM ......................................................................................................................22 
1.3.5 Prognosis of UM .......................................................................................................................24 
1.3.6 Chromosomal alteration in UM ................................................................................................25 
1.3.7 Mutations associated with Melanoma .....................................................................................27 
1.4 AMBIGUITY OF CHROMOSOME 6 CHANGES IN UM ............................................................ 32 
1.5 SUMMARY ................................................................................................................ 35 
1.6 HYPOTHESIS AND AIMS OF THE STUDY ............................................................................. 37 
CHAPTER 2: MATERIALS AND METHODS.......................................................................................... 38 
2.1 MATERIALS ............................................................................................................... 39 
2.1.1 General reagents and consumables .........................................................................................39 
2.1.2 Sample collection ......................................................................................................................40 
2.1.3 Cell lines ....................................................................................................................................40 
2.1.4 DNA extraction from patients’ blood and frozen tumour tissue samples ................................40 
2.1.5 Primer design for GNAQ, GNA11, SF3B1, EIF1AX and TERTp ...................................................41 
2.1.6 Polymerase chain reaction (PCR) ..............................................................................................43 
2.1.7 Array-comparative genomic hybridisation (array-CGH) ...........................................................44 
2.1.8 Immunochemistry .....................................................................................................................45 
2.1.9 Tissue culture ............................................................................................................................47 
2.1.10 Western blot (WB) ..................................................................................................................47 
2.1.11 CRISPR knockout .....................................................................................................................49 
2.1.12 MTT proliferation assay ..........................................................................................................50 
2.2 METHODS ................................................................................................................. 51 




2.2.2 Sequencing analysis for GNAQ, GNA11, SF3B1, EIF1AX and TERTp .........................................53 
2.2.3 Genomic-wide analysis using array-CGH ..................................................................................60 
2.2.4 Tissue culture ............................................................................................................................67 
2.2.5 Immunochemistry .....................................................................................................................67 
2.2.6 Western blot .............................................................................................................................71 
2.2.7 AMD1 knockout using CRISPR ..................................................................................................77 
2.2.8 MTT proliferation assay ............................................................................................................84 
CHAPTER 3: CORRELATION OF CHROMOSOME 6 ABERRATIONS WITH OTHER GENETIC ALTERATIONS85 
3.1 INTRODUCTION .......................................................................................................... 86 
3.2 RESULTS ................................................................................................................... 88 
3.2.1 Sample collection and preparation ...........................................................................................88 
3.2.2 PCR and gel electrophoresis optimisation ................................................................................88 
3.2.3 Mutational screening for GNAQ and GNA11 ............................................................................88 
3.2.4 Mutational screening for SF3B1, EIF1AX and TERTp ................................................................91 
3.2.4 Array-CGH ............................................................................................................................96 
3.2.5 The correlation between genetic mutations and chromosomal aberrations .........................101 
3.3 DISCUSSION ............................................................................................................ 104 
3.3.1 Correlation of genetic changes with clinical features ............................................................104 
3.3.2 What other correlations do mutations of SF3B1 and EIF1AX have? ......................................105 
3.3.3 What is the sequence of genetic progression for UM?...........................................................106 
CHAPTER 4: ANALYSIS OF CHROMOSOME 6 USING ARRAY-CGH TO DETERMINE CANDIDATE GENES IN 
UM .............................................................................................................................................. 108 
4.1 INTRODUCTION ........................................................................................................ 109 
4.2 RESULTS ................................................................................................................. 111 
4.2.1 The classification of chromosome 6 .......................................................................................111 
4.2.2 Confirmation of target genes on chromosome 6....................................................................112 
4.2.3 Clinicopathological details for UM data set ...........................................................................115 
4.2.4 IHC analysis for FOXQ1, FARS2 and AMD1 .............................................................................119 
4.3 DISCUSSION ............................................................................................................ 132 
4.3.1 Chromosome 6 changes and prognosis ..................................................................................132 
4.3.2 Confirmation of target genes .................................................................................................133 
4.3.3 Are target genes potentially relevant to UM? ........................................................................133 
CHAPTER 5: THE KNOCKOUT EFFECT OF AMD1 ON UM CELL LINES ................................................. 137 




5.2 RESULTS ................................................................................................................. 140 
5.2.1 UM cell lines and chromosomal aberrations ..........................................................................140 
5.2.2 Immunocytochemistry of UM cell lines ..................................................................................145 
5.2.3 AMD1 knockout using CRISPR/Cas9 .......................................................................................147 
5.3 DISCUSSION ............................................................................................................ 155 
5.3.1 What is the correlation between AMD1 and mTOR pathway? ..............................................156 
5.3.2 The knockout efficiency differences in CRISPR........................................................................156 
5.3.3 The effect of polyamines on beta-tubulin ...............................................................................157 
CHAPTER 6: GENERAL DISCUSSION................................................................................................ 159 
6.1 OVERVIEW OF THIS STUDY .......................................................................................... 161 
6.1.1 Can the importance of AMD1 to UM be independently validated? .......................................162 
6.2 STUDY LIMITATIONS .................................................................................................. 165 

















LIST OF PUBLICATIONS  
• Doherty, R. E., Alfawaz, M., Francis, J., Lijka-Jones, B. and Sisley, K. 
(2018) 'Genetics of Uveal Melanoma', in Scott, J.F. & Gerstenblith, M.R. 
(eds.) Noncutaneous Melanoma. Brisbane (AU). – Book chapter. 
 
• “Introduction to CRISPR/Cas9 Genome editing”– certificate of attending 
















LIST OF FIGURES 
Figure 1.1. The anatomy of the eye and the origins of UM. .............................................................. 20 
Figure 1.2. The chromosomal changes that occur in UM cells. .......................................................... 34 
Figure 1.3. The correlation of prognostic biomarkers in UM with different clinical, histological, 
chromosomal and genetic changes. ........................................................................................ 36 
Figure 2.1: Flowchart of the array-CGH protocol. ............................................................................. 61 
Figure 2.2: The standard curve for the Biorad protein assay. ............................................................ 73 
Figure 2.3: The transfer methods for protein from SDS-PAGE gel to PVDF membrane. ...................... 75 
Figure 2.4: The area where gRNA binds and Cas9 will cut. ................................................................ 78 
Figure 2.5: The FASTA file for AMD1 exon 1. .................................................................................... 78 
Figure 3.1: The Sanger sequencing chromatogram and gel electrophoresis for GNAQ exon 5. ............ 89 
Figure 3.2: The Sanger sequencing chromatogram and gel electrophoresis of GNA11 exon 5. ............ 90 
Figure 3.3: The Sanger sequencing chromatogram and gel electrophoresis of SF3B1 exon 14. ........... 91 
Figure 3.4: The Sanger sequencing chromatogram and gel electrophoresis for EIF1AX exon 1............ 93 
Figure 3.5: The Sanger sequencing chromatogram and gel electrophoresis for EIF1AX exon 2............ 94 
Figure 3.6: Total percentage of gain and loss in each chromosome among all the primary UM tissue 
samples. ............................................................................................................................... 97 
Figure 3.7: Comparison between chromosomes 3, 8 and 6 deletion and amplification. ..................... 99 
Figure 3.8: Array-CGH for the highest and lowest number of chromosomal aberrations. ................. 100 
Figure 3.9: Ideograms for the samples with a mutation of the for SF3B1 gene. ............................... 102 
Figure 3.10: Ideograms for the samples with a mutated EIF1AX gene. ............................................ 103 
Figure 4.1: Groups classification of different gain and loss of chromosome 6 in UM. ....................... 112 
Figure 4.2: A high-resolution view of the gain of chromosome 6p and 6q with gene view. ............... 114 
Figure 4.3: Kaplan-Meier analysis of patients’ mortality based on sex, tumour location and cell type.
 ........................................................................................................................................... 116 
Figure 4.4: Kaplan-Meier analysis of the patients’ mortality based on groups of altered chromosome 
6. ........................................................................................................................................ 118 
Figure 4.5: The expression of FOXQ1 protein in UM tissue sections using IHC. ................................ 121 
Figure 4.6: Allred scoring and Kaplan-Meier analysis of FOXQ1 protein expression. ........................ 123 
Figure 4.7: The expression of FARS2 protein in UM tissue sections using IHC. ................................. 125 
Figure 4.8: Allred scoring and Kaplan-Meier analysis of FARS2 protein expression. ......................... 127 
Figure 4.9: The expression of AMD1 protein in UM tissue sections using IHC. ................................. 129 
Figure 4.10: Allred scoring and Kaplan-Meier analysis of AMD1 protein expression. ....................... 131 
Figure 5.1: Phase contrast micrographs and array-CGH ideogram of MEL-577. ................................ 141 
Figure 5.2: Phase contrast micrographs and array-CGH ideogram of MEL-585. ................................ 142 
Figure 5.3: Phase contrast micrographs and array-CGH ideogram of MEL-627. ................................ 143 




Figure 5.5: Immunocytochemistry for AMD1 antibody against UM cell lines. .................................. 146 
Figure 5.6: The cleavage efficiency for AMD1 knockout in UM cell lines. ......................................... 148 
Figure 5.7: Chromatogram of AMD1 for UM cell lines and total efficiency calculation. .................... 150 
Figure 5.8: The effect of AMD1 protein expression knockout and WT UM cell lines. ........................ 152 
Figure 5.9: Analysis of UM cell viability using MTT assay after AMD1 knockout............................... 154 
Figure 6.1: Summary of this study and the findings for each chapter. ............................................. 160 
Figure 6.2: Analysis using UCSC Xena for AMD1. ............................................................................ 163 





















LIST OF TABLES  
Table 2.1: Primer design for GNAQ, GNA11, SF3B1, EIF1AX, and TERTp. ............................................ 42 
Table 2.2: Summary of primary antibodies and their conditions. ...................................................... 46 
Table 2.3: PCR master mix for GNAQ, GNA11, SF3B1, EIF1AX, and TERTp. ......................................... 54 
Table 2.4: 3-step PCR conditions for GNAQ exon 4 ........................................................................... 55 
Table 2.5: 3-step PCR conditions for GNAQ exon 5 ........................................................................... 55 
Table 2.6: 3-Step PCR conditions for SF3B1 exon 14 and EIF1AX exon 1. ........................................... 55 
Table 2.7: Touchdown PCR conditions for EIF1AX exon 2 ................................................................. 56 
Table 2.8: Touchdown PCR conditions for TERTp. ............................................................................ 56 
Table 2.9: Modified Touchdown PCR conditions for GNA11 exon 4. .................................................. 57 
Table 2.10: Modified Touchdown PCR for GNA11 exon 5. ................................................................ 58 
Table 2.11: Digestion master mix components. ............................................................................... 62 
Table 2.12: Components of labelling master mix.............................................................................. 63 
Table 2.13: Components of the hybridisation master mix................................................................. 64 
Table 2.14: Quality control metric to assess the array performance.................................................. 66 
Table 2.15: gRNA complex with Cas9 in Opti-MEM I media. ............................................................. 79 
Table 2.16: Thermocycler condition for cell lysis. ............................................................................. 80 
Table 2.17: components for CRISPR PCR amplification. .................................................................... 81 
Table 2.18: Thermocycler conditions for CRISPR PCR amplification. .................................................. 82 
Table 2.19: Thermocycler condition for mismatch digestion. ............................................................ 83 
Table 3.1: The mutational analysis for the 30 UM patient samples and the distribution of mutations.95 
Table 3.2: Default Agilent Genomic Workbench software preferences. ............................................. 96 












LIST OF ABBREVIATIONS  
°C Degrees Celsius 
ABC Avidin-Biotin-peroxidase complex  
ABL Abelson murine leukaemia viral oncogene 
ADM-2 Aberration detection method-2 
AE Elution buffer 
AL Lysis buffer 
AMD1 Adenosylmethionine decarboxylase 1  
Array-CGH Array comparative genomic hybridisation 
ATL Tissue lysis buffer 
AW1 Washing buffer 1 
AW2 Washing buffer 2 
BAC Bacterial artificial chromosome 
BAP1 BRCA1-associated protein 1  
BCR Breakpoint cluster region  
bp base pair 
BRAF B-Raf proto oncogene 
BSA Bovine serum albumin 
C Cysteine 
Cas9 CRIPSR associated endonuclease protein 9 
CML Chronic myeloid leukaemia  
CO2 Carbon dioxide  
COMS Collaborative Ocular Melanoma Study  
CRISPR Clustered regularly interspaced short palindromic repeats  
CRUK Cancer Research United Kingdom 
Cy3 Cyanine-3 
Cy5 Cyanine-5 
CYSLTR2 cysteinyl-leukotriene receptor 2  
DAB 3,3’-dianimobenzidine  
ddNTPs Dideoxyribonucleotide triphosphates  
dH2O Deionized water  
DLRS Derivative log ratio spread 
DNA Deoxyribonucleic acid  
dNTPs Deoxyribonucleotide triphosphates  
DPBS Dulbecco’s phosphate buffer saline  
DPX Mixture of Distyrene, plasticiser and xylene 
E Glutamate 
E2F1 E2F transcription factor 1 
EBV Epstein-Barr virus  
EDTA Ethylenediaminetetraacetic acid 






ESC Embryonic stem cell  
FACS Fluorescence activated cell sorting  
FARS2 Phenylalanyl-tRNA synthetase 2 
FASST2 Fast adaptive states segmentation technique 2 
FE Feature extraction 
FFPE Formalin Fixed Paraffin-Embedded  
FISH Fluorescence in situ hybridisation  
FNAB Fine-needle aspiration biopsy 
FOXQ1 Forkhead box Q1 
g Gram  
GCD Genomic cleavage detection  
gDNA Genomic DNA 
GISTIC Genomic identification of significant targets in cancer  
GNA11 Guanine nucleotide-binding protein alpha 11 
GNAQ Guanine nucleotide-binding protein Q polypeptide 
H Histidine 
H2O2 Hydrogen peroxide 
HDR Homology directed repair  
HMM Hidden Markov model 
HPV Human papilloma virus  
HRP Horseradish peroxidase 
ICC Immunocytochemistry 
IHC Immunohistochemistry 
K Lysine  
KDa Kilo Dalton 
KIT Kit proto-oncogene receptor tyrosine kinase  
KO Knockout 
L Leucine 
MAPK Mitogen-activated protein kinase 
mg Milligram 
Ml Millilitre 
MLPA Multiple ligation-dependent probe amplification 
mm Millimetre 
MSA Microsatellite Analysis 
mTORC1 Mechanistic target of rapamycin complex-1  
MTT (4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
NA Not applicable  
ng/μl Nanogram per microliter 
NGS Next-generation sequencing 





NRAS Neuroblastoma Ras viral oncogene 
O.D.  Optical density 
ODC Ornithine decarboxylase  
P Proline 
PAM protospacer adjacent motif  
PBS Phosphate buffer saline  
PBST Phosphate buffer saline with tween 20 
PCR Polymerase chain reaction  
PFS progression-free survival  
PLCB4 phospholipase C Beta 4  
Pre-mRNA Precursor messenger RNA 
PVDF Polyvinylidene fluoride 
Q Glutamine  
QC Quality control  
R  Arginine  
RNA Ribonucleic acid  
RNP Ribonucleoprotein 
RPM Revolution per minute 
SCNA  Somatic copy number aberrations 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis  
SEM Standard error of mean 
SF3B1 Splicing factor 3B subunit 1  
SKY Spectral karyotyping  
SNR Signal to noise ratio 
STAC Significance testing for aberrant copy number 
TAE Tris-Acetate-EDTA 
TCGA The Cancer Genome Atlas  
TE Tris-EDTA 
TERTp Telomerase reverse transcriptase promoter 
TGF Transforming growth factor  
TIDE Tracking of indel by decomposition  
UM Uveal melanoma  
UV Ultraviolet  
WB Western blot 
WES Whole exome sequencing  
WHO World Health Organization  
WT Wild type 





























1.1 Introduction  
Cancer is a genetic disease arising as a result of a failure to control cell growth. 
Most cancers are considered sporadic or somatic events, although there are 
some germline mutations that influence hereditary malignancy. According to the 
World Health Organization (WHO), malignant neoplasms are now considered to 
be the leading cause of death in Europe and North America (Bray et al., 2018). 
According to Cancer Research UK (CRUK), in 2016, there were more than 
300,000 new cancer cases registered in the U.K. (Cancer Research UK, 2016). 
The number of new cases is expected to rise by 2% annually in the next two 
decades to be more than half million cases by 2035 (Smittenaar et al., 2016). 
Although some types of cancer can be treated effectively, others still have no 
effective treatment. This combination of the increasing number of cases of cancer 
and the lack of effective treatment highlights the need for new and improved ways 
of understanding and promoting suitable treatments for the disease. 
1.1.1 Historical aspect of cancer as a genetic disease 
Many theories have tried to explain the role of genetics in cancer and how its 
development is initiated. According to Balmain (2001), the first theory was 
established by Boveri (1902), who hypothesised that chromosomal changes 
occur in cancer cells that do not necessarily transpire in normal cells. According 
to Wunderlich (2007), meanwhile, Tyzzer (1916) was the first to use the term 
“somatic mutation” to describe the events of cancer progression. It was not until 
1960, however, that Nowell and Hungerford became the first to discover a 
particular chromosomal translocation, now referred to as the Philadelphia 
chromosome, that could be linked to the incidence of chronic myeloid leukaemia 
(CML) (Nowell and Hungerford, 1960). In the Philadelphia chromosome, 
translocation occurred between chromosomes 9 and 22, resulting in tyrosine 
kinase gene fusion between the breakpoint cluster region (BCR) and Abelson 
murine leukaemia viral oncogene (ABL) (Rowley, 1973a, Rowley, 1973b, Thijsen 
et al., 1999). The final product of this BCR-ABL gene fusion is a new protein that 




proliferation in the bone marrow and blood stream, which is an essential step in 
the transformation towards malignancy in CML (Daley and Baltimore, 1988).  
This led to a hypothesis called the ‘two hits hypothesis’, that was proposed by 
Knudson (1971), and which stated that tumour suppressor genes should have 
two mutations, consequently affecting both alleles to cause a carcinogenesis, as 
reviewed by Knudson (2001). This hypothesis was evaluated on hereditary and 
non-hereditary retinoblastoma using age and family history, with the findings 
indicating that the retinoblastoma 1 (Rb1) gene was mutated on both alleles and 
was involved in both cell proliferation and the cell cycle (Murphree and Benedict, 
1984, Knudson, 1988, Knudson, 1993). However, this theory did not explain other 
cancer characteristics, such as haploinsufficiency or epigenetic hypermethylation 
of the gene, rather than genetic mutation (Merlo et al., 1995, Tsihlias et al., 1999). 
For instance, PTEN is a tumour suppressor gene and it was found that 
haploinsufficiency of this gene is correlated with prostate cancer (Muller et al., 
2000). In addition, the promoter hypermethylation of PTEN found in various types 
of cancers such as gastric, cervical and lung (Kang et al., 2002, Soria et al., 2002, 
Rizvi et al., 2011).  
In 1947, Berenblum and Shubik proposed another theory, arguing that, rather 
than cancer resulting from a single genetic mutation, a multistage process is 
involved, where DNA is damaged first, and this unrepaired DNA segment then 
progresses into further cancer cell growth, which may finally convert into a fully-
fledged malignant disease. Subsequently, many studies have provided evidence 
in support of this contention, as reviewed in Jeggo et al. (2016).  
At the beginning of the twenty-first century, a remarkable paper was published 
by Hanahan and Weinberg (2000) explaining six important capabilities acquired 
in cell physiology that together dictate cancer development: self-sufficiency in 
growth signals, insensitivity to antigrowth signals, evasion from apoptosis, 
limitless replicative potential, sustained angiogenesis and tissue evasion and 
metastasis. A decade later, Hanahan and Weinberg (2011) expanded these 
capabilities to include four new ones: genome instability and mutation, tumour-




cellular energetics. These capabilities have helped researchers gain a greater 
understanding of cancer development and its essential mechanisms. 
1.1.2 Aetiology of cancer development  
Carcinogenesis may be promoted because of different aetiologies such as 
environmental agents, bacterial and viral infection as well as the ageing process. 
As reviewed by Luch (2005), Brookes and Lawley (1964) were the first to 
document the carcinogenic effect of DNA adducts and chemical agents, such as 
mustard gas. These researchers showed how alkylating agents can directly react 
with DNA to form a stable chemical adduct that might disrupt the normal function 
of the DNA molecule. The chemical adducts that bind with DNA induced the DNA 
repair machinery, which may result in DNA mutations that is correlated with an 
increased chance of carcinogenesis. Another example is smoking tobacco, which 
plays a definitive role in oral, lung and other types of cancers due to the fact that 
it increases the chemical adducts in the DNA molecule which in turn can damage 
the DNA to such a point that it can no longer be repaired, and this may initiate 
cancer (Hecht, 2002, Ma and Li, 2017, O'Keeffe et al., 2018). In addition, many 
reports have emphasised the role of obesity in oesophageal, colorectal and 
breast cancer, among others (Calle et al., 2003, Renehan et al., 2008, Basen-
Engquist and Chang, 2011). Thus, there are myriad environmental factors that 
can cause cancer, some of which are not yet fully known; and an individual’s risk 
for cancer will therefore reflect exposure to these numerous environmental 
factors.  
Microorganisms, such as bacteria and viruses, also play an important role in 
increasing the likelihood of an individual developing cancer. One example of a 
strain of bacteria that can cause cancer is Helicobacter pylori, since infection with 
this bacterium increases one’s risk of developing gastric cancer (Parsonnet et al., 
1991, Eslick et al., 1999, Ishaq and Nunn, 2015). Viruses can also increase the 
risk of cancer among infected individuals. For instance, the human papilloma 
virus (HPV) increases the risk of cervical, breast and head and neck cancers 
(Boshart et al., 1984, Durst et al., 1983, Heng et al., 2009), while Hepatitis B and 




1970, Choo et al., 1989, Bartosch, 2010). Epstein-Barr virus (EBV) is strongly 
correlated with Burkitt’s lymphoma (Epstein et al., 1964, Brady et al., 2007) and 
has also shown a moderate correlation in the development of Hodgkin’s 
lymphoma (Glaser et al., 1997, Sarwari et al., 2016). These viral and bacterial 
infections can disrupt the integrity of human DNA at the infection site, potentially 
increasing the chances of cancer initiating.  
Age or the ageing process may also be associated with the likelihood of an 
individual developing cancer, since in ageing persons cells exhibit a decreased 
ability to repair the DNA abnormalities that occur during replication, particularly 
in response to other environmental factors, as described in the review by 
DePinho (2000). The transformation of a normal cell into a cancerous cell is 
therefore a multifactorial process that includes an accumulation of DNA damage 
and mutations, which over time disrupt the DNA repair and cell growth regulation 
system (Vijg and Suh, 2013). It is still not well known, however, whether the 
relationship between cancer risk and age is due to an accumulation of genetic 
and epigenetic mutations over time or to the high susceptibility to oncogenic 
mutations of elderly people (Rodriguez-Rodero et al., 2011, Lepez-Otin et al., 
2013).  
1.1.3 Genetic changes associated with cancer 
There are different types of cytogenetic and genetic mutations that can lead to 
the onset of cancer. Most cancers have changes at the chromosomal level, such 
as the loss or gain of chromosomes (aneuploidy), or the loss or gain of part of a 
chromosome (Mitelman et al., 1994). In addition, chromosome translocation 
plays a role in initiating cancer, as has been mentioned before with respect to 
CML (Nowell and Hungerford, 1960). These aberrations can be detected using 
various cytogenetic techniques for obtaining images of clonal and non-clonal 
aberrations at the single cell level, such as karyotyping, fluorescence in situ 
hybridisation (FISH) and spectral karyotyping (SKY). Additionally, molecular 
cytogenetic techniques, such as array comparative genomic hybridisation (array-
CGH), can be used to detect genomic amplification, deletion and information 
about copy number aberrations in cancer cells (Albertson and Pinkel, 2003, 




techniques cannot detect balanced chromosomal alterations, translocations or 
inversions. Furthermore, these techniques do not have sufficient resolution to 
detect nucleotide mutations.  
Two key inventions opened a new era for molecular genetics and the effective 
and accurate identification of point mutations in DNA. These were the 
development of Sanger DNA sequencing technology, which uses chain inhibitor 
termination to detect DNA bases and determine the sequence of the targeted 
DNA (Sanger et al., 1977), and the discovery of the polymerase chain reaction 
(PCR) process by (Mullis et al., 1986), which allowed a particular piece of DNA 
to generate millions of copies using an enzyme called Taq DNA polymerase. 
Furthermore, in the past decade, the field of cancer research has experienced 
immense developments following the completion of the human genome project 
by the International Human Genome Sequencing (2004). This completion has led 
to an improvement in the understanding of the mutational screening of regulatory 
genes that regulate the cell cycle and other cellular pathways, as reviewed by 
Stratton et al. (2009). This has revealed that some genes that can cause cancer 
are tumour suppressor genes in their original form, involved in DNA repair 
machinery and serving to control cell division when functioning normally; in their 
mutated state, however, they can lead to loss-of-function and the development 
of cancer. In addition to tumour suppressor genes, oncogenes can also cause 
normal cells to grow uncontrollably because of gain-of-function mutations in the 
normal proto-oncogene. 
More recently, the introduction of next-generation sequencing (NGS) technology 
has revolutionised genetic research, allowing the investigation of different types 
of mutational, translocational and epigenetic phenomena. In addition, a 
previously unrecognised phenomenon of genetic instability in cancer, called 
chromothripsis, was discovered by Stephens et al. (2011) using microarray 
analysis and confirmed by NGS. This is a phenomenon where hundreds of 
genomic rearrangements occur in a single cellular crisis. While, surprisingly, the 





1.2 Overview of Melanoma 
Melanoma is a type of cancer that affects the melanocytes, which produce a 
pigment called melanin that serves to protect the human body from ultraviolet 
(UV)-light radiation damage. Melanocytes are found mostly in the skin and uveal 
tract. Although some melanomas may develop when a group of melanocytes 
(naevi) undergo malignant transformation, the majority of melanomas are 
developed without the association with naevi. Annually, there are around 300,000 
new cases of cutaneous melanoma worldwide, this being the most common form 
of melanoma that is responsible for about 60,000 deaths annually, based on an 
estimate from 2018 (Bray et al., 2018). It is thus considered the fifth most 
frequently-diagnosed cancer in developed countries (Siegel et al., 2019).  
1.3 Uveal Melanoma (UM) 
Uveal melanoma (UM) is considered the most common primary intraocular 
malignancy among adults, accounting for 80% of all non-cutaneous melanoma 
(Singh et al., 2011). The incidence of UM is between 5.3 and 10.9 cases for every 
million individuals in the general population. While this means that UM is an 
uncommon disease when compared to other malignancies (Singh and Topham, 
2003), it has a higher mortality rate than cutaneous melanoma (Jemal et al., 
2010).  
UM is a tumour that arises from neural crest-derived melanocytes, which 
populate the pigmented layer of the uveal tract. The uveal tract consists of two 
segments: the anterior segment and the posterior segment (Figure 1.1). The 
anterior segment contains the iris, which accounts for 10% of all UM and rarely 
metastasises (Shields et al., 2012). The most common form of UM, however, (90% 
of all cases) arises from the posterior segment, which consists of choroid tissue 





Figure 1.1. The anatomy of the eye and the origins of UM.  
The eye consists of an anterior segment (iris) and a posterior segment (choroid and 
ciliary body). The sclera is the eye’s outer membrane, while the retina is the inner 
membrane. The eye is filled with vitreous humour, which gives the eye its round shape. 
UM is dependent on the location in which it develops, such as in the choroid, ciliary body 
or iris. Modified from Chattopadhyay et al. (2016). 
 
1.3.1 Risk factors of UM 
There are different risk factors that can increase the incidence of melanoma 
disease. The primary risk factor in cutaneous melanoma, for instance, is sun 
exposure (UV-radiation exposure) among those with white skin pigment; as such, 
this cancer occurs at higher incidences among Caucasian populations who live 
in North America, Europe, Australia and New Zealand, and is far less common 
among darker-skinned populations, such as those in Africa or Asia, where the 
incidence of acral and mucosal melanomas is low, as reviewed by Schadendorf 
et al. (2015). Although exposure to UV radiation exhibits a strong association with 




UM is still controversial (Singh et al., 2004). For example, while some research 
articles correlated UV exposure to UM as a risk factor (Holly et al., 1990, Seddon 
et al., 1990, Vajdic et al., 2003), others showed no such correlation (Pane and 
Hirst, 2000, Lutz et al., 2005). In addition, cutaneous melanoma occurs in young 
adults and also commonly occurs in people aged between 40 to 60 (Garbe and 
Leiter, 2009). However, diagnoses of UM are usually made in older adults, 
especially those patients who are between the ages of 60 and 80 years old, with 
no apparent difference in incidence rates between males and females (Shields 
and Shields, 1992, Singh and Topham, 2003, Virgili et al., 2007).  
UM is believed to be associated with ocular melanocytic lesions, including 
choroidal naevi and ocular melanocytosis. In addition, there are some skin 
disorders associated with UM, such as dysplastic nevus syndrome and the nevus 
of Ota (Hammer et al., 1996). A light-coloured iris, which is common in Caucasian 
populations, is considered to be a risk factor for the development of UM (Schmidt-
Pokrzywniak et al., 2009). No association has been found, however, between UM 
and other environmental habits, such as smoking, alcohol consumption or dietary 
habits (Seddon et al., 1989). 
1.3.2 Diagnosis of UM  
Most UM patients present with metamorphopsia or a painless loss of vision, but 
larger tumours may sometimes be linked to retinal detachment, which causes 
photopsia (Eskelin and Kivela, 2002). Also, in some cases, patients may be 
entirely asymptomatic and unaware that they have UM until the tumour is 
identified through a routine funduscopic examination by the ophthalmologist. 
Most UM tumours have a very distinct dome or mushroom shape (Bedi et al., 
2006). Patients who have anterior UM may notice discoloration of the iris or a 
permanent injection in the outer layer of the eye (episclera). The presence of sub-
retinal fluid and an orange pigment are also associated with a diagnosis of UM 
(Melia et al., 1997). The Collaborative Ocular Melanoma Study (COMS, 1990) 
reported that the accuracy of a UM diagnosis is greater than 99% with enucleated 
eyes. The characterisation of UM is usually done by using different supportive 




autofluorescence (Shields et al., 2014). Additionally, fine-needle aspiration 
biopsy (FNAB) can also aid in the accurate diagnosis of UM, and this can also 
help the analysis of cytogenetic and gene expression to determine the prognostic 
factors (Char and Miller, 1995, McCannel, 2013). 
1.3.3 Metastasis of UM 
The prognosis with UM patients is that about 50% of them will develop metastasis 
to another organ within five to ten years, and when this occurs the survival rate 
is strikingly decreased to less than a year (Gragoudas et al., 1991, Kath et al., 
1993, Diener-West et al., 2005, Rietschel et al., 2005). The most common organ 
that UM cells disseminate to is the liver, accounting for about 90% of cases. The 
survival rate after secondary metastasis of UM patients to the liver varies 
between six and twelve months (Diener-West et al., 2005). UM cells are 
disseminated directly through blood circulation due to the absence of lymph 
nodes in the uvea tract. Additionally, UM patients with metastasis risk may 
develop metastasis to other organs such as lungs, bone and, rarely, the skin and 
brain (The Collaborative Ocular Melanoma Study, 2001, Kujala et al., 2003, 
Bedikian, 2006). UM patients who experience metastasis to organs than the liver 
as a first site showed longer survival rate and more favourable prognosis (Kath 
et al., 1993).  
1.3.4 Treatment of UM 
Due to the poor survival rate once UM metastasises, a key aim in the treatment 
of UM is the prevention of the metastasis of the primary tumour. As mentioned 
earlier, however, half of UM cases show metastasis to the liver, with an 
associated reduction in the survival rate to less than a year. The main approach 
once UM has been diagnosed therefore is eye enucleation, as reviewed in 
Shields and Shields (2015). Even with eye enucleation, however, metastasis to 
the liver has not decreased.  
In the 1970s, Zimmerman and colleagues hypothesised that eye enucleation may 
contribute to metastasis by releasing the tumour cells into the blood circulation 




which radioactive plaque brachytherapy became available for selective UM 
patients (Packer and Rotman, 1980). This allowed the hypothesis to be tested in 
three trials that found that the survival for both medium- and large-sized UM 
tumours were similar after enucleation of the eye and use of brachytherapy, thus 
rejecting the ‘Zimmerman hypothesis’ (Davis et al., 1994, The Collaborative 
Ocular Melanoma Study, 1998, Diener-West et al., 2005). Besides surgical 
enucleation and radiotherapy, phototherapy using photocoagulation and 
transpupillary thermal therapy appear to be effective for some select small-sized 
UM. However, these types of therapy are associated with various side effects 
such as haemorrhage, occlusions of the retina and retinopathy (Singh et al., 2003, 
Mashayekhi et al., 2015). In addition, the use of new surgical techniques, such 
as stereotactic radiosurgery and proton beam therapy, appear to be effective for 
some UM patients with large-sized tumours and for cases that are unsuitable for 
plaque radiotherapy (Fakiris et al., 2007, Damato et al., 2013, Sikuade et al., 
2015). These surgical techniques, however, have failed to increase the 
progression survival rate and overall survival for UM patients (Fabian et al., 2017). 
Furthermore, adjuvant therapy for UM patients using surgical techniques 
followed by chemo- or immunotherapy, have also failed to decrease the 
metastasis risk and improve the survival rate (Desjardins et al., 1998, Lane et al., 
2009).  
The chemotherapeutic regimens used for metastatic UM were originally adapted 
from cutaneous melanoma. These include dacarbazine, temozolomide, cisplatin 
and other combinations; however, the use of these drugs has neither led to an 
improvement in the survival rate nor lowered the risk of metastasis (Schmittel et 
al., 2006, Augsburger et al., 2009, Spagnolo et al., 2012, Spagnolo et al., 2013). 
In addition, several attempts have been made to use immunotherapeutic agents 
such as anti-CTLA-4 and anti-PD-1 on metastatic UM onsets, but the outcome 
remains unclear (Rodriguez et al., 2014, Kottschade et al., 2015, Zimmer et al., 
2015). Recently, some molecular targeted therapies, such as mitogen-activated 
protein kinase (MAPK) pathway, have been tested for use in UM, however, the 
preliminary results showed that there was a partial response was found among 




ongoing without any result been published yet, as reviewed in Chokhachi 
Baradaran et al. (2020). 
1.3.5 Prognosis of UM  
The prognosis of UM depends on a myriad of factors, such as clinical findings, 
histopathology, cytogenetics and genetics. The point of origin of the tumour (the 
ciliary body, choroid or iris) has clinical implications for predicting the mortality 
rate of UM patients (Shields et al., 2001). Origin in the ciliary body usually has 
the worst prognosis and highest risk of metastasis, while origin in the choroid and 
iris suggests a good prognosis (Shields et al., 2009). Additionally, the tumour size, 
which is calculated from the height and base diameter of the mass, plays a role 
in predicting the prognosis of UM (Dienerwest et al., 1992). The large-tumour 
size is considered as a poor prognosis while the small-tumour size is considered 
as a good prognosis for UM. Moreover, a solid mushroom-shaped tumour 
correlates with a good prognosis while a diffuse lesion is considered as a bad 
prognostic marker for UM (Shields et al., 1996). Furthermore, the older patient’s 
age is also correlated with UM poor prognosis; however, no correlations between 
prognosis and gender have been shown for UM (Kroll et al., 1998). 
In addition to these clinical prognostic factors, the histopathology of the tumour 
following enucleation can be used to accurately predict a patient’s survival. 
Callender (1931) was the first to propose a classification system for UM patients, 
which depended on cell type, while McLean et al. (1977) improved this system, 
as reviewed by Rennie (1997). McLean’s classification system showed that there 
are three types of cells in UM, namely spindle, epithelioid and mixed cell, which 
combined both epithelioid and spindle cells in the same tumour. These cells are 
respectively associated with a good, poor and intermediate prognosis. (McLean 
et al., 1983). However, these clinical and histopathological parameters do not 
provide a conclusive determination of the prognostication risk for UM onsets. For 
this, there is a need to determine the effect of both cytogenetic and molecular 




1.3.6 Chromosomal alteration in UM 
Cutaneous melanoma and UM have distinctive genetic differences, despite both 
being considered to be melanomas. For instance, cutaneous melanoma exhibits 
different chromosomal and genetic aberrations that turn normal melanocyte cells 
into cancerous cells. The main chromosomal aberration found in cutaneous 
melanoma is the loss of chromosome 10 (monosomy 10), which accounts for 
about 60% of the cases (Bastian et al., 1998, Hoglund et al., 2004, Carless and 
Griffiths, 2008, Lin et al., 2008). Moreover, a recent study by Hirsch et al. (2013) 
using array-CGH found that the chromothripsis phenomenon occurs in malignant 
melanoma patients with a poor prognosis, and this result was confirmed using 
NGS (with paired-end sequencing) to emphasise the role of both inter- and intra-
chromosomal rearrangement. Chromosomal instabilities such as the partial or 
complete loss of chromosomes 1p and 6q also occur in cutaneous melanoma, 
similar to UM, however, the cytogenetic changes in UM are not random and can 
in fact be characterised by key chromosomal aberrations, such as loss of 
chromosome 3 (monosomy 3), gain of the chromosome 8q arm and gain of 
chromosome 6p arm (Bastian et al., 2003, van den Bosch et al., 2010, van der 
Kooij et al., 2019).  
The first chromosomal changes to be reported in UM were determined by Rey et 
al. (1985), who found abnormalities in both chromosomes 6 and 8 that are 
associated with increased risk of brain metastasis. Furthermore, the first two 
cytogenetic analyses were performed on a set of UM cases, revealing consistent 
abnormalities at the chromosomal level (Prescher et al., 1990, Sisley et al., 1990). 
These studies reported that the most frequently found abnormality was 
monosomy 3, while gain of chromosome 8q and deletion of the 1p arm were seen 
less frequently. Sisley et al. (1990) emphasised that UM originating in the ciliary 
body was associated with abnormalities at chromosomes 3 and 8. Detection of 
these anomalies was usually made by karyotyping and FISH using tumour 
biopsies obtained from UM patients (Sisley et al., 1990, Patel et al., 2001). 
Furthermore, microarray analysis using array-CGH is able to provide high-




be used with different tissues, such as paraffin-embedded, formalin-fixed or 
frozen samples (Minca et al., 2014). 
Monosomy 3 is associated with high rates of metastasis to the liver and is 
therefore also linked with a poor prognosis (Sisley et al., 1990, Prescher et al., 
1996, Damato et al., 2007, Shields et al., 2007). Several studies have shown a 
correlation between large-size tumours, epithelioid cells and monosomy 3 with a 
poor overall prognosis (Prescher et al., 1996, Kilic et al., 2006, Damato et al., 
2009, Shields et al., 2011, Van Beek et al., 2015). Moreover, Sisley et al. (1997) 
revealed that monosomy 3 and gains in chromosome 8q are associated with a 
poor prognosis. Additionally, the deletion of chromosome 1p and a gain of 
chromosome 8q are believed to be markers for a poor prognosis of UM (Aalto et 
al., 2001, Kilic et al., 2005). Conversely, Cross et al. (2006) and Abdel-Rahman 
et al. (2011) showed that the partial deletion of chromosome 3 correlated with an 
intermediate prognosis, while Trolet et al. (2009) reported that a normal 
chromosome 3 (disomy 3) is correlated with a good prognosis. In addition to 
disomy 3, a gain in chromosome 6p is associated with the best prognosis and 
non-metastatic UM (Landreville et al., 2008). The structural aberrations of 
chromosome 6 will be discussed in-depth in section 1.4. 
Gain of chromosome 8q is usually associated with monosomy 3 and a ciliary 
body origin, which is correlated with poor prognosis in 50% of UM cases (Sisley 
et al., 1997, White et al., 1998, Singh et al., 2009). In fact, the use of more modern 
molecular cytogenetic technologies, such as array-CGH, has indicated the 
presence of monosomy 3 and gain of chromosome 8q in an even higher 
proportion of UM samples, between 51% and 75%, respectively (Hammond et 
al., 2015). Some researchers, however, have argued that the gain of 
chromosome 8q, either alone or with monosomy 3, is not a reliable prognostic 
factor to predict the outcome for UM patients (Kilic et al., 2005, Ehlers et al., 
2008).  
Besides these major chromosomal abnormalities in UM, there are other 
aberrations in chromosomes 1, 9, 11, 16 and 21. The loss of chromosome 1p 
arm in UM appears to be correlated with monosomy 3 and thence a poor 




loss of chromosome 9p and structural re-arrangement of chromosome 11 in UM 
appears to correlate with good prognosis (Speicher et al., 1994, Sisley et al., 
2000, Sisley et al., 2006). Small recurrent aberrations, such as trisomy 21 and 
loss of chromosome 16q arm, have also been found to have a role in the UM 
prognosis (Horsman and White, 1993, Sisley et al., 2000, Kilic et al., 2006).  
1.3.7 Mutations associated with Melanoma 
Although cytogenetic analysis is able to provide a more accurate prognosis than 
when using clinical and histopathologic characteristics alone to assess different 
types of melanomas, the determination of a high or low risk for metastasis 
requires still more accurate information. In this regard, the main genetic mutation, 
accounting for more than half of melanomas, occurs in the B-Raf proto-oncogene 
(BRAF) (Davies et al., 2002), while the neuroblastoma Ras viral oncogene 
(NRAS) is responsible for around 20% of melanomas (Wilson and Nathanson, 
2012). Kit proto-oncogene receptor tyrosine kinase (KIT) mutations commonly 
take place in acral and mucosal melanomas, although they rarely occur in skin 
cancer (Carvajal et al., 2011). While other types of melanomas, such as 
cutaneous, conjunctival and iris, also exhibit mutations in BRAF and KIT (Davies 
et al., 2002, Cohen et al., 2003, Spendlove et al., 2004, Thomas et al., 2006, 
Henriquez et al., 2007), they are rare or absent in cases of UM (Malaponte et al., 
2006).  
New technologies, however, are now identifying the unique genetic mutations in 
UM cells and thus a greater understanding of the associated molecular 
mechanisms and interactions. Genetic profiling of UM using COMS has been 
able to establish two classes of tumours based on the prognosis: class 1 and 
class 2 tumours. These respectively represent a tumour’s low and high metastatic 
potential (Onken et al., 2010, Onken et al., 2012).  
1.3.7.1 GNAQ and GNA11 mutations  
Guanine nucleotide-binding protein Q polypeptide (GNAQ) and guanine 
nucleotide-binding protein alpha 11 (GNA11) gene mutations commonly occur in 




Raamsdonk et al., 2010). The GNAQ and GNA11 genes are located in 
chromosomes 9q21 and 19p13, respectively, which are found to have mutated 
in around 90% of UM patients (Van Raamsdonk et al., 2009, Van Raamsdonk et 
al., 2010, Koopmans et al., 2013). These mutated genes also tend to be found 
mutated in more than half of those patients with blue naevi (Van Raamsdonk et 
al., 2010, Sisley et al., 2011). Most of the GNAQ and GNA11 mutations are found 
in codon Q209 of exon 5, although some are also found in codon R183 of exon 
4. Furthermore, GNAQ and GNA11 mutations appeared to occur in early 
tumourigenesis in UM; these mutations have also been observed throughout all 
tumour progression processes. GNAQ and GNA11 play a role in oncogenic 
behaviour because they encode G-proteins, meaning that their mutation can lead 
to G-proteins becoming constitutively active, upregulating the MAPK pathway. 
Recently, cases with mutations in GNAQ and GNA11 have showed activation of 
the yes-associated protein (YAP), an effector on the Hippo tumour-suppressor 
pathway, which may enhance the oncogenic properties of these genes (Feng et 
al., 2014, Yu et al., 2014). Although GNAQ and GNA11 are important because 
they are a driver mutations for melanocytic transformation, these genes do not 
have an impact on the prognosis for UM because they are found in early stages 
of UM, including in benign lesions, as well as in all further stages of progression 
(Dhillon et al., 2007, Bauer et al., 2009, Kim and Choi, 2010).  
There are other genetic mutations besides GNAQ and GNA11 that correlate with 
the development of UM. For instance, cysteinyl-leukotriene receptor 2 (CYSLTR2) 
which is a member of the G-protein family, similar to GNAQ and GNA11 (Moore 
et al., 2016). In addition, phospholipase C Beta 4 (PLCB4) has been found to be 
mutated in UM, apparently activated by its interaction with GNAQ (Johansson et 
al., 2016). The mutations of CYSLTR2 and PLCB4 account for around 5% of UM, 
yet these mutations appear to be mutually exclusive from mutations of GNAQ 
and GNA11 (Robertson et al., 2017). Although these newly identified gene 
mutations seem to have a similar functional effect on UM development as the 





1.3.7.2 BAP1 mutations  
Harbour et al. (2010) were the first to describe the inactivation of a mutated 
BRCA1-associated protein 1 (BAP1) gene in more than 80% of UM cases 
exhibiting tumour metastasis. This gene is interestingly located in chromosome 
3p21, which is an area that is frequently lost in metastatic UM. Mutations in the 
BAP1 gene can terminate the BAP1 premature protein and some of these 
mutations can affect the ubiquitin carboxyl-terminal hydrolase domain which alter 
its deubiquitinase activity (Jensen et al., 1998). Pan et al. (2015) showed that the 
BAP1 protein may interact with the promoters that regulate E2F transcription 
factor 1 (E2F1), which may in turn have an effect on those genes involved in cell 
cycle progression that are controlled by the E2F family. In addition, the 
dysfunction of  BAP1 protein has implications on cell pluripotency (Moon et al., 
2017). Although the genetic mutations of BAP1 appear to be correlated with the 
dysregulated expression of BAP1 protein, immunohistochemical assessment of 
the protein is more reliable than genetic mutational analysis (Kalirai et al., 2014). 
Furthermore, BAP1 has been described in germline mutations among younger 
patients with UM, which suggests that it may be a predisposing gene among 
hereditary UM patients (Singh et al., 1996a, Singh et al., 1996b, Aoude et al., 
2013, Cebulla et al., 2015). When BAP1 mutations are found in UM, they are 
considered class 2 tumours (i.e. they are associated with a high risk of metastasis 
and a poor prognosis) (Harbour et al., 2013, Martin et al., 2013). The complete 
role of the dysregulation of BAP1 protein in UM is still unclear, however, and 
BAP1 dysregulation alone does not predict poor prognosis in UM cases (Harbour 
et al., 2010, Abdel-Rahman et al., 2011, Robertson et al., 2017). 
1.3.7.3 SF3B1 mutations 
The splicing factor 3B subunit 1 (SF3B1) gene is located in chromosome 2q33. 
It is a component of the spliceosome, which is a large and complex intracellular 
machine that processes precursor messenger RNA (pre-mRNA) into the mature 
transcript (Alsafadi et al., 2016). The mutation of this gene is responsible for 
different alternative splicing events, such as alternative terminal exon usage, 
intron retention and cryptic splicing within exons, for both protein coding and non-




reported in different types of cancers, such as blood, breast and pancreatic 
cancer, where the predominant mutation hotspot in these cancers is in codon 
K700 (Malcovati et al., 2011, Wang et al., 2011, Biankin et al., 2012, Cancer 
Genome Atlas, 2012). The most common mutation hotspot of this gene in UM, 
however, is found in codon R625 of exon 14, occurring in between 10 and 20% 
of UM cases without the complete or partial loss of chromosome 3 (Furney et al., 
2013, Harbour et al., 2013, Martin et al., 2013). In contrast, mutations in SF3B1 
occur only rarely in cutaneous melanoma (1% of cases) (Kong et al., 2014). 
Mutations in SF3B1 gene are associated with a good UM prognosis, and are 
almost completely exclusive of mutations in BAP1 (Harbour et al., 2013). A recent 
report by Luscan et al. (2015), however, revealed that some UM cells with 
mutations in the SF3B1 gene can be observed in UM cases featuring liver 
metastasis. In addition, Yavuzyigitoglu et al. (2016b) showed that 79% of UM 
patients with mutated SF3B1 exhibited late metastasis, although those patients 
were disomy 3. They emphasised that mutations of SF3B1 in UM were likely to 
be correlated with gain of chromosome 6p, possibly indicating a role for 
chromosome 6 in terms of predicting the UM prognosis. Furthermore, this may 
be because of the partial gain of chromosome 8q in UM that appears to correlate 
with the poor prognosis (Sisley et al., 1997, Hammond et al., 2015, Robertson et 
al., 2017). Although it has been shown that SF3B1 mutations in leukaemia lead 
to the accumulation of DNA damage by altering the DNA damage response (Te 
Raa et al., 2015), the biological role of splicing genes by mutated SF3B1 in UM 
remains unclear (Furney et al., 2013, DeBoever et al., 2015). 
1.3.7.4 EIF1AX mutations 
Eukaryotic translation initiation factor 1A, X-linked (EIF1AX), which is located in 
chromosome Xp22, encodes for a protein that plays an essential role in both the 
recognition of the target mRNA start codon and mRNA translation (Chaudhuri et 
al., 1997). The use of new technologies, such as whole exome sequencing 
(WES), has revealed that 13% of UM with disomy 3 demonstrates mutations in 
EIF1AX exons 1 and 2 (Martin et al., 2013). Mutations in this gene are uncommon 
in UM patients with monosomy 3 and it appears to be mutually exclusive to 




Similar to SF3B1, mutations of EIF1AX in UM appear also to be correlated with 
the gain of chromosome 6p (Yavuzyigitoglu et al., 2016a). This is another gene 
that has recently been shown to be associated with UM prognosis when it is 
mutated. EIF1AX mutations are therefore considered class 1 tumours (at low risk 
of metastasis) and are associated with a good prognosis (Harbour et al., 2013, 
Decatur et al., 2016, Robertson et al., 2017). In addition, about 42% of EIF1AX 
mutations occur in iris melanoma cases, while mutations in other types of UM, 
such as ciliary body and choroidal, accounted for only 13% (Scholz et al., 2017). 
In a recent study Johnson et al. (2017) performed analyses on EIF1AX aiming to 
understand its function in UM cells. They found that UM cells with mutated 
EIF1AX have a deviant translational regulation in comparison with the normal 
EIF1AX, and they suggest that this may explain the selective advantage of 
mutant EIF1AX in UM.  
1.3.7.5 TERTp mutations 
The telomerase reverse transcriptase (TERT) gene is located in chromosome 
5p15, where it encodes the catalytic reverse transcriptase subunit of telomerase, 
which is part of the ribonucleoprotein complex that maintains the telomere length 
(Cesare and Reddel, 2010, Horn et al., 2013). Telomerase activity has been 
found to be present in more than 90% of somatic cancer cells, but is absent in 
normal human cells (Shay and Bacchetti, 1997). Telomere maintenance is not 
TERT’s only function: it is also involved in regulation of gene expression, cellular 
signalling, cell cycle and DNA damage response, apoptosis inhibition and 
maintenance of mitochondria DNA (mtDNA), as reviewed in Wu et al. (2013). 
These diverse functions indicate that the disruption of this protein may increase 
the cellular instability and thus tumourgenesis. Mutations in TERT promoter 
(TERTp) create a new binding motif for E-twenty-six (ETS) transcription factors 
and upregulate the expression of TERT (Huang et al., 2013). Interestingly, 
TERTp mutations have been shown to be a good prognostic marker in various 
cancers such as melanoma, thyroid, lung, liver and glioma (Yuan et al., 2016). 
Only two studies, however, have found mutations in TERTp gene in UM (one UM 
case in each study), which indicates the rarity of mutated TERTp mutations for 




TERTp mutations for UM cells has been found to be similar to patients with good 
prognosis. Although the TERTp mutations are more common in other types of 
melanomas, such as cutaneous (Horn et al., 2013, Huang et al., 2013) and 
conjunctival melanomas (Griewank et al., 2013) than in UM, the discovery that 
they do appear in UM cells may provide a new insight into the role of TERTp in 
UM. 
1.4 Ambiguity of chromosome 6 changes in UM 
While structural aberrations of chromosome 6 have often been observed in UM, 
such as gain of 6p only, or loss of chromosome 6q and gain of 6p 
(isochromosome 6p), little is known about the implications of this chromosome 
and the involvement of genes in this chromosome. Chromosome 6 aberrations 
in other types of cancer, such as cutaneous melanoma, retinoblastoma and 
osteosarcoma, are correlated with poor prognosis (Ozaki et al., 2002, Bastian et 
al., 2003, Namiki et al., 2005, Zielinski et al., 2005, Gerami et al., 2010, Martin et 
al., 2012, Theriault et al., 2014) but in UM the gain of chromosome 6p is 
correlated with good prognosis and favourable outcomes (Aalto et al., 2001, 
Onken et al., 2004). Although some studies have argued that the gain of 
chromosome 6p is unlikely to be correlated with monosomy 3 in UM and thus the 
outcome is good prognosis (Prescher et al., 1995, Parrella et al., 1999, Ehlers et 
al., 2008, Landreville et al., 2008), other studies have showed that monosomy 3 
occurs with gain of chromosome 6p in the same UM tumour  (Sisley et al., 2000, 
Aalto et al., 2001).   
The deletion of chromosome 6q has also been reported in different cancer types 
such as cutaneous melanoma, prostate cancer and acute lymphoblastic 
leukaemia, and correlates with a poor outcome (Healy et al., 1998, Nupponen et 
al., 1998, Mancini et al., 2002). The change in UM for chromosome 6q is usually 
correlated with gain of 6p to form an isochromosome 6p, which is correlated with 
monosomy 3, gain of chromosome 8q and poor prognosis (Sisley et al., 2000, 
Aalto et al., 2001, Kilic et al., 2006, Damato et al., 2009). Little is known, however, 
about the effect of the loss of chromosome 6q in UM because it is believed that 




(Prescher et al., 1990, Gordon et al., 1994, White et al., 1998). Sisley et al. (2006) 
rationalised that structural aberrations and translocation events for chromosome 
6 been found in around 70% of the UM cases. This finding may indicate that 
structural aberrations of chromosome 6 have a role in the prognosis of the UM.  
Parrella et al. proposed a bifurcated pathway for UM tumour prognosis describing 
the chromosomal alteration events in which monosomy 3 and gain of 
chromosome 6p were mutually exclusive and then both advanced to gain of 
chromosome 8q that indicates a poor prognosis (Parrella et al., 1999). In an 
extension of this proposal, Sisley (2015) proposed an alternative pathway that 
include aberrations in chromosome 3 and chromosome 6 as an initiative pathway 
for UM progression and one correlated with the tumour origin, as seen in Figure 
1.2. These genetic pathways for UM may therefore indicate the role of those 
aberrant chromosomes and determine their effect on UM development and 
progression. Generally, different research groups have come up with different 
results regarding the alterations of chromosome 6 in UM, making this 
chromosome a priority for further studies and gene exploration to clarify its role 





Figure 1.2. The chromosomal changes that occur in UM cells. 
The figure indicates the tumour’s origin (ciliary or choroid) then these cells develop to 
gain of 6p, loss of 6q or monosomy 3 (M3) that determine a patient’s prognosis. The 
dashed lines indicate that these changes are possible, albeit this finding is not yet well 












1.5 Summary  
In summary, the prognosis of UM depends on different clinical and cellular 
characteristics. An increasingly important area of research over the last twenty 
years has been the association of chromosomes 1, 3, 6 and 8 in predicting the 
prognosis of UM patients. Little is known, however, about the effect of 
chromosome 6 alterations on the progression of UM and thus it is necessary to 
identify genes in chromosome 6 and determine their effect on UM development 
and progression. Moreover, the last ten years have witnessed an increase in the 
identification of specific mutations in genes such as GNAQ and GNA11 which 
have an association with the development of UM; while mutations in SF3B1, 
EIF1AX and TERTp have showed some association with the prognosis of UM; 
as summarised in Figure 1.3 (Doherty et al., 2018). 
This introduction has emphasised the role of both chromosomal and genetic 
alterations in UM cells that can lead to an increase or decrease in metastasis to 
the liver. Although a number of studies have reported associations between 
chromosomal and genetic mutations and the development and progression of 
UM, some of these studies are fairly preliminary, and data on long-term follow up 
is not yet available, meaning that the evidence is not yet strong enough to validate 
their claims. Moreover, these genetic mutations do not seem to provide a clear 
indication of the way UM patients are going to behave, and instead the best 





Figure 1.3. The correlation of prognostic biomarkers in UM with different 
clinical, histological, chromosomal and genetic changes. 
This simple model elucidates the tumour progression in UM from a normal melanocyte 
to the mutations in GNAQ and GNA11 that transformed it into a malignant melanocyte. 
Clinicopathological considerations then determine the progression of UM, along with 
changes in chromosomes such as chromosomes 1, 3, 6 and 8; and the effect of genetic 





1.6 Hypothesis and aims of the study  
UM is an aggressive disease and there is not yet an effective therapeutic 
approach for secondary disease (Violanti et al., 2019). Genetic biomarkers of UM 
can successfully indicate prognosis, yet there is some debate over the 
importance and implications of changes in chromosome 6 aberrations. 
Furthermore, the genes involved in chromomere 6 are not yet identified. 
Therefore, the hypothesis is that:  
Chromosome 6 aberrations can affect UM prognosis and there are genes 
on both arms which contribute to the development, prognosis and 
metastasis of UM. 
This present study aims to continue the investigation initiated previously for a 
PhD study by Nawal Alshammari (Alshammari, 2017), which found candidate 
genes in chromosomes 6p and 6q that are relevant to the prognosis of UM using 
high-resolution array-CGH.  
 The present study will continue this investigation to cover in more detail 
the cytogenetic changes effect of chromosome 6 aberrations associated 
with known genetic mutations.  
 This study will then use high-resolution array-CGH to further assess other 
implicated regions of chromosomes 6p and 6q in respect the prognosis of 
UM.  
 This study will also determine some of the underlying genetic 
abnormalities in those regions and explore the effect of targeting, using 






























2.1 Materials  
2.1.1 General reagents and consumables  
Reagents  
Reagent Supplier Reagent Supplier 
Agarose  Fisher 
Scientific™ 




Sigma™ Glycine  Sigma™ 
Deionised H2O Millipore™ Hydrogen Peroxide (H2O2) Sigma™ 




Nuclease Free H2O Invitrogen™ 
Ethanol (EtOH) Fisher 
Scientific™ 
















Xylene  Fisher 
Scientific™ 
Consumables 
Reagent Supplier Reagent Supplier 
Centrifuge tubes 
(15, 25 and 50ml)  
Starstedt™ Sterile filter pipette tips (10, 
20, 200 and 1000l) 
StarLab™ 
Coverslips (22 x 
22mm and 22 x 
30mm) 







(0.2, 0.5, 1.5 and 
2.0ml) 





StarLab™ Sterile pipette tips (10, 20, 
200 and 1000l) 
StarLab™ 
Serological 
pipettes (5ml, 10ml 
and 25ml) 
Corning® Tissue culture flasks (T25 
and T75) 
Nunc® 
Sterile petri dishes  Nunc® Tissue culture plates (6, 12, 
24, 48 and 96 wells) 
Nunc® 






2.1.2 Sample collection  
Tumour tissue from 30 patients who were diagnosed with primary UM and who 
had undergone enucleation between 1994 and 2016, was instantly snap frozen 
and stored at -80 °C until DNA extraction (the Ocular Oncology Unit at the Royal 
Hallamshire Hospital, Sheffield, UK). Some of genomic DNA (gDNA) was 
previously extracted from the same patients’ whole blood using standard 
extraction methods and was available for the archived samples. Ethical approval 
and patient consent were obtained from the Central Research Ethics Committee 
for research purposes (SSREC 94/247 and 09/H1008/141).  
2.1.3 Cell lines  
In this study, four cell lines were used as disease models. The cell lines were 
derived at the University of Sheffield from tumours that were diagnosed as UM 
and collected between 2009 and 2017 by Dr. Karen Sisley. These cell lines were 
given a laboratory designation numbers of MEL-577, MEL-585, MEL-627 and 
MEL-644. All these cell lines were phenotypically and genetically examined and 
correlated with their parent tumours by Dr. Karen Sisley. The HepG2 cell line 
(supplied by Dr. Nigel Bird) was used as a biological positive control for both 
immunocytochemistry and western blot (WB) experiments, following the 
manufacturer’s recommended protocol.  
2.1.4 DNA extraction from patients’ blood and frozen 
tumour tissue samples 
Patients’ whole blood DNA extraction was prepared using QIAamp® DNA blood 
midi kit (QIAGEN®). Reagents that were used contained:  
• QIAGEN® Protease. 
• Lysis buffer (Buffer AL). 
• Washing buffers (Buffer AW1 and AW2) after an addition of the 
appropriate volumes of absolute ethanol. 
• Elution buffer (Buffer AE). 




DNA extraction for patients’ snap-frozen tumour tissue was prepared using 
DNeasy® blood and tissue kit (QIAGEN®). Reagents that were used contained:  
• QIAGEN® proteinase K. 
• Tissue lysis buffer (Buffer ATL). 
• RNase A 
• Lysis buffer (Buffer AL).  
• Washing buffers (Buffers AW1 and AW2) after an addition of the 
appropriate volumes of absolute ethanol.  
• Elution buffer (Buffer AE)  
• DNeasy® mini spin columns and collection tubes.  
 
2.1.5 Primer design for GNAQ, GNA11, SF3B1, 
EIF1AX and TERTp 
Forward and reverse primers for GNAQ and GNA11 were previously designed 
by Onken et al. (2008) and Van Raamsdonk et al. (2010) (Table 2.1). Forward 
and reverse primers for SF3B1, EIF1AX and TERTp were also designed by Dono 
et al. (2014). In this study, these primers were confirmed using primer-BLAST 
website (www.ncbi.nlm.nih.gov/tools/primer-blast) to determine their specificity 
for the targeted genes. These primers were supplied lyophilised from (Eurofins 
Genomics) and were re-concentrated with nuclease free H2O to a concentration 










Table 2.1: Primer design for GNAQ, GNA11, SF3B1, EIF1AX, and TERTp. 
Gene Exon Primer 
Direction 









GNAQ 4 Forward 
TCTTTTTCTCCCACCC
CTTGC 













GNA11 4 Forward 
GTGCTGTGTCCCTGT
CCTG 












SF3B1 14 Forward TGATTATGGAAAGAAA
TGGTTGAAG 




EIF1AX 1 Forward GAAAAGCGACGCAAA
GAGTC 










TERTp Promoter Forward GTCCTGCCCCTTCAC
CTT 








2.1.6 Polymerase chain reaction (PCR) 
For all PCR reactions, IMMOLASE™ DNA polymerase kit (BIOLINE, London, UK) 
was used and stored at -20 °C. The kit contained:  
• 10✕ ImmunoBuffer. 
• 50 mM MgCl2 solution. 
• IMMOLASE™ DNA polymerase. 
Deoxyribonucleotide triphosphates (dNTPs): dNTPs set (BIOLINE™) 
containing dATP, dCTP, dGTP, and dTTP (100 mM). To make the working 
concentration of 50 mM of dNTPs, 25 l of each was added to 100 l of dH2O.  
Thermal cycler: Mastercycler® nexus gradient (Eppendorf). 
Running buffer: 50✕ Tris-Acetate-EDTA (TAE) stock solution, prepared in 1000 
ml of dH2O as followed: 
• 242 g tris base. 
• 57.1 ml glacial acetic acid. 
• 18.6 g EDTA.  
Storage was at room temperature and was diluted to 1✕ for use. 
Electrophoresis unit: Multi sub-choice electrophoresis unit (Geneflow), 
comprising: 
• Gel casting tray (15 ✕ 15 cm).  
• Sample comb (20 samples).  
• Electrophoresis tank. 
Power source: Power-Pac 3000 basic power supply for electrophoresis (Biorad).  
Ethidium bromide: Ready-to-use 20 mg/ml ethidium bromide (Sigma™) and 
stored at room temperature.  




Loading buffer: 6✕ loading buffer 0.25% (w/v) bromophenol blue and 30% (v/v) 
glycerol prepared by adding 25 mg bromophenol blue to 3 ml glycerol and made 
up to 10 ml using dH2O and stored at 4 °C. 
Gel documentation: Gel Doc™ EZ imager (Biorad). 
2.1.7 Array-comparative genomic hybridisation 
(array-CGH) 
Restriction digestion enzymes (Promega™) were stored -20 °C and contained: 
• 10✕ Buffer C. 
• Alu1 (10U/l). 
• Rsa1 (10U/l). 
• Acetylated bovine serum albumin (10g/ml). 
Genomic DNA enzymatic labelling kit (Agilent™) was stored at -20 °C containing:  
• Random primers.  
• 5✕ Buffer. 
• 10✕ dNTPs. 
• Cyanine 3-dUTP (Cy3) (1.0 mM). 
• Cyanine 5-dUTP (Cy5) (1.0 mM). 
• Exo-Klenow fragment. 
Amicon® 30 kDA filters and 1✕ TE buffer for labelling DNA purification stored at 
room temperature.  
Human Cot-1 DNA™ (Invitrogen™). 
Oligo array-CGH Hybridisation kit (Agilent™) containing: 
• Agilent 2✕ Hi-RPM hybridisation buffer stored at room temperature.  
• Agilent 10✕ Blocking agent.  




• SurePrint® G3 Human CGH Microarray Slide 4✕180K. 
• Hybridisation gasket slide.  
• Hybridisation champer kit-SureHyb® enabled, stainless steel.  
Microarray hybridisation oven (Agilent™) fitted out with removable rotator rack.  
Washing buffer kit: oligo array-CGH/ChIP-on chip wash buffer kit containing:  
• Oligo array-CGH wash buffer 1. 
• Oligo array-CGH wash buffer 2.  
Microarray slide scanner system (G2565CA) (Aglient™).  
2.1.8 Immunochemistry 
Phosphate Buffered Saline (PBS): 10 tablets of PBS (Oxiod) dissolved into 1 L 
of H2O. 
Phosphate Buffered Saline with TWEEN 20 (PBST): 10 tablets of PBS 
dissolved into 1 L of H2O with 0.1% of TWEEN 20® (1ml) (Sigma™). 
Peroxidase quenching solution: 3% of hydrogen peroxide (H2O2) (Sigma™) in 
Methanol (Fisher Scientific™) prepared freshly by adding 30 ml of 30% H2O2 into 
270 ml absolute methanol. 
Melanin bleaching: 1.5% of H2O2 (Sigma™) in PBS prepared freshly by adding 
15 ml of H2O2 into 285 ml of PBS. 
Target retrieval solution (10✕): 1:10 working solution prepared by adding 10 ml 
of DAKO (DAKO™) into 90 ml of deionised H2O adjusted to pH 6.0.  
Antigen retrieval instrument: 2100 Antigen Retriever (Aptum®) 
Blocking kit: Consisting of two solutions: solution A (Avidin) and B (Biotin) 
(Vector Laboratories). 
Blocking serum: Normal goat serum (Vector Laboratories) was stored at 4 °C 
and diluted in PBS with 10✕ casein solution (Vector Laboratories) to give a 10% 




Primary antibodies: All primary antibodies were provided by (Abcam), and were 
stored at -20 C, and diluted in 2% normal goat serum prior to use (Table 2.2).  
Table 2.2: Summary of primary antibodies and their conditions. 





















Secondary antibody: Made from goat anti-rabbit, biotinylated IgG (Vector 
Laboratories) was stored at 4 C and diluted 1:200 in 2% blocking serum. 
Avidin/Biotin peroxidase kit: VECTASTAIN® Avidin-biotin complex (ABC) kit 
stored at 4C and used according to the manufacturer’s instructions.  
Peroxidase Substrate Kit: 3,3’-dianimobenzidine (DAB) peroxidase (HRP) 
substrate kit (with Nickel) (VECTASTAIN®) stored at 4 C and used according to 
the manufacturer’s instructions.  
Mounting media: DPX mountant, a mixture of Distyrene, a Plasticiser, and 





2.1.9 Tissue culture  
Culture medium: RPMI-1640 culture medium (Lonza™) was used and 
supplemented with 10% foetal bovine serum (Lonza™), 1% L-Glutamine (200mM 
in 0.85% NaCl; Lonza™), 1% Penicillin/streptomycin (10kU/ml; Lonza™) and 0.4% 
D-glucose (45% solution, Sigma™) in order to maintain UM cell lines; the media 
was then stored at 4 C and warmed to 37 C prior to use. 
Trypsin-EDTA: 0.4% Trypsin-EDTA solution (Lonza™) was stored -20 C and 
warmed to 37 C prior to use. 
Dulbecco’s phosphate buffer saline (DPBS): 1✕ of DPBS that contains 
9.5 mM PO4 without Calcium and Magnesium, 500 ml (Lonza™). 
2.1.10 Western blot (WB) 
Lysis buffer: Radioimmunoprecipitation assay (RIPA) buffer is a ready-to-use 
reagent containing 150 mM of NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0. Stored at 4 C (Sigma™) 
Protease and phosphatase inhibitor: Ready-to-use cocktail stored at -20 C 
(Sigma-Aldrich™). 
Bradford protein assay: BCA protein assay Dye reagent (Biorad). 
Filter paper: Whatman® qualitative filter paper, grade 1 (Sigma™). 
Protein standard: Measuring 1 mg of BSA (Fisher Scientific™) and diluted with 
1 ml of deionised H2O. 
Spectrophotometer reader: Multiskan™ microplate photometer (Thermo 
Scientific™).  
Sample Loading buffer: NuPAGE® 4✕ lithium dodecyl sulphate (LDS) 
(Thermofisher™). 




Protein marker standard: Precision plus protein™, dual colour standards 
(Biorad). 
Running buffer: For 10✕ buffer, 250 mM Tris-base (30.3 g) (Fluorochem) with 
1.9M Glycine (Sigma™) (144 g) and 50 ml of 20% Sodium dodecyl sulphate (SDS) 
(Fisher Scientific™) with the volume being brought up to 1 L with H2O. 
Precast gel: 4-15% mini-PROTEAN® TGX™ precast protein gel (Biorad). 
Electrophoresis chamber: Mini-PROREAN® tetra vertical electrophoresis cell 
(Bio-rad) 
Transfer buffer: For 1✕ buffer, measuring 25 mM of Tris-base (Fluorochem) 
(3.03 g) with 192 mM Glycine (Sigma™) (14.4 g) and 20% of methanol (Fisher 
Scientific™) (200 ml), with the volume being brought up to 1 L with H2O. 
Filter papers: Whatman® gel blotting paper 30 ✕ 60 cm (Sigma Aldrich™). 
Polyvinylidene difluoride (PVDF) membrane: Immobilon-P PVDF membrane 
(Millipore™) 1 roll, 26.5 cm ✕ 3.75 m, 0.45 µm pore size. 
Semi-dry transfer system: Transblot® turbo™ transfer system (Biorad). 
PBST: 1✕ phosphate buffer saline (PBS) with 0.1% TWEEN® 20 (Fisher 
Scientific™). 
TBST: Supplied in a powder pouch containing (0.05M Tris-buffered saline 
(0.138M NaCl; 0.0027M KCl); 0.1% TWEEN® 20, pH 8.0) (Sigma™) and 
dissolved in 1 L of H2O. 
Blocking reagent: 5% non-fat dry milk diluted in PBST or TBST.  
Primary antibody: Anti-AMD1 polyclonal rabbit antibody was provided by 





Secondary antibody: Goat anti-rabbit IgG antibody conjugated to horseradish 
peroxidase (HRP) (Cell signalling Technology®) stored at -20 C and diluted to 
1:2000 with blocking solution prior to use.  
Stripping buffer: Restore™ western blot stripping buffer (Thermofisher 
Scientific™). 
Housekeeping antibody: Anti-beta tubulin antibody was provided by (Abcam), 
stored at -20 C and diluted 1:5000 with blocking solution prior to use.  
Detection reagent: Amersham™ Enhanced Chemiluminescence (ECL) western 
blotting detection reagent consist of two reagents, reagent A: luminol solution and 
reagent B: peroxide solution (GE healthcare). 
Detection instrument: ChemiDoc™ MP (Biorad) imaging System. 
2.1.11 CRISPR knockout 
Single-guide RNA (sgRNA): TrueGuide™ Modified Synthetic sgRNA for AMD1 
(ID: CRISPR843561_SGM), sequence (5’CCGACGCAAACCAAGGATCT’3) 
(Invitrogen™). 
Cas9 protein: GeneArt™ TrueCut™ Cas9 Protein v2, 1µg/µl, (Invitrogen™). 
Lipofectamine: Lipofectamine CRISPRMAX Transfection Kit (Invitrogen™) 
containing the following: 
• Lipofectamine CRISPRMAX Transfection reagent.  
• Lipofectamine™ Cas9 Plus™ reagent.  
Serum-free media: Opti-MEM™ I Reduced serum media (Gibco™).  
Full growth media: RPMI-1640 complete growth media (Lonza™).  
Genomic cleavage detection (GCD): GeneArt™ Genomic Cleavage Detection 
Kit, containing the following:  
• Cell lysis buffer, 1 ml.  




• AmpliTaq Gold™ 360 master mix, 1 ml.  
• Water, 1 ml.  
• Detection enzyme, 20 µl.  
• 10✕ Detection reaction buffer, 40 µl.  
• Control template and primers, 10 µl.  
 
2.1.12 MTT proliferation assay 
Tetrazolium reagent (Sigma™): (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) (MTT) was dissolved to 5mg/ml stock 
concentration in sterile PBS and stored at 4 C. 
Cell counter: TC20™ automated cell counter (Biorad). 















The laboratory work was done according to the health and safety measures. All 
Chemicals were used according to the Control of Substances Hazardous to 
Health (COSHH) guidelines.   
2.2.1 DNA isolation and purification  
2.2.1.1 Whole blood DNA isolation and purification  
Patients’ peripheral blood was collected into both purple 
ethylenediaminetetraacetic acid (EDTA) and light blue (sodium citrate) bottles 
provided by BD™ Vacutainer® to avoid blood clotting. Then, 200 l of protease 
was added into a 15 ml centrifuge tube and 2 ml of whole blood were added to 
the same tube. After shaking and mixing several times, 2.4 ml of Buffer AL was 
added to the tube with another shaking and mixing step for the tube. The mixture 
was then incubated at 70 C for 10 minutes. After incubation, 2 ml of absolute 
ethanol were added to the mixture with subsequent vigorous shaking and 
inverting. Following the addition of absolute ethanol, half of the mixture (around 
3 ml) was transferred to a QIAamp® midi column (provided by the kit) and the 
tube were centrifuged at 1850✕g for three minutes. The filtrate was then 
discarded. This prior step was repeated again with the remaining (around 3 ml) 
of the mixture, again with centrifuging at 1850✕g for three minutes and discarding 
of the filtrate. 2 ml of Buffer AW1 was then added to the column and centrifuged 
at 3,500✕g for one minute. 2 ml of Buffer AW2 was added to the column and 
centrifuged at 3,500✕g for 15 minutes; the tube was discarded and a new 15 ml 
collection tube was used. The column was incubated at 70 C for ten minutes to 
remove any ethanol residue. Finally, 300 l of Buffer AE was added to the column, 
incubated for five minutes at room temperature and centrifuged at 3,500✕g for 






2.2.1.2 DNA isolation and purification from frozen tumour 
tissue 
Frozen tumour tissue that been stored at -80 C was transferred into a 1.5 ml 
centrifuge tube and cut into small pieces using a sterile 32G needle (BD™). Then, 
180 l of Buffer ATL and 20 l of proteinase K were added to the sliced tumour 
tissue; and the sample was incubated overnight at 56 C to homogenise the solid 
tissue. After the incubation, 4 l of RNase A was added to the sample which was 
vortexed for 15 seconds and incubated at room temperature for one minute. 
Afterwards, 200 l of Buffer AL and 200 l absolute ethanol were added to the 
sample and vortexed. The whole mixture was then transferred to a DNeasy® mini 
spin column (provided by the kit) and was centrifuged at 6,000✕g for one minute. 
The column was then transferred to a new collection tube and 500 l of Buffer 
AW1 was added to the column and centrifuged at 6,000✕g for one minute; the 
flow-through was discarded. The column was transferred again to a new 
collection tube and 500 l of Buffer AW2 was added to the column and 
centrifuged at 16,100✕g for three minutes. The spin column was transferred after 
the centrifugation to a new-clean 1.5 ml collection tube and 200 l of Buffer AE 
was added and incubated at room temperature for one minute. The sample was 
finally centrifuged at 6,000✕g for one minute; the last step was repeated again 
in another new and clean 1.5 ml collection tube to have a higher quantity of DNA. 
2.2.1.3 Genomic DNA quantification and purity assessment  
The DNA extracted and purified from both the blood and frozen tumour samples 
was measured to establish its concentration in ng/l using UV-VIS 
spectrophotometry NanoDrop® ND-1000 (Fisher Scientific™). The DNA 
absorbance at a wavelength of 260 nm was used to determine the amount of 
nucleic acid in the solution. The determination of DNA purity was measured using 
the ratio of absorbance 260/280 nm, which indicates any protein contamination 
at 280 nm while the ratio of absorbance 260/230nm indicates any contamination 
from other organic compounds such as phenol, EDTA and carbohydrates, which 




To operate the NanoDrop® ND-1000, the lens was first wiped with Kimwipes® 
and 2 l of nuclease-free H2O was added to initialise the instrument. A similar 
volume of Buffer AE was added to serve as a blank solution. After that, 2 l of 
the DNA sample was applied into the cleaned lens and the concentration of DNA 
was recorded in ng/l, as well as the absorbance at both 260/280 nm and 
260/230 nm, where an acceptable range was considered to be between 1.8 and 
2. 
2.2.2 Sequencing analysis for GNAQ, GNA11, SF3B1, 
EIF1AX and TERTp 
2.2.2.1 Standard PCR  
Standard PCR was used to amplify a specific DNA fragment based on three main 
steps: denaturation, annealing and extension. Denaturation means the double 
strand DNA was separated at 95 C; annealing allows the primers to bind to a 
specific location on the DNA; where the annealing temperature varies between 
50 and 65 C. The final step of PCR is primer extension when the Taq polymerase 
together with dNTPs copies the original strand. These three steps are repeated 
across 25 to 30 cycles so as to produce an exponential amount of the specific 
product. Table 2.3 specifies each component and the amount that was added to 
attain 23 l of master mix. Then, 2 l of DNA (25 ng/l) was added to the sample 
in addition to a negative control to check for any contamination that may occur 
during the protocol. Afterwards, PCR reaction tubes were transferred to the 
thermocycler using either three-step PCR, touchdown PCR or modified 









Table 2.3: PCR master mix for GNAQ, GNA11, SF3B1, EIF1AX, and TERTp. 







Immunobuffer 10X 2.5l Immunobuffer 10X 2.5l 
MgCl2 50mM 0.75l MgCl2 50mM 0.75l 
dNTPs 50mM 0.5l dNTPs 50mM 0.5l 
Forward Primer 10pmol/l 1l Forward Primer 10pmol/l 1l 
Reverse Primer 10pmol/l 1l Reverse Primer 10pmol/l 1l 
Immolase 250U 0.5l Immolase 250U 0.5l 
H2O  16.75l H2O  16.75l 
Amount of DNA 50ng 2l Amount of DNA 50ng 2l 







Immunobuffer 10X 2.5l Immunobuffer 10X 2.5l 
MgCl2 50 mM 0.375l MgCl2 50mM 0.25l 
dNTPs 50 mM 0.5l dNTPs 50mM 0.5l 
Forward Primer 10pmol/l 1l Forward Primer 10pmol/l 1l 
Reverse Primer 10pmol/l 1l Reverse Primer 10pmol/l 1l 
Immolase 250U 0.5l Immolase 250U 0.5l 
H2O  17.125l H2O  17.25l 




Table 2.4: 3-step PCR conditions for GNAQ exon 4 
Stage Temperature Time Cycles Comment 
Activation 95 °C 10 min 1X  
Denature 95 °C 30 sec 
30X  Anneal 53 °C 30 sec 
Extension 72 °C 60 sec 
Hold 4 °C ∞   
Table 2.5: 3-step PCR conditions for GNAQ exon 5 
Stage Temperature Time Cycles Comment 
Activation 95 °C 10 min 1X  
Denature 95 °C 30 sec 
30X  Anneal 60 °C 30 sec 
Extension 72 °C 60 sec 
Hold 4 °C ∞   
Table 2.6: 3-Step PCR conditions for SF3B1 exon 14 and EIF1AX exon 1. 
Stage Temperature Time Cycles Comment 
Activation 95 °C 10 min 1X  
Denature 95 °C 30 sec 
30X  Anneal 61 °C 30 sec 
Extension 72 °C 90 sec 
Final 
extension 
72 °C 5 min 1X  




Table 2.7: Touchdown PCR conditions for EIF1AX exon 2 
Stage Temperature Time Cycles Comment 
Activation 95 °C 10 min 1X  




Anneal 64 °C 30 sec 
Extension 72 °C 90 sec 
Denature 95 °C 30 sec 
30X  Anneal 60 °C 30 sec 
Extension 72 °C 90 sec 
Final 
extension 
72 °C 5 min 1X  
Hold 4 °C ∞   
Table 2.8: Touchdown PCR conditions for TERTp. 
Stage Temperature Time Cycles Comment 
Activation 95 °C 10 min 1X  




Anneal 61 °C 30 sec 
Extension 72 °C 90 sec 
Denature 95 °C 30 sec 
30X  Anneal 56 °C 30 sec 
Extension 72 °C 90 sec 
Final 
extension 
72 °C 5 min 1X  




Table 2.9: Modified Touchdown PCR conditions for GNA11 exon 4. 
Stage Temperature Time Cycles Comment 
Activation 95 °C 10 min 1X  
Denature 95 °C 30 sec 
3X  Anneal 64 °C 30 sec 
Extension 72 °C 60 sec 
Denature 95 °C 30 sec 
3X 
 
Anneal 62 °C 30 sec  
Extension 72 °C 60 sec  
Denature 95 °C 30 sec 
3X 
 
Anneal 59 °C 30 sec  
Extension 72 °C 60 sec  
Denature 95 °C 30 sec 
30X  Anneal 56 °C 30 sec 
Extension 72 °C 60 sec 










Table 2.10: Modified Touchdown PCR for GNA11 exon 5. 
Stage Temperature Time Cycles Comment 
Activation 95 °C 10 min 1X  
Denature 95 °C 30 sec 
3X  Anneal 62 °C 30 sec 
Extension 72 °C 60 sec 
Denature 95 °C 30 sec 
3X 
 
Anneal 59 °C 30 sec  
Extension 72 °C 60 sec  
Denature 95 °C 30 sec 
3X 
 
Anneal 56 °C 30 sec  
Extension 72 °C 60 sec  
Denature 95 °C 30 sec 
30X  Anneal 53 °C 30 sec 
Extension 72 °C 60 sec 
Hold 4 °C ∞   
 
2.2.2.2 Agarose gel electrophoresis  
Agarose gel was prepared in 1.8% by dissolving 2.7 g of agarose into 150 ml of 
1X TAE buffer in a flask. The mixture was then heated in a microwave at high 
power to have a clear solution without any residue of undissolved agarose. The 
solution was cooled to be warm and 10 l of EtBr was added to the solution, 
which was then poured into the gel tray with a comb and left for around twenty 




removed and the gel tray was put into a gel tank prefilled with 1X TAE buffer. 
Then, 5 l of the sample was mixed with 1 l of 6✕ loading dye and pipetted into 
the well. Also, 5 l of 100 bp standard size marker was applied into the well to 
determine the actual size of the product. The power source was turn on at 120V 
for 40 minutes; and then the gel was visualised using a UV trans-illuminator gel 
documentation instrument (Biorad) and it was photographed. 
2.2.2.3 DNA sequencing  
DNA sequencing of the PCR products was achieved using the Sanger 
sequencing method. The aim of this procedure is to identify any insertion, 
deletion or substitution within the targeted gene. The DNA sequencing for all 
samples was carried out by the sequencing core facility at University of Sheffield, 
Medical School, UK. Briefly, the PCR product that was generated previously was 
added with one primer direction (forward or reverse) together with DNA 
polymerase and a fluorescent dideoxyribonucleotide triphosphate (ddNTPs) in a 
programmed thermocycler. The ddNTPs is similar to the dNTPs used for PCR 
except lacking the 3’ hydroxyl group that allows the nucleotide synthesis to 
terminate for the next nucleotide binding. These ddNTPs were randomly 
incorporated with the PCR product on different sizes. Thus, unique nucleotide 
sequences of A, T, C, G were generated based on the size of each incorporated 
ddNTPs after running the sample in a capillary gel which was then detected by 
laser camera using API 3730xl (Applied Biosystems™).  
2.2.2.4 Sequencing analysis  
FinchTV sequence analysis software (Geospiza) was used to visualise the 
generated sequence data. The sequences were screened in comparison to 
reference sequences for GNAQ, GNA11, SF3B1, EIF1AX and TERTp in order to 






2.2.3 Genomic-wide analysis using array-CGH 
2.2.3.1 Array-CGH concept  
This recently developed molecular cytogenetic technique is used to study whole 
gDNA to detect copy number aberrations (CNAs). The gDNA isolated from 
tumour and blood samples of the same patient were labelled with two different 
fluorescent dyes, Cyanine-5 (Cy5) and Cyanine-3 (Cy3). The Agilent™ labelling 
system uses random priming with exo-klenow DNA polymerase (enzymatic 
method) to label the gDNA; and this method uses Human Cot-1 DNA 
(Invitrogen™) to block the binding of repetitive elements prior to hybridisation. 
The labelled gDNA was then hybridised to a customised microarray slide 
specifically designed for UM (4✕180K probes) (Hammond et al., 2015), and 
focused on specific areas of the genome such as chromosomes 1, 3, 6, 8 and 
11. For example, the probes in chromosome 6 had a spacing mean of 14.5 kb 
compared to the off-shelf array that had a mean probe spacing of 36.6 kb. This 
customised microarray slide helps to uncover regions of chromosomal gain and 
loss which may contain oncogenes and tumour suppressor genes. The array was 
then washed and scanned, whereby the differential intensity of the fluorescent 
dyes at each probe served as a surrogate for the ratio of copy numbers of the 
probe sequence in the tumour versus the reference genome, as shown in Figure 
2.1 below. In the figure, the red spots specify a duplicate region in the genome 
of the patient’s DNA whereas the green spots specify the missing regions in the 
patient’s genome compared to the reference genome; consequently, 






Figure 2.1: Flowchart of the array-CGH protocol.  
The experiment starts by labelling and mixing Cy3-reference DNA with Cy5-tumour DNA 
and hybridising them on an Agilent™ slide. The slide then was incubated for 24 hours at 
65 °C followed by washing steps. Directly, the slide was scanned so as to produces an 
image that will be analysed using the software. The image of the microarray laser 
scanner was adapted from www.biocompare.com. 
 
2.2.3.2 Array-CGH protocol  
DNA digestion  
A gDNA input of between 0.5-1.0 g for each sample was required and the DNA 
digestion for both patient and control samples was carried out by adding two 
restriction enzymes, Alu1 and Rsa1, to digest the DNA into smaller strands of 
random size; a digestion master mix was prepared for nine samples (four 
reference DNA and four tumour DNA with one dead volume), as shown in Table 
2.11. Then, 5.8 l of the digestion master mix was added to each tube containing 
20.2 l of gDNA to make a total volume of 26 l. Tubes were transferred to a 




hours, then turned up to 65 C for 20 minutes. The samples were then held at 
4 C. 
Table 2.11: Digestion master mix components. 
Component Per tube (l) For 9 tubes (l) 
Nuclease-free H2O 2.0 18 
10X buffer 2.6 23.4 
Acetylated BSA (10 g/l) 0.2 1.8 
Alu1 (10 g/l) 0.5 4.5 
Rsa1 (10 g/l) 0.5 4.5 
Total 5.8 52.2 
 
DNA labelling and purification  
The digested gDNA was then labelled by two fluorescent dyes using the Agilent® 
labelling kit; 5 l of random primers were added to each reaction tube, the DNA 
was denatured and the primers were annealed at 95 C for three minutes. A total 
of 19 l of labelling master mix was made of the components illustrated in Table 
2.12 with 3 l of Cy3-dUTP (1.0 mM) being added to each control sample and a 
similar labelling master mix with 3 l of Cy5-dUTP (1.0 mM) being added to each 
tumour sample with an extra tube for dead volume; reaction tubes were then 
transferred to thermocycler and incubated for two hours at 37 C, then at 65 C 
for ten minutes. The samples were then held at 4 C. 
The labelled gDNA was purified using Amicon® 30 kDA filters that trapped the 
labelled gDNA based on their size. Firstly, the samples were centrifuged at 




TE buffer and transferred to Amicon® 30 kDA filters that were placed in a 1.5 ml 
collection tube and centrifuged at 14,000✕g for ten minutes. The flow-through 
was discarded and the wash repeated again by adding 480 l 1✕ TE buffer to 
each sample and centrifuged at 14,000✕g for ten minutes.  The flow-through and 
collection tubes were discarded, and the filter was inverted into a fresh collection 
tube and centrifuged at 1,000✕g for one minute. The final volume expected in 
the collection tube was around 21 l of clean, labelled DNA.  
Table 2.12: Components of labelling master mix. 
Component Per tube (l) For 5 tubes (l) 
5X buffer 10.0 50.0 
10X dNTPs 5.0 25.0 
Cy3-dUTP or Cy5-dUTP 3.0 15.0 
Exo-klenow fragment 1.0 5.0 
Total 19.0 95.0 
 
The total mixture volume of each sample was measured after purification, and 
the clean, labelled gDNA was used to quantifiy the concentrations of Cy3 at 550 
m and Cy5 at 650 nm using NanoDrop® with 1✕ TE buffer as a blank. These 
values were used to determine the yield of gDNA and the dye specific activity of 
the labelled DNA. The calculation methods for these parameters are shown 
below, with a normal range for the DNA yield being between 8 and 11 g, and 
the normal range for Cy3 and Cy5 specific activity varying between 20 and 35 
pmol/g, and 20 and 30 pmol/g, respectively. Samples within the optimum 








𝑫𝑵𝑨 𝒚𝒊𝒆𝒍𝒅 (𝝁𝒈) = 𝑫𝑵𝑨 𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏(𝝁𝒈/𝝁𝒍) × 𝒗𝒐𝒍𝒖𝒎𝒆(𝝁𝒍) 
 
Microarray hybridisation and assembly  
The optimum range of labelled gDNA for both the tumour and the reference were 
mixed together by taking 19.5 l of each of them and mixing in a 0.5 ml microfuge 
tube. The hybridisation master mix was prepared as shown in Table 2.13; and 71 
l of this master mix was added to each sample with an extra tube for dead 
volume. Then, the reaction tube was transferred to the thermocycler at 95 C for 
three minutes, and 37 C for thirty minutes. The samples were then immediately 
centrifuged at 16,100✕g for one minute to pull the mixture down. Finally, 100 l 
of the mixture was added to a gasket slide and sandwiched with the active side 
of the Agilent™ SurePrint® G3 human microarray slide 4✕180K and placed into 
a clamped chamber; the assembled slide chamber was placed into the rotator 
rack in the hybridisation oven set at 65 C and 20 rpm for 24 hours.  
Table 2.13: Components of the hybridisation master mix. 
Component Per tube (l) For 5 tubes (l) 
Human Cot-1 DNA 5.0 25.0 
10✕ Blocking agent 11.0 55.0 
2✕ Hi-RPM buffer 55.0 275.0 






Microarray washing and scanning  
Oligo array-CGH Wash Buffer 2 with a slide-staining dish 3 was pre-warmed at 
37 C overnight for optimal performance. A slide-staining dish 1 with an Oligo 
array-CGH wash buffer 1 was used to detach the array-gasket sandwich so as 
to obtain the array slide after being removed from the hybridisation oven. After 
that, the slide rack was placed into the slide dish with washing buffer 1 for five 
minutes at room temperature, and then into wash buffer 2 (37 C) for one minute, 
the slide rack was removed slowly in order to minimise the number of droplets 
left on the slides. The microarray slide was then scanned directly using an 
Agilent™ DNA Microarray scanner with Sure-scan® high-resolution technology. 
The scanned images were saved in a *.tiff format to evaluate any microarray 
damage or hybridisation artefacts.  
Array quality assessment  
The scanned images were analysed with Agilent™ feature extraction (FE) 
software (version 11.0.1.1). The software normalises the intensity of both 
fluorescents (red and green) and calculates the ratio for each probe. It expresses 
the probe intensity on a logarithmic scale (log ratio), which is then exported as a 
*.txt file. Then, the FE software produces an image processing quality control 
(QC) report that assess the reliability and reproducibility of the experiment, 
including the background noise (BGNoise), signal to noise ratio (SNR) of the 
array and the derivative log ratio spread (DLRS) (Table 2.14). The DLRS is the 
standard deviation of the log ratio difference between consecutive probes, where 
this algorithm estimates the noise from the array only. This ratio is necessary if 









Table 2.14: Quality control metric to assess the array performance. 
Background noise 
(BGNoise) 
This metric is calculated as the standard 
deviation of the signals on the negative control 




Signal to noise 
ratio (SNR) 
This metric calculates the ratio signal to noise 
ratio by dividing the signal intensity by BGNoise. 
It is used to distinguish the real signal from the 








This metric calculates the standard deviation of 
the log ratio differences between consecutive 
probes, so as to smooth the data and estimate 





Microarray analysis using Agilent Genomic Workbench 
Agilent Genomic Workbench (Version 7.0.4.0) analysis software with an array-
CGH licence obtained from http://www.genomics.agilent.com was used to 
analyse, visualise and detect any chromosomal aberration from the microarray 
profiles. The Agilent Genomic Workbench software requires a design file 
matched to the feature extraction files; thus, Agilent GEML-based (*.xml) array 
design files were imported prior to any FE data. The Agilent Feature Extraction 
(*.txt) data files from each experiment were imported into the software and a new 
experiment was created for the FE files. A centralisation algorithm was applied 
to centre the log ratio after applying preselected filters. Afterwards, the data were 
analysed by applying the Aberration Detection Method-2 (ADM-2) algorithm, 
which incorporates quality information for each log ratio value, with the threshold 
adjusted to 6.0, as recommended by the manufacture. In addition, fuzzy zero was 
used with ADM-2 to identify extended aberrant segments with a low mean ratio. 





2.2.4 Tissue culture  
The procedure was carried out under the class II biological hood. Cells were sub-
cultured when they reached 80-90% confluence by checking the flask under the 
inverted microscope (4✕ magnification) prior to the sub-culture for any noted 
changes. Afterwards, culture media was carefully removed, and cells were 
washed twice with DPBS. Trypsin-EDTA was added (2 ml for T25 and 4 ml for 
T75) and cells were incubated for 1-3 minutes in a humidified incubator at 37 C 
and 5% CO2. Then, cells were monitored under an inverted microscope until the 
cells detached. The trypsinisation was then stopped by adding an equivalent 
volume of fresh culture media. The cell suspension was mixed up and down 
several times to recover any residual cells. Afterwards, the cell suspension was 
transferred into a 15 ml conical tube and spun down at 1,000✕g for five minutes 
at room temperature and the supernatant was discarded. Cells were then 
resuspended in a fresh culture media and were split into an appropriate number 
of flasks. The new flasks were then incubated in the humidified incubator at 37 C 
and 5% CO2. 
2.2.5 Immunochemistry  
Cultured cells fixed on glass slides were used for Immunocytochemistry (ICC) 
while FFPE sections (0.45 m thickness) were used for immunohistochemistry 
(IHC) experiments. These experiments were done at the histopathology core 
facility laboratory at The University of Sheffield Medical School with help of (lead 
technician Mrs. Maggie Glover).  
This experiment used a modified Avidin-Biotin-Peroxidase complex (ABC) 
method, as described by Hsu et al. (1981). A melanin removal step was also 
used, because the UM tissue sections were highly melanotic. This step was 
adapted from Sheffield Teaching Hospital, UK.  
To summarise the experiment, tissue sections were processed to remove the 
melanin because UM sections were highly melanotic. This served to expose the 
relevant antigen and to block any non-specific antibody binding by incubating 




sections were then incubated overnight with the specific primary antibody at its 
optimum dilution. The next day, these tissue sections were washed and a 
relevant biotinylated secondary antibody was added, which binds to the FC 
portion of any bound primary antibody. Then, a colorimetric reaction was used in 
forms of complexes of avidin molecules linked to an enzyme reporter system and 
bound to the secondary antibody.  
Negative control tissues were incubated in the absence of the primary antibody; 
however, both positive control tissues and test tissue samples were incubated 
with primary antibody diluted in blocking serum, and these controls were included 
in every run.  
2.2.5.1 Antibody optimisation  
All antibodies used in this study were optimised prior to staining. The 
manufacturer’s recommended conditions were used as a guide, with a range of 
antibody dilutions. In this study, three independent observers (Mohammed 
Alfawaz (MA), Ahmad Alshammari (AA) and Dr. Karen Sisley (KS)) assessed the 
specific antibody staining with minimal non-specific background staining, and 
identified the optimal antibody conditions, as summarised earlier in Table 2.2.  
2.2.5.2 Formalin fixed paraffin-embedded (FFPE) tissue 
preparation  
The FFPE tissues were cut into pieces 0.45 m thick and were collected onto 
positively charged slides that had been dried in an oven overnight at 37 C. The 
tissue cutting and preparation was conducted by Mrs. Maggie Glover.  
Prior to staining, tissue sections were dewaxed by placing them into two 
consecutive xylenes for ten minutes and five minutes, respectively. They were 
then hydrated in a graded series of EtOH (100% EtOH for five minutes, 100% 
EtOH for five minutes, and 95% EtOH for three minutes). The endogenous 
peroxidase was then blocked by placing the tissue sections in a freshly prepared 
3% H2O2/methanol for thirty minutes at room temperature, which then 




2.2.5.3 Melanin bleaching  
The melanin removal or bleaching was done by preparing 1.5% of H2O2/PBS into 
a staining dish and the tissue sections were incubated in the dark overnight at 
room temperature. The next day, the tissue sections were washed for five 
minutes under running tap water.    
2.2.5.4 Antigen retrieval treatment for IHC 
Antigen retrieval treatment was an essential step for the preparation of FFPE 
tissue sections for staining. It was carried out by immersing the tissue sections in 
target retrieval solution, so as to detach the protein cross-links cluster formed 
from formalin particles on the tissues’ antigen binding sites. The complexity of 
this cluster increased in the tissue with longer formalin embedding time; therefore, 
inadequate antigen retrieval treatment risks leaving some clusters that may 
shield the antigen binding site from antibody attachment. Many antigen retrieval 
methods are available in the laboratory. The method applied in this study started 
by immersing the tissue sections in a pressure cooker in 0.01M DAKO (PH 6.0) 
for twenty minutes. Then, the tissue sections were allowed to cool down in the 
same buffer for approximately two hours. This was followed by rinsing with PBST 
and washing twice for five minutes, before the remaining staining steps were 
completed.  
2.2.5.5 Slide preparation of ICC 
For the ICC, glass slides were cleaned by immersion in absolute methanol for at 
least 24 hours at room temperature; left to dry under a laminar flow hood for at 
least ten minutes and arranged in a single layer in a sterile petri dish (145/20 mm). 
Cells were trypsinised and dissociated from the flask as described in Section 
2.2.4, and then suspended in fresh media and counted (12,000 cells per 0.5 ml). 
After counting, cells were seeded onto a glass slide that been put onto the petri 
dish lengthways to ensure even distribution. The petri dish was carefully placed 
in the humidifier incubator at 37 C and 5% CO2 for three hours to allow the cells 
to adhere to the slide. Then, 30 ml of prewarmed fresh media was added to the 




washed four times with PBS and slides were immersed and fixed by incubation 
on 1:1 ice-cold methanol/acetone for ten minutes. The slides were left to dry 
under the laminar flow hood for ten minutes before use or stored at -20 C until 
needed. The cells on slides were then treated similar to tissue sections for 
blocking, antibody incubation, counter staining and mounting. 
2.2.5.6 Blocking and primary antibody incubation for 
immunochemistry  
An ImmEdge™ hydrophobic Barrier Pen was used to outline the relevant area of 
tissue sections. Afterwards, a blocking step was conducted using an avidin/biotin 
blocking kit. Solution A from the kit was applied to the tissue sections and 
incubated for fifteen minutes at room temperature. This was then washed by 
PBST and then the solution B from the blocking kit was applied to the tissue 
sections, which were again washed subsequently by PBST. In addition, another 
blocking step was done by applying 10% of appropriate blocking serum (normal 
goat serum and casein) before incubation at room temperature for thirty minutes. 
These blocking steps were done to eliminate any non-specific binding 
substances present in the tissue sections. After incubation for thirty minutes with 
10% blocking serum, it was removed by tapping the slide only. Next, the primary 
antibody was diluted in 2% blocking serum and applied to the positive control and 
the tissue sections. In addition, 2% blocking serum (without antibody) was 
applied to the negative control. These slides were subsequently incubated 
overnight at 4 C. 
2.2.5.7 Secondary antibody incubation and immunoreactivity 
The next day, the tissue sections were rinsed and washed twice in PBST for five 
minutes each, and the appropriate Secondary Antibody (goat anti-rabbit, 
Biotinylated IgG), diluted in 2% blocking serum, was applied on all tissue sections 
and incubated at room temperature for one hour. During the secondary antibody 
incubation, ABC reagent was prepared and allowed to stand at room temperature 
for thirty minutes. The tissue sections were then rinsed and washed twice with 
PBST for five minutes each, and the ABC reagent was applied and incubated at 




twice with PBST for five minutes each. During the last wash, the peroxidase 
enzyme substrate (DAB) was freshly prepared, and this was then applied on the 
tissue sections after the last wash and incubated at room temperature for up to 
ten minutes so as to allow the stain to develop until the desired brown stain 
intensity was reached. At this point, the reaction was stopped by washing the 
stained tissue sections with deionised H2O.   
2.2.5.8 Counterstaining and mounting  
The tissue sections were washed under running tap water for five minutes, and 
these sections were counterstained in Gill’s haematoxylin for 60 seconds and 
washed again under running tap water for five minutes. The stained tissue 
sections were then dehydrated with graded series of EtOH (70%, 90%, 95%, 100% 
and 100%) for three minutes each. Afterwards, the stained sections were cleared 
two consecutive incubations in xylene for three minutes each, under a fume hood. 
Finally, while the stained sections were wet with xylene, they were mounted with 
DPX and covered with 22 mm ✕ 32 mm coverslips, and then allowed to dry 
overnight at room temperature. The ICC was analysed using a light microscope 
at 40✕ magnification, while the tissue slides were examined using an automated 
slide scanner (3DHISTECH, Panoramic 250 Flash III). 
2.2.6 Western blot  
2.2.6.1 Protein extraction  
To get a cell lysate, cells were grown in a T75 flask until they reached a 
confluence of 80-90% and being checked under the inverted microscope (4✕ 
magnification) prior to the extraction for any noted changes. This procedure was 
carried out under a class II biological hood. The media in the T75 flask was 
carefully removed and discarded and cells were washed twice with 4 ml of DPBS. 
4 ml of Trypsin-EDTA was added to the flask and incubated in a humidified 
incubator at 37 C and 5% CO2 for 1-3 minutes in order to detach the cells from 
the surface of the flask. The cells were checked under 4✕ magnification to check 
whether any cells remained adherent to the flask’s wall. The trypsinisation was 




suspension was mixed up and down several times to recover any residual cells. 
Afterwards, the cell suspension was transferred into a 15 ml conical tube and 
spun down at 1000✕g for five minutes at room temperature and the supernatant 
was discarded. Next, 5 ml of ice-cold DPBS was added to the cells and mixed up 
and down several times to wash them before being centrifuged at 1,000✕g for 
five minutes at 4 C. This step was repeated twice. After the supernatant was 
discarded, 100 µl of (RIPA) lysis buffer and 1 µl of protease and phosphatase 
inhibitor was freshly prepared (1% final concentration v/v) and were added to the 
cell pellet. The cells were then transferred to a 1.5 ml micro-centrifuge tube and 
incubated on ice for thirty minutes, the tube was vortexed every ten minutes. The 
cells were passed through a 20G needle up and down ten times. Then, the extract 
was centrifuged at 16,000✕g for twenty minutes at 4 C and the supernatant was 
transferred and aliquoted to a new 1.5 ml micro-centrifuges and stored at -80 C. 
2.2.6.2 Protein quantification  
To measure the protein concentration, the stock protein standards were prepared 
by measuring 1 mg of BSA and dissolving it into 1 ml of deionised water. The dye 
reagent was prepared by diluting 1:4 with deionised water and the mixture was 
filtered using Whatman® grade 1 filter paper. 200 µl of the filtered dye reagent 
was applied into the 96-well plate. Then, six protein standards were prepared in 
serial dilutions (1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, 0.0625 mg/ml and 
0.0312 mg/ml). The cell lysate was aliquoted and diluted 1:50 and 1:100 to have 
an accurate reading. Afterwards, 10 µl of each standard and the test sample were 
added to the filtered dye reagent in triplicate, after vortexing each sample. All 
wells were mixed up and down several times and incubated at room temperature 
for between five minutes to one hour. The absorbance was measured using the 
spectrophotometer at 595 nm. The background absorbance was eliminated to 
calculate the actual protein concentration by subtracting the control well 
absorbance, which has only 200 µl of filtered dye reagent, from each test well 
absorbance. The results of the absorbances reading were then plotted using 
GraphPad Prism 8 (GraphPad Software, Inc.) to produce a standard curve and 





Figure 2.2: The standard curve for the Biorad protein assay. 
This shows the protein standard plotted against the O.D.595 nm with R2: 0.9909. 
 
2.2.6.3 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
After the determination of the protein concentration, the protein extracts were 
diluted with RIPA buffer to reach 30 µg of protein in a new 1.5 ml micro-centrifuge 
tube. Then, 10 µl of 4✕ sample loading buffer and 4 µl of 10✕ reducing agent 
were added to the micro-centrifuge tube and the volume was made up to 40 µl 
using RIPA buffer. The samples were then heated at 95 °C for five minutes and 
put on ice to cool down. Samples were loaded together with the protein marker 
standard onto the precast gel that the tank been filled with 1✕ running buffer 
(100 ml of 10✕ running buffer with 900 ml of H2O) and run at 80 V for thirty 
minutes for the stacking gel and the voltage was increased to 120 V for the 




2.2.6.4 Protein blotting and visualisation  
When the SDS-PAGE run finished, the precast gel was disassembled and blotted 
onto the ethanol-activated PVDF membrane using two types of transfer system: 
semi-dry and wet transfer. The semi-dry transfer was done by making a sandwich 
that consisted of, from cathode to anode: filter papers merged into the transfer 
buffer, the SDS-PAGE gel, the PVDF membrane and more filter papers (Figure 
2.3 A). Then, the sandwich was placed onto the Transblot® turbo™ transfer 
system and run for seven minutes at 25 V. Wet transfer, meanwhile, entailed 
making a sandwich that consisted of, from anode to cathode: sponge, filter 
papers, PVDF membrane, SDS-PAGE gel, filter papers and sponge (Figure 2.3 
B). After the sandwich had been assembled and no bubbles were present, the 
tank was filled with cold transfer buffer and with an ice pack, to keep the transfer 





Figure 2.3: The transfer methods for protein from SDS-PAGE gel to PVDF 
membrane. 
 (A) the semi-dry transfer method showing the assembly of filter papers, SDS-PAGE gel 
and PVDF membrane from cathode to anode; (B) the wet transfer method, showing the 
assembly of sponge, filter papers, SDS-PAGE gel, PVDF membrane, filter papers and 
sponge from cathode to anode for the protein transfer. The direction of transfer is the 






The membrane was washed twice with H2O and blocked with blocking reagent 
(5% non-fat dry milk in PBST or TBST) for one hour. Afterwards, the primary 
antibody (AMD1) was diluted 1:300 in blocking reagent and added to the 
membrane and incubated overnight at 4 C. The next day, the membrane was 
washed using PBST or TBST three times for five minutes each. Then, the HRP-
conjugated secondary antibody was diluted 1:2000 using the blocking reagent 
and added to the membrane and incubated for one hour at room temperature. 
The membrane was washed three times for five minutes each using PBST or 
TBST. All incubations and washings were carried out on an orbital shaker. For 
the detection of protein bands, Amersham™ ECL detection reagent was used on 
the membrane according to the manufacturer’s instructions. The membrane 
imaging was done using the ChemiDoc™ MP imaging system to visualise the 
detected bands. 
To incubate the same membrane with the housekeeping antibody (Beta-tubulin), 
the membrane was washed three times with PBST or TBST for ten minutes each 
and the membrane was incubated with stripping buffer for fifteen minutes 
followed by another three times washing for thirty minutes. Then, the membrane 
was blocked using the blocking reagent, as mentioned above. The housekeeping 
antibody was diluted 1:5000 using the blocking reagent and added to the 
membrane and incubated overnight at 4 C. The membrane was treated again 










2.2.7 AMD1 knockout using CRISPR 
2.2.7.1 CRISPR overview  
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a new 
technology that allows human DNA to be edited, creating stable deletions, 
insertions and modifications. Basically, the CRISPR technology consists of two 
main components: single guide RNA (sgRNA) and CRIPSR associated 
endonuclease protein (Cas9), which together form a ribonucleoprotein (RNP) 
complex.  
SgRNA consists of two segments CRISPR RNA (crRNA) and transactivating 
CRISPR RNA (tracrRNA) (Jinek et al., 2012). The crRNA contains a specific 
sequence of twenty nucleotides that complements the targeted DNA and 
preceded by three nucleotides (5’NGG’3 sequence) called protospacer adjacent 
motif (PAM) sequence (Sternberg et al., 2014). The PAM sequence is a short 
nucleotide sequence that is important to be present in the targeted DNA to allow 
the Cas9 to bind at the specific DNA site. In addition, the tracrRNA activates and 
guide the Cas9 protein to bind with the foreign DNA. Thus, the sgRNA basically 
bind to its target site and the Cas9 nuclease specifically cleaves the targeted 
DNA about three nucleotides after the PAM sequence. 
2.2.7.2 Design the sgRNA 
The sgRNA was designed using ThermoFisher™ software and was confirmed 
using the Synthego™ website (http://www.synthego.com) for any mismatches 
(Figure 2.4). The target has a minimal target-mismatch and is located in a 
common exon with high activity, based on Doneach et al.’s (2016) scoring system.  
In addition, the forward primer 5’ACAGTATGGCCGGCGACATT’3 and reverse 
5’GGAGAGCGGCCATGTCCA’3 were designed using ThermoFisher™ software 
around the area of knockout area to detect the efficiency of the transfection using 





Figure 2.4: The area where gRNA binds and Cas9 will cut.  
The light blue (GGG) is PAM sequence and the green is the designed gRNA together 
with trcrRNA. The orange arrow indicates where the site of cut that will happen. Image 
















Figure 2.5: The FASTA file for AMD1 exon 1. 
The figure shows the gRNA (green) with PAM sequence (GGG) (pink) and the forward 




2.2.7.3 Lipid-based transfection of synthetic gRNA and Cas9 
nuclease 
UM cells were seeded, the day before transfection, into a 24-well plate at 90,000 
cells per 0.5 ml of RPMI-1640 media and the plate was incubated in a humidified 
incubator at 37 C and 5% CO2. The next day, cells were checked under an 
inverted microscope (4✕ magnification) to ensure cell adherence. Then, the lipid 
complexing was prepared for transfection together with the negative control, as 
shown in Table 2.15. It is important to note that the Cas9 plus reagent was added 
last. These components were mixed by vortexing and then incubated on ice. In 
another sterile tube, 7.5 µl of lipofectamine CRISPRMAX transfection reagent 
was diluted onto 125 µl of Opti-MEM™I Reduced serum media and then mixed 
and incubated at room temperature for one minute.  
Table 2.15: gRNA complex with Cas9 in Opti-MEM I media. 
Volumes are for 2 reactions 
Tube 1 





Opti-MEM™I Reduced serum media 50 µl 50 µl 








Cas9 Plus Reagent 5.0 µl 5.0 µl 
 
Afterwards, 50 µl of the diluted CRISPRMAX reagent was added to both tubes 
and mixed up and down without any vortexing and incubated at room 
temperature for fifteen minutes to allow the CRISPR/lipid complexes to form. 




plate was then incubated in a humidified incubator 37 °C and 5% CO2 for 48 
hours. 
2.2.7.4 Genomic cleavage detection (GCD) assay 
Cell harvesting and lysis 
The cells that had been transfected with CRISPR were harvested after 48 hours. 
The plate was examined under an inverted microscope to note any changes. 
Then, the media was aspirated and 100 µl of Trypsin-EDTA was added to each 
well. The plate was incubated in the humidified incubator at 37 °C and 5% CO2 
for three minutes and the cells were checked under the inverted microscope to 
confirm that all cells were detached. Immediately, 500 µl of RPMI-1640 media 
was added to each well to stop the trypsinisation reaction, and the cells were 
transferred to a new 1.5 ml micro-centrifuge tube. The tubes were centrifuged at 
1,000Xg for ten minutes and the supernatant was discarded.  Next, 50 µl of lysis 
buffer and 2 µl of protein degrader were mixed by vortexing and added to each 
tube, the suspension was transferred to a new 0.2 ml PCR and these steps were 
performed for all wells. The PCR tubes were then placed onto the thermocycler 
for cell lysis, as described in Table 2.16. 
Table 2.16: Thermocycler condition for cell lysis. 
Temperature Time 
68 °C 15 min 
95 °C 10 min 







PCR amplification  
The samples were vortexed briefly after the lysis, and the PCR reaction was 
prepared as described in Table 2.17. Then, the tubes were mixed and spun down 
using a mini-centrifuge after adding all components; and the tubes were placed 
onto a thermocycler for PCR amplification, as shown in Table 2.18. The PCR 
products were then examined on 1.8% agarose gel at 120 V for 45 minutes, as 
previously described in Section 2.2.2. 
Table 2.17: components for CRISPR PCR amplification.  
 Samples 






Cell Lysate - 2 µl 2 µl 
Target specific 
10µM F and R 
GCD primers 
1 µl 






360 master mix 
25 µl 25 µl 25 µl 
Water 24 µl 22 µl 22 µl 










Table 2.18: Thermocycler conditions for CRISPR PCR amplification. 
Stage Temperature Time Cycles Comment 
Activation 95 °C 10 min 1 X  




Anneal 61 °C 30 sec 
Extension 72 °C 30 sec 
Denature 95 °C 30 sec 
30 X  Anneal 58 °C 30 sec 
Extension 72 °C 30 sec 
Final 
extension 
72 °C 5 min 1 X  
Hold 4 °C ∞ 1 X  
 
Mismatch digestion  
The mismatch digestion was bone by denaturing and randomly re-annealing the 
PCR fragments so that some strands for edited samples would anneal with wild-
type strands to form a heterogenous DNA duplex. Accordingly, 2 µl of the PCR 
product was added together with 1 µl of 10X detection reaction buffer and the 
volume was made up to 10 µl by nuclease-free H2O in new 0.2 ml PCR tubes. 
The solution was mixed and spun-down using a mini-centrifuge; and the tubes 
were added onto the thermocycle (Table 2.19). After the program was completed, 
1 µl of detection enzyme was added to all transfected samples and placed onto 
the thermocycler at 37 °C for one hour. Finally, the samples were examined again 
using 1.8% agarose gel, as previously described in Section 2.2.2, so as to detect 
the digestion site and determine the knock-out efficiency using Image Lab 





Table 2.19: Thermocycler condition for mismatch digestion. 
Stage Temperature Time Ramp rate 
°C temp/time 
1 95 °C 5 min 3 °C 
2 85 °C 0 sec 2 °C 
3 25 °C 0 sec 0.1 °C/1 second 


















2.2.8 MTT proliferation assay  
This experiment was kindly done by Mr. Ahamd Alshammari, a fellow PhD 
student in the RTRG group, as he was very experienced with the methodology 
and time limitations were restrictive. This procedure done to find any differences 
in proliferation between the normal cell lines and the knocked-out cell lines. Cells 
were therefore dissociated with trypsin, as described in Section 2.2.4. Cells were 
counted by adding an equivalent volume of cell suspension to trypan blue which 
was then applied to the cell counter to count the live compared to dead cell. Then, 
cells were seeded at a density of 2000 cells in 100 μl of culture media to each 
well of a 96-well plate and incubated in a humidified incubator at 37 C and 5% 
CO2. Control wells contained only the media without cells being added. Four 
plates were set up to measure the cells’ growth over four days at 24-hour intervals.   
At each time point, 10 μl of MTT solution (5 mg/ml dissolved in PBS) was added 
to each well, including the controls, and the plate was returned to the humidified 
incubator at 37 C and 5% CO2 for three hours. Media were then removed and 
replaced with 100 μl DMSO and incubated again for thirty minutes. A Multiskan™ 
spectrophotometer reader was used to measure the optical density at 570 nm. 
The background absorbance was eliminated to estimate the MTT activity by 
subtracting the control well absorbance from each test well absorbance. The MTT 
activity was then plotted against the time points and standard error of the mean 
(SEM) was calculated using GraphPad® Prism software (Version 8). Using the 
software, the exponential growth equation was used to calculate the doubling 

















Chapter 3: Correlation of chromosome 













3.1 Introduction  
UMs are considered relatively free of high genetic instability unlike other solid 
tumours (Cross et al., 2003). Different technologies such as FISH, CGH, 
microsatellite analysis (MSA), multiple ligation-dependent probe amplification 
(MLPA) and array-CGH have been used to study the well-known changes of 
chromosomes 1, 3, 6 and 8 (Horsman and White, 1993, Gordon et al., 1993, 
Speicher et al., 1994, Sisley et al., 2000, Kilic et al., 2006, Aronow et al., 2012, 
Cassoux et al., 2014). These studies however provided different frequencies for 
these changes and can still underestimate the effect on the prognosis of UM.  
Thus, the prognosis of UM is still usually linked to changes in chromosomes 3 
and 8, whilst deletion of chromosome 1p is an indicator for poor outcome, but the 
relevance of chromosome 6 aberrations to the prognosis of UM remains unclear 
(Prescher et al., 1996, Sisley et al., 1997, White et al., 1998, Sisley et al., 2000, 
Aalto et al., 2001, Damato, 2010, Hammond et al., 2015, Jager et al., 2018, Shain 
et al., 2019). A large study conducted by Cassoux et al., analysed 338 UM 
samples using array-CGH to confirm that monosomy 3 with chromosome 8q gain 
presents the highest risk, but the role of chromosome 6 in prognosis was not 
described (Cassoux et al., 2014). Other studies have also confirmed that the 
greatest risk is associated to monosomy 3 and more copies of 8q gain (Sisley et 
al., 1997, White et al., 1998, Singh et al., 2009). Most investigations, including 
those using array-CGH, did not specifically emphasize the role of chromosome 6 
alterations in UM cases (Damato et al., 2007, Damato, 2010, Hammond et al., 
2015).  
Chromosome 6 alterations in UM usually occur as a gain of chromosome 6p with 
disomy 3, or as an isochromosome 6p associated with monosomy 3, gain of 
chromosome 8q and loss of chromosome 1p (Aalto et al., 2001, Naus et al., 2001, 
Hausler et al., 2005, Kilic et al., 2005). Additionally, UM patients with gain of 
chromosome 6p only are proposed to be in a separate group associated with 
disomy 3 and having a better prognosis (Prescher et al., 1995, Sisley et al., 1997, 
Parrella et al., 1999, Landreville et al., 2008, Robertson et al., 2017, Drabarek et 




were however likely to be underestimated, depending on the methodology used, 
and more recent studies have confirmed these observations (Cassoux et al., 
2014, Hammond et al., 2015). Although few articles specifically mention the loss 
of chromosome 6q, there may be an association with metastasis; the majority of 
studies emphasize the relationship of gain of chromosome 6p with good 
prognosis (Prescher et al., 1990, Speicher et al., 1994, White et al., 1998, Sisley 
et al., 2000, Kilic et al., 2006, Damato et al., 2007). 
More recently, mutational analysis has identified specific mutations in UM, as 
mentioned in section 1.3.7, but only SF3B1 and EFI1AX are relevant for the 
prognosis of UM (Harbour et al., 2013, Martin et al., 2013, Dono et al., 2014, 
Koopmans et al., 2014a, Luscan et al., 2015, Yavuzyigitoglu et al., 2016b). As 
most mutational changes found in UM do not clearly indicate the way UM patients 
are going to behave, reliance is still placed on chromosomal imbalances 
(Robertson et al., 2017, Shields et al., 2019). Therefore, it is necessary to further 
study known mutations together with chromosomal aberrations, and to seek to 
identify specific genes on these prognostically relevant chromosomes.  
The use of a high-resolution array-CGH specifically designed for UM found 
detailed information about CNA of commonly altered chromosomes such as 
chromosomes 1, 3, 6 and 8 (Hammond et al., 2015). This specifically designed 
array-CGH for UM has more probes on the commonly altered chromosomes, 
including chromosome 6. More detailed information about chromosome 6 allows 
a more in-depth analysis of the relevant changes and relationship to other 
alterations of UM. Previously, the array designed by Dr. Hammond had been 
used to analyse 137 cases (Alshammari, 2017). In this study, a further 22 UM 
cases were analysed by array-CGH to consolidate the dataset, and mutational 





3.2 Results  
3.2.1 Sample collection and preparation  
The mutation analysis for 28 primary UMs for SF3B1 exon 14, EIF1AX exons 1 
and 2 and TERTp was initially worked up and performed. In addition, two samples, 
MEL-312 and MEL-352, were included in the series as internal controls, because 
they were metastatic samples from another organ to the eye. Therefore, the total 
collection was 30 samples for mutational analysis screening. Later in this study, 
mutational screening been done for GNAQ and GNA11 exons 4 and 5 for the 
same series, however, MEL-672 did not have sufficient DNA and there was not 
enough frozen tissue to re-extract the DNA.  
3.2.2 PCR and gel electrophoresis optimisation  
The PCR was optimised for SF3B1 exon 14, EIF1AX exons 1 and 2 and TERTp 
using different methods such as gradient, touchdown and modified touchdown. 
However, GNAQ and GNA11 exons 4 and 5 had been previously optimised within 
the research group as a 3-step PCR and modified touchdown. To optimise, a 
single blood DNA sample was used to determine the optimum annealing 
temperature for all of these genes and was then used for all UM patients’ DNA 
samples. After optimising all genes, gel electrophoresis was used to visualise the 
amplified product under UV-light, as mentioned in section 2.2.2. All amplified 
products were then sent for Sanger sequencing to obtain detailed information 
and screening for any mutations in those genes. 
3.2.3 Mutational screening for GNAQ and GNA11  
The main mutation for these genes occurs in exon 5; a single substitution 
mutation that changes the amino acid glutamine (Q) into a different amino acid. 
Sanger sequencing was therefore done on 27 primary UMs and 2 metastases to 





Figure 3.1: The Sanger sequencing chromatogram and gel electrophoresis 
for GNAQ exon 5. 
(A) The chromatogram for the wild type (WT) of GNAQ exon 5, (B) the red arrow 
shows a homozygous substitution mutation of A>C, (C) shows the heterozygous 
mutation from A>T and (D) shows the substitution mutation of two nucleotides AA>TT 
which is the same amino acid change p.Q209L. (E) The gel electrophoresis of GNAQ 






Figure 3.2: The Sanger sequencing chromatogram and gel electrophoresis of 
GNA11 exon 5. 
(A) shows the WT sequence of GNA11 exon 5 while in (B) the red arrow shows the 
substitution mutation of A>T. (C) The gel image of GNA11 exon 5 that indicate all bands 
are amplified on 147bp. 
It was found that about 93% of the samples (25 of 27) had mutations in either 
GNAQ or GNA11 exon 5. However, two samples, MEL-665 and MEL-491, did 
not harbour any mutations for GNAQ or GNA11 exons 4 and 5, as well as the 
control metastatic samples (MEL-312 and MEL-352). In this series, the most 
common mutation for GNAQ and GNA11 exon 5 was a single substitution 
mutation of the amino acid (Q) to leucine (L) [c.626A>T;p.Q209L].  GNA11 exon 
5 was mutated at around 52% (14 of 27 cases), and around 15% of cases (4 of 
27) had mutations of GNAQ exon 5.  Additionally, GNAQ exon 5 had a single 




[c.626A>C;p.Q209P], which accounted for around 26% (7 out of 27) of all UM 
samples. However, no mutations were detected for exon 4 of GNAQ and GNA11 
after analysing 27 primary UM samples. 
3.2.4 Mutational screening for SF3B1, EIF1AX and 
TERTp 
The main mutation of the SF3B1 gene in patients with UM usually occurs in exon 
14, with a single substitution mutation that changes the amino acid arginine (R) 
into a different amino acid. Thus, mutational analysis using Sanger sequencing 
was done on 30 frozen tissue samples (Figure 3.3).  
 
Figure 3.3: The Sanger sequencing chromatogram and gel electrophoresis of 
SF3B1 exon 14.  
(A) shows the WT sequence of SF3B1 exon 14, (B) the red arrow shows the point 
mutation of G>A, (C) another point mutation for the same nucleotide from C>T and (D) 






It was found that four out of the 30 analysed samples had a mutation in SF3B1 
exon 14. Two UM samples had a mutation that changes the amino acid (R) into 
cysteine (C) [c.1873C>T;p.R625C], while the other two had a mutation at the 
same spot that changes the amino acid (R) into histidine (H) 
[c.1874G>A;p.R625H]. The results of SF3B1 exon accounts for around 14%, 
which was consistent with previous reports (Harbour et al., 2013, Furney et al., 
2013, Dono et al., 2014).  
Mutations in the EIF1AX gene vary in different codons, but they occur mostly at 
codons 2, 3 and 4. Therefore, two exons were used to screen for genetic 
mutations in the 30 tissue samples. In EIF1AX exon 1, only one sample was 
found to be mutated at the same hotspot that usually had a mutation, but it had 






Figure 3.4: The Sanger sequencing chromatogram and gel electrophoresis for 
EIF1AX exon 1.  
(A) The chromatogram shows the WT EIF1AX exon 1 and the red arrow indicates the 
area in which six nucleotides (TCTTGC) were inserted as shown further in (B). (C) The 
gel image of EIF1AX exon 1 that indicated all bands were amplified at 320 bp. 
 
Besides EIF1AX exon 1, a mutation in codon 3, lysine (K) to glutamate (E), was 
found in only one sample with the EIF1AX exon 2, where the mutation was 
[c.7A>G;p.K3E] (Figure 3.5), which was similar to previous findings (Martin et al., 
2013, Dono et al., 2014). However, the frequencies detected in the samples 
analysed were about 7% which is broadly consistent with the frequencies in other 





Figure 3.5: The Sanger sequencing chromatogram and gel electrophoresis for 
EIF1AX exon 2.  
(A) The chromatogram shows the WT of EIF1AX exon 2 and (B) the red arrow shows 
the point mutation of A>G. (C) The gel image of EIF1AX exon 2 indicates that all bands 
were amplified at 406bp.  
 
For the TERTp gene, however, after amplifying and analysing 30 tissue samples, 
there was no mutation detected, which previous reports concluded that mutations 
of TERTp gene are rarely found in UM cells (Dono et al., 2014, Koopmans et al., 
2014a). Thus, the results of all mutational screening are presented in Table 3.1, 




Table 3.1: The mutational analysis for the 30 UM patient samples and the distribution of mutations. 
 
WT= Wild type; MEL-672 did not have enough DNA for GNAQ and GNA11 mutation analysis; MEL-665 and MEL-491 did not harbour any mutations for all 
tested genes; MEL-312 and MEL-352 were metastatic from another organ to the eye and used as internal controls. 
Sample Number GNAQ Ex.4 GNAQ Ex.5 GNA11 Ex.4 GNA11 Ex.5 SF3B1 Ex.14 EIF1AX Ex.1 EIF1AX Ex.2 TERTp 
MEL-672 FAILED FAILED FAILED FAILED WT WT WT WT
MEL-671 WT A>T (Q209L) WT WT WT WT WT WT
MEL-670 WT WT WT A>T (Q209L) WT WT WT WT
MEL-667 WT WT WT A>T (Q209L) WT WT WT WT
MEL-665 WT WT WT WT WT WT WT WT
MEL-664 WT AA>TT (Q209L) WT WT WT WT WT WT
MEL-663 WT WT WT A>T (Q209L) WT WT WT WT
MEL-661 WT A>T (Q209L) WT WT WT WT WT WT
MEL-660 WT WT WT A>T (Q209L) WT WT WT WT
MEL-659 WT WT WT A>T (Q209L) C>T (R625C) WT WT WT
MEL-658 WT WT WT A>T (Q209L) WT WT A>G (K3E) WT
MEL-657 WT WT WT A>T (Q209L) WT WT WT WT
MEL-656 WT WT WT A>T (Q209L) WT WT WT WT
MEL-655 WT WT WT A>T (Q209L) WT WT WT WT
MEL-654 WT WT WT A>T (Q209L) WT WT WT WT
MEL-652 WT A>C (Q209P) WT WT WT Ins (CTCTTG) WT WT
MEL-530 WT WT WT A>T (Q209L) C>T (R625C) WT WT WT
MEL-529 WT A>C (Q209P) WT WT WT WT WT WT
MEL-528 WT WT WT A>T (Q209L) WT WT WT WT
MEL-524 WT A>C (Q209P) WT WT WT WT WT WT
MEL-523 WT A>C (Q209P) WT WT WT WT WT WT
MEL-522 WT A>C (Q209P) WT WT WT WT WT WT
MEL-521 WT A>T (Q209L) WT WT WT WT WT WT
MEL-492 WT A>C (Q209P) WT WT WT WT WT WT
MEL-491 WT WT WT WT WT WT WT WT
MEL-489 WT A>C (Q209P) WT WT G>A (R625H) WT WT WT
MEL-486 WT WT WT A>T (Q209L) G>A (R625H) WT WT WT
MEL-485 WT WT WT A>T (Q209L) WT WT WT WT
MEL-352 WT WT WT WT WT WT WT WT





This study was carried out with array-CGH for 22 primary UM tissue samples to 
investigate any somatic copy number aberrations (SCNAs), as mentioned in 
section 2.2.3. The gDNA were extracted from primary UM frozen tissue and 
compared with the patient’s normal blood gDNA as a reference DNA. The tumour 
and blood gDNA were labelled and hybridised onto a microarray slide comprised 
of 180,000 probes, which was specially designed for UM by Dr. David Hammond, 
Rare Tumour Research Group (RTRG), University of Sheffield. Subsequently, 
the analysis of these samples was done with Agilent Genomic Workbench 
software (Version 7.0.4.0) using ADM-2 algorithm, as shown in Table 3.2. The 
ADM-2 algorithm was based on the probes distribution with a threshold of 6.0. 
The software is validated log ratio using ADM-2 algorithm by having the log ratio 
of amplification of >0.6 and the deletion of ≤–1.0, which appeared as red and 
green, respectively. 
Table 3.2: Default Agilent Genomic Workbench software preferences. 
Genome hg18 
Aberration algorithm ADM-2 (Threshold: 6.0, Fuzzy zero: ON) 
GC correction ON (window size: 2kb) 
Centralisation (legacy) OFF 
Combine replicates (IntraArray) ON 
Array level filter NONE 
Aberration filter DefaultAberrationFilter_V2 
 
After analysing the 22 primary UM tissue samples, the results showed that partial 
or complete gain of chromosome 8q arm was the most detected chromosomal 
aberration, which varied between 60% to 80% depending on whether the 
aberration was a complete or partial gain of chromosome 8q (Figure 3.6). Also, 
monosomy 3 was found in around 60% of all primary UM tissue samples. The 
gain of the chromosome 6p and deletion 6q appeared in around 45% and 32%, 
respectively. Additionally, aberrations in chromosome 1, such as the loss of 1p 
and gain of 1q, were found in around 20% of all samples. However, aberrations 
in other chromosomes did not reach 10%, except for the chromosome 16p and 





Figure 3.6: Total percentage of gain and loss in each chromosome among all the primary UM tissue samples.  
The red shows the percentage of gain among the chromosomes, showing chromosome 8q to be the most common gain. The green shows the 
losses, with a loss in chromosome 3 being the most common. Images output from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 





In addition, these results demonstrated that there was a correlation between the 
complete loss of chromosome 3, the amplification of chromosome 8q and the 
gain of chromosome 6p and loss of 6q (Figure 3.7). The amplification of 6p only 
was found in around 13% of the samples while the gain of chromosome 6p and 
deletion of 6q (isochromosome 6p) was found in around 32% of the samples. 
Furthermore, all the samples with amplification of chromosome 6p only had 
disomy 3 and no gain in chromosome 8q arm.  
There were only two of the samples found to have an isochromosome 6p together 
with a complete loss of chromosome 3 and gain of chromosome 8q. However, 
four samples showed isochromosome 6p, but they had disomy 3. Only one 
sample that showed isochromosome 6p that have partial deletion of chromosome 





Figure 3.7: Comparison between chromosomes 3, 8 and 6 deletion and amplification. 
The figure shows all UM patient samples that were analysed using array-CGH to compare the gain and loss among the most recurrent aberrations 
in these chromosomes. The green shows losses while red shows gains. Images output from Agilent Genomic Workbench software v7.0.4.0. The 




In addition, one primary UM had greater instability with a much higher level of 
SCNA, and one sample had no SCNA at all (Figure 3.8). The UM that did not 
show any apparent chromosomal aberrations, also had no mutations amongst 
the genes that were screened.  
 
Figure 3.8: Array-CGH for the highest and lowest number of chromosomal 
aberrations. 
Array-CGH ideogram showing: (A) a sample with a deletion of chromosomes 1p, 3, 4, 7, 
10, 12, 15 and 21, and a gain of chromosomes 8, 18, 20 and 22; (B) a sample with no 
chromosomal aberration detected. 
Images output from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 






3.2.5 The correlation between genetic mutations and 
chromosomal aberrations 
An observation comparison between the samples that were found to have 
mutations for genes SF3B1 and EIF1AX and chromosomal aberrations showed 
some interesting results. Specifically, all the samples that had a mutated SF3B1 
gene showed no deletion in chromosome 3; however, all of those mutated 
samples showed an isochromosome 6p (Figure 3.9). Furthermore, two samples 
showed partial gain of chromosome 8q and one sample showed a complete 
amplification of chromosome 8q, while only one sample (MEL-659) did not have 
any alterations for chromosome 8q. In addition, three out of four samples showed 





Figure 3.9: Ideograms for the samples with a mutation of the for SF3B1 
gene.  
All samples showed a gain of chromosome 6p and loss of 6q (isochromosome 6p). (A) 
The sample showed a partial loss of the bottom chromosome 11q and a complete loss 
of chromosome 19. (B) The sample showed a gain in part of chromosome 8q, partial 
loss of 11q and loss of the chromosome 16q arm. (C) The ideogram shows a partial gain 
of chromosome 8q with a focal deletion in chromosome 11q. (D) The ideogram shows a 
gain in chromosome 8q, deletion in chromosome 1p, and a partial deletion of 
chromosomes 4q, 15q 16q, and 19p arm.  
Images output from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 




In addition to the SF3B1 mutations and their correlation with chromosome 6, 
chromosomal aberrations in the EIF1AX gene showed that they consisted mainly 




Figure 3.10: Ideograms for the samples with a mutated EIF1AX gene. 
(A) shows a gain in chromosome 6p arm and similarly (B) shows the same amplification 
of chromosome 6p but there is an addition of a small amplification in the chromosome 
11q.  
Images output from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 







3.3 Discussion  
The assessment of prognosis by genetic markers for UM has gone through 
different stages of cytogenetic and genetic classifications over the last two 
decades, such as the chromosomal classification (Prescher et al., 1996, Sisley 
et al., 1997), and genetic profiling class 1 and 2 (Onken et al., 2004). However, 
some high-risk UM patients are still misclassified (Field et al., 2016).  
In this study, the SCNA for chromosome 8q (80%) was the most frequent 
chromosome change, followed by monosomy 3 (60%) and abnormalities of 
chromosome 6 (45%). These findings together with other chromosomal 
aberrations of chromosomes 1, 16, and 19 are in agreement with previous reports 
(Sisley et al., 1990, Sisley et al., 1997, Aalto et al., 2001, Kilic et al., 2005, 
Cassoux et al., 2014, Hammond et al., 2015). Activating mutations in UM are in 
GNAQ and GNA11 which occur in a mutually exclusive pattern (Van Raamsdonk 
et al., 2009, Van Raamsdonk et al., 2010, Sisley et al., 2011) and are found in 
around 90% of UM cases that are considered  as early progression events of UM 
(Onken et al., 2008, Bauer et al., 2009). In this current study about 93% of the 
UM samples (25 out 27) were GNAQ and GNA11 mutated, similar to previously 
mentioned reports. One UM sample had no SCNA and also had no mutations. 
However, these mutations are not predictive of UM prognosis in comparison to 
monosomy 3, gain of chromosome 8q and gain of chromosome 6p. Mutations of 
potential relevance to prognosis (SF3B1 and EIF1AX) were also broadly 
consistent with previous studies (Furney et al., 2013, Harbour et al., 2013, Martin 
et al., 2013, Dono et al., 2014, Yavuzyigitoglu et al., 2016b).   
3.3.1 Correlation of genetic changes with clinical 
features  
The involvement of ciliary body is usually indicative of a worse prognosis in UM 
(Kaliki et al., 2015). Monosomy 3 is consistently reported to correlate with ciliary 
body melanomas (Prescher et al., 1996, Scholes et al., 2003, Kilic et al., 2005, 
Damato et al., 2007). Furthermore, mutation frequencies for SF3B1 and EIF1AX 




(Table 3.3). Overall mutated SF3B1 is more often correlated with ciliary body 
than EIF1AX mutations.  
Table 3.3: Mutation frequency for both SF3B1 and EIF1AX and ciliary body. 






(Harbour et al., 2013) 102 19 (18.6%) 47% 
(Martin et al., 2013) 111 23 (20.7%) 48% 









(Martin et al., 2013) 111 20 (18%) 30% 
(Yavuzyigitoglu et al., 2016a) 133 28 (21%) 
4 (14.4%) 
 
3.3.2 What other correlations do mutations of SF3B1 
and EIF1AX have? 
The data in this study indicates that most of the cases of disomy 3 (except for 
MEL- 491) also had gain of 6p and mutations in either SF3B1 or EIF1AX.  Disomy 
3 and gain of 6p are well known to be associated with favourable prognosis 
(Parrella et al., 1999). Correlation between chromosome 6 alterations and 
mutations of SF3B1 and EIF1AX have also been related previously 
(Yavuzyigitoglu et al., 2016a). They found that the mutant samples with SF3B1 
harboured a gain of chromosome 6p in more than 80% of their samples, while 
the loss of chromosome 6q was found in about half of the analysed samples. 
They also mentioned that the role of SF3B1 mutations in disomy 3 may have a 
late metastatic risk; and the findings have also been confirmed in more recent 
investigations (Robertson et al., 2017). The results of this current study can 
qualify these observations to some extent. Specifically, cases of UM with disomy 
3 could be further subdivided on the basis of mutational profile and the type of 




had mutations of E1FAX (MEL-652 and MEL-658, Figure 3.10).  Disomy 3 cases 
with both gain of chromosome 6p and loss of 6q (or an effective isochromosome 
6p) had mutations of SF3B1. Given that SF3B1 mutations may indicate later risk 
of metastasis, it is interesting that isochromosome 6p occurs as a potentially later 
event for monosomy 3 cases after gain of chromosome 8q, and the findings were 
again seen for cases in Figure 3.9. The findings of this study are slightly at odds 
with those of Yavuzyigitoglu et al. (2016a), which did not indicate whether there 
is a risk of metastasis or not for UM patients with mutated SF3B1 and EIF1AX,  
because there was no long follow-up for those UM patients in this series. 
A limited number of research studies found deletions on chromosome 11 in UM 
cells (Sisley et al., 2000, Kilic et al., 2006, White et al., 2006, Drabarek et al., 
2019). Sisley et al. (2000) highlighted that aberrations of chromosome 6 and 
deletion of chromosome 11q25 in UM are frequent and associated with choroid 
origin. Moreover, it was found recently that isochromosome 6p is associated with 
gain of chromosome 8q and loss of chromosome 11q in UM (Drabarek et al., 
2019). Remarkably, this study showed that focal deletion of chromosome 11q 
appeared in 3 out of 22 UM samples and were correlated with mutations in SF3B1 
and isochromosome 6p (Figure 3.9). This outcome emphasises that loss of 
chromosome 11q may follow isochromosome 6p in indicating the prognosis of 
UM.  
3.3.3 What is the sequence of genetic progression for 
UM? 
Robertson et al. (2017) clustered the metastatic risk of UM into four distinctive 
groups based on the chromosomal aberrations and concurrent mutations of 
EIF1AX and SF3B1. However, they only considered the role of gain of 
chromosome 6p with disomy 3 and gain of chromosome 8q with the low and 
medium risk of metastasis, respectively. In addition, they proposed a sequence 
of events for UM metastasis which it started with monosomy 3, BAP1 mutation, 
whole genome doubling and then gain of chromosome 8q.  
However, based on Figure 3.7, this study is proposing an alternative sequence 




mutations in GNAQ and GNA11, which one case of this current study did not 
have a mutation of these genes. Therefore, an alternative pathway may exist, or 
more likely as has been reported previously mutations in other genes affecting 
the same pathway may be implicated such as CYSTLR2 or PLCB4. 2) UM cases 
subdivide on the basis of whether they acquire monosomy 3 or not. 3A) For those 
UM with monosomy 3 the sequence follows as reported in the literature, gain of 
chromosome 8q, loss of chromosome 1p and isochromosome 6p, and no 
mutations of SF3B1 or EIF1AX. 3B) UM cases with disomy 3 and gain of 
chromosome 6p only, then have mutations of EIF1AX. Alternatively, disomy 3 
cases can acquire isochromosome 6p followed by mutations in SF3B1 and then 
partial or complete gain of chromosome 8q. This proposed sequence of events 
highlights the importance of the isochromosome 6p in the prognosis of UM, which 
was ignored by previous reports. In a recent report by Drabarek and colleagues, 
they supported the proposed idea that isochromosome 6p should be in a 
separate group with disomy 3 (Drabarek et al., 2019).  
In summary, this study performed 22 array-CGH analyses out of 28 cases in 
order to obtain a detailed information about the SCNA of UM. The study applied 
mutational screening for SF3B1, EIF1AX and TERTp. The finding of apparent 
associations between mutated SF3B1 and EIF1AX genes with different 
abnormalities in chromosome 6 is an interesting, and qualified some of the 
subgrouping of UM and has potential implications for prognosis. Thus, detailed 
analysis of chromosome 6 aberrations may help identify candidate genes of 



















Chapter 4: Analysis of chromosome 6 
using array-CGH to determine candidate 











4.1 Introduction  
In the previous chapter, the correlation between chromosome 6 aberrations with 
other genetic alterations in UM was examined. This correlation highlighted the 
importance of the recurrent abnormalities of chromosome 6 in UM such as gain 
of chromosome 6p only and isochromosome 6p, and how the relationship with 
other chromosomes and mutational changes can be used to further subdivide 
UM.  
Beroukhim et al., meanwhile found most cancers that have SCNA of whole 
chromosome length or arm length are more frequent than the focal SCNA 
(Beroukhim et al., 2010). They also highlighted that focal SCNA were more likely 
to have a potential target gene or genes than whole arm SCNA in different 
cancers, as it is easier to identify those potential genes if the region of aberration 
is smaller. Previous studies using SKY, CGH or bacterial artificial chromosome 
(BAC) arrays may have missed these small focal SCNA due to the limited 
resolution (Speicher et al., 1994, Naus et al., 2001, Sisley et al., 2006, Ehlers et 
al., 2008). Therefore, the goal of using a high-resolution array-CGH technology 
is to accurately access these SCNAs, that may help identifying the location of 
novel oncogenes or tumour suppressor genes. For instance, the use of high-
resolution array-CGH helped to identify novel target genes in different tumours 
such as breast and ovarian cancers, lymphomas and oral cancer (Cheng et al., 
2004, Tagawa et al., 2005, Nakaya et al., 2007).  
Although there have been some attempts to identify focal SCNA on the 
chromosome arms implicated in UM (Parrella et al., 2001, Tschentscher et al., 
2001, Cross et al., 2003, Parrella et al., 2003, Ehlers and Harbour, 2005, Ehlers 
et al., 2005, van Gils et al., 2008), for the most part these have failed to identify 
strong candidates. For example, candidate genes within the recurrent abnormal 
chromosomes, such as gain of chromosome 8q, have been investigated in UM, 
with mixed results (Parrella et al., 2001, Ehlers and Harbour, 2005, Ehlers et al., 
2005). It was found that the amplification of the c-Myc oncogene is associated 
with gain of chromosome 8q, however, the expression of c-Myc was significantly 




al., 1992, Parrella et al., 2001). Furthermore, UM frequently have monosomy of 
chromosome 3 and mutations of BAP1 located on chromosome 3p21 are of 
relevance (Harbour et al., 2010). More specifically, the nuclear protein expression 
of BAP1 in UM is considered as a poor prognostic marker using IHC with 
monosomy 3 rather than the mutational status of BAP1, mainly because there is 
not a specific point mutation to correlate with the prognosis (Koopmans et al., 
2014b, van de Nes et al., 2016, Field et al., 2018). There are also indications that 
other genes on chromosome 3 may also be implicated, but there was no strong 
association with the prognosis of UM (Tschentscher et al., 2001, Parrella et al., 
2003, van Gils et al., 2008). As previously stated, the impact of chromosome 6 
aberrations and relationships to prognosis of UM is unclear. There have been a 
number of studies proposing target genes on chromosome 6 (Millikin et al., 1991, 
Hijiya et al., 1994, Ogino et al., 2006, Gautrey et al., 2015, Shukla et al., 2015), 
but no strong candidates have immerged for UM. A recent study however found 
that there is a gene called PHF10 in the aberrant chromosome 6q27 may have a 
role in UM development and adhesion (Anbunathan et al., 2019).  
Previously, a specifically designed high-resolution array-CGH for UM by 
(Hammond et al., 2015), and used to study 137 UM samples as part of combined 
research group and PhD project (Alshammari, 2017). Preliminary analysis using 
Nexus software (BioDiscovery) identified regions on chromosome 6p and 6q that 
were preferentially amplified and deleted, respectively. Those genes on 
chromosome 6p are forkhead box Q1 (FOXQ1) and phenylalanyl-tRNA 
synthetase (FARS2); and the gene implicated on chromosome 6q is 
adenosylmethionine decarboxylase 1 (AMD1). An attempt to validate the 
expression of these target genes using IHC, was performed by Alshammari 
(2017), the results however were inconclusive, and the sample size was too small 
to validate.  
In this study, array-CGH was previously performed on 22 UM (Figure 3.6). This 
series acted as a small independent cohort and was analysed separately using 
different software, to confirm and validate the previous observations, and IHC 





4.2 Results  
4.2.1 The classification of chromosome 6 
Of 22 cases of UM, 10 had abnormalities of chromosome 6 in this study (section 
3.2.4, Figure 3.7). This study, as mentioned in the previous chapter, had 10 UM 
samples with aberrations of chromosome 6 out of 22 and that counts for around 
45%, which is similar to previous reports (Prescher et al., 1996, Sisley et al., 1997, 
White et al., 1998, Sisley et al., 2000, Aalto et al., 2001, Damato et al., 2010).  
The aberrations of chromosome 6 were divided into 4 groups, independent of 
other common aberrations, such as loss of chromosome 1p, monosomy 3 and 
gain of chromosome 8q (Figure 4.1).  
The first group consists of just chromosome 6p amplification located from 6pter-
6p12.1, creating chromosome 6p trisomy, as represented in Figure 4.1 A. There 
were three UM samples which accounted for around 14% of the total samples is 
in the first group. The second group consists of the gain of chromosome 6p arm 
and the loss of chromosome 6q arm (isochromosome 6p or pseudo-
isochromosome 6p). The aberrations of this group consist of gains spanning from 
6pter-6p12.1 and losses spanning from 6qter-6q12 with a breakpoint near the 
centromere (Figure 4.1 B). There were seven UM samples which accounted for 
around 32% of the total samples in this group. The third group covers any other 
aberrations for chromosome 6, either the gain or loss of the whole chromosome 
or any other partial deletions or gains (Figure 4.1 C). However, the collection of 
this present study did not have any UM to fit in this group. The fourth group covers 
examples where there were no aberrations of chromosome 6, as represented in 






Figure 4.1: Groups classification of different gain and loss of chromosome 
6 in UM. 
The figure shows the types of aberrations of chromosome 6. The grey line in the middle 
represents zero line with gains on the right and losses on the left. (A) The amplification 
of chromosome 6p only, (B) gain of chromosome 6p and loss of 6q to form 
(isochromosome 6p). (C) An example of different aberrations of chromosome 6 either 
loss of whole chromosome 6 as seen or any other type of aberrations that does not follow 
groups (A) or (B). This image was adapted from Dr. Alshammari’s thesis (Alshammari, 
2017). (D) The last group where no changes in chromosome 6 was identified. Images 
output for ideograms were taken from Agilent Genomic Workbench software v7.0.4.0. 
The ADM-2 algorithm was used to detect all the aberrations. 
 
4.2.2 Confirmation of target genes on chromosome 6 
In Dr. Alshammari’s thesis, three potential genes FOXQ1, FARS2 and AMD1 
were implicated in UM (Alshammari, 2017). Therefore, this study tried to confirm 
these findings by analysing a small independent cohort (22 UM samples). 
Furthermore, as the Nexus software (BioDiscovery) was unavailable, a different 
software (Agilent Genomic Workbench software) was used to independently 
confirm previous findings.  
After searching for genes in group 1 (the gain of chromosome 6p only) (Figure 
4.2 A), the results showed that the Agilent Genomic Workbench software called 
for more than 100 genes within the region. These genes included the FARS2 
gene that located at chr.6p25.1, but not FOXQ1. In addition, for group 2 
(isochromosome 6p) more than 200 genes were called, but neither FARS2 nor 
FOXQ1 were called. However, it been found in group 2 that AMD1 gene was 




software did not call for FOXQ1, which is located on 6p25.3, for the samples 
within groups 1 and 2, due to limitation in statistical tools, it was manually pointed 
out for illustration (Figure 4.2 C). Even though this outcome is not as reliable, the 
information broadly confirmed the previous findings which suggest these target 









Figure 4.2: A high-resolution view of the gain of chromosome 6p and 6q 
with gene view. 
The figure shows a high-resolution view with gene view in the Agilent Workbench 
Software shows the red dots represent the gain where the green dots represent the loss, 
the black dots in the middle represent the log ratio that been calculated for gain and loss 
(≤–0.1->0.6). (A) The call for FARS2 gene in the gain of chromosome 6p only, evident 
in three UM samples. (B) The software also the call for AMD1 gene in the 
isochromosome 6p, evident in seven UM samples. However, (C) the FOXQ1 gene was 
pointed out for the isochromosome 6p, evident in seven UM samples. Images output for 
ideograms were taken from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 





4.2.3 Clinicopathological details for UM data set 
In the next stage, a larger group of UM samples were studied for the expression 
of the target genes. For this part of the study, a total of 80 UM had both array-
CGH analyses and also available tissue sections for IHC. Unfortunately, the 
clinicopathological data was not always complete for all patients, due to patients 
becoming lost to follow up,  
Thus, the range of UM patients’ ages in this series between 13 and 89 years old 
with a median of 62, and the UM tumours’ mean diameter ranged between 7.58 
to 22.15 mm. In addition, the follow-up of this series ranged between 6 to 187 
months with an average of 54.6 months. The follow up of patients with liver 
metastasis ranged between 7 to 131 months with an average of 33.5 months. In 
addition, the metastasis to other organs for UM patients other than liver ranged 
between 11 and 123 months with an average of 49.1 months. Three UM patients 
were lost to follow-up where there were 10 patients died from unknown causes 
and 4 patients died as a result of unrelated causes. Based on this clinical data, 
about 54% of male in this study have UM while female was accounted for around 
46% of the cases. Thus, there were no statistical differences between males and 
females for the tumour distribution (Figure 4.3 A).  
About 62% of the UM tumours in this study were choroid, and these correlated 
with good prognosis while 19% involved the ciliary body and were associated 
with poor prognosis (Figure 4.3 B). The inclusion of choroidal and ciliary body 
tumours comprised about 17% of all cases and were also associated with poor 
prognosis. One sample involved a tumour encompassing the choroid, ciliary body 
and iris. Besides the location, more than 45% of the tumours had a spindle cell, 
10% epithelioid and around 44% have mixed cells morphology (Figure 4.3 C). A 
spindle cells morphology was correlated with better prognosis than epithelioid 
and mixed cells. The survival for UM patients with metastasis to the liver or other 
organs was lower compared to other UM patients (Figure 4.3 D). About 40% of 
patients with UM in this series had a low survival, while more than 17% died for 
reason unrelated to metastasis. About 33% of patients had metastasis to the liver 




The outcomes of this current clinical data for UM patients based on sex, age, 
tumour location, cell type and metastasis were comparable with previous 
reported studies (Mooy and De Jong, 1996, Kujala et al., 2003, Kaliki et al., 2015). 
In addition, this suggest that the clinicopathological data for UM in this study is 
representative, and this study has no selection bias.  
 
Figure 4.3: Kaplan-Meier analysis of patients’ mortality based on sex, 
tumour location and cell type. 
The Kaplan-Meier analysis of UM showed that the X-axis represents the survival time in 
months and the Y-axis represents the percentage of survival among UM patients. (A) 
Survival based on sex, indicating no significant difference. (B) Survival based on the 
location of the UM with ciliary body and ciliary body/choroid location having a poor 
prognosis than a choroid location only. (C) Survival according to cell type: a spindle cell 
types suggest longer survival than epithelioid and mixed cell morphology. (D) Survival 
according to metastasis: liver metastasis was associated with a poor prognosis, while 
metastasis to other organs showed a slightly better than liver metastasis. The unrelated 
deaths for UM patients were considered a separate event unrelated to UM prognosis. 







4.2.3.1 Survival analysis based on chromosome 6 groups  
In respect to the groups that were used to categorise chromosome 6 alterations 
group 1 (gain of chromosome 6p arm only) comprised 20% of the series (16 out 
80), group 2 (isochromosome 6p) around 21% (17 out of 80), group 3 (different 
chromosome 6 aberrations) around 19% (15 out of 80) and group 4 (no 
chromosome 6 changes) comprised 40% (32 out of 80) of all cases.  
Survival analysis was undertaken to establish the effect of different chromosome 
6 alterations and relationship to prognosis. For overall survival, group 1 have a 
better survival than the other three groups. Nonetheless, group 2 had poorer 
survival rate than group 1, but better than groups 3 and 4 (Figure 4.4 A).  
Liver metastasis is the most common site for UM patient compared to other 
organs and it showed the worst overall survival, as seen earlier in Figure 4.3 D. 
The comparison of chromosome 6 groups in respect to liver metastasis identified 
that those with group 1 aberrations survived longer than in those other groups, 
while group 3 showed the worst survival rate. (Figure 4.4 B). This is because 
there are differences based on the type of chromosome 6 changes only and 
excluded the classical chromosomal aberrations in UM such as monosomy 3, 





Figure 4.4: Kaplan-Meier analysis of the patients’ mortality based on 
groups of altered chromosome 6.  
The Kaplan-Meier analysis showed the X-axis represents the survival time in months 
and the Y-axis represents the percentage of survival among UM patients. (A) The overall 
survival rate based on chromosome 6 aberrations, showing that group 1 (gain of 
chromosome 6p only) had a better prognosis than groups 3 and 4 (different aberration 
on chromosome 6 and no chromosome 6 aberrations, respectively). Group 2 
(isochromosome 6p) showed an intermediate survival rate in comparison with other 
groups. (B) In respect to liver metastasis only, group 1 had a better survival than other 
groups while group 3 had the worst survival, (n=56). These graphs were designed and 





4.2.4 IHC analysis for FOXQ1, FARS2 and AMD1 
The total number of samples used for IHC in this study is 80 FFPE UM tissue 
sections, all with matched array-CGH to compare the subdivision of changes of 
chromosome 6 with survival. This number expanded the pilot study initially 
undertaken in Dr. Alshammari’s thesis where there was also an issue with 
melanin pigmentation. 
In this study, the optimisation of FOXQ1, FARS2 and AMD1 antibodies was done 
to determine the optimum staining of those proteins. Additionally, a melanin 
removal step was applied to enhance the quality of the tissue and decrease the 
melanin pigmentation in the UM tissues by incubating the slides with 1.5% of 
H2O2/PBS in the dark for overnight. This melanin removal technique was 
recommended by the Department of Pathology at Hallamshire Teaching Hospital 
in Sheffield UK, and enhanced the results. There was another issue with staining 
the negative controls at the beginning of the optimisation, however, it showed 
positive results although no primary antibody was added to those negative 
controls. To overcome this issue, an extra blocking step using an avidin/biotin 
blocking kit was added to the protocol before the addition of the primary antibody 
to avoid any endogenous biotin or non-specific binding present in the section. 
This was done to increase the specificity of the IHC and to eliminate any false 
positives appearing in the negative controls and UM tissue sections.  
All of these tissue sections were treated the same with an addition of negative 
and positive control to each run to confirm findings. The slides were scanned 
using the automated slide scanner (Panoramic 350 Flash III) and were then 
stored as a digital image. The image was then viewed and analysed using 
Qupath software (Version 0.1.0) to visualise and zoom in and out for the whole 
of the tissue section.  
4.2.4.1 Allred scoring system  
The scoring system that was used for analysing those tissue sections was the 
Allred scoring system (Allred et al., 1998, Harvey et al., 1999). This system is a 




from 0 to 5 and an intensity score of the staining (IS) is from 0 to 3, which are 
added together to form a total score (PS+IS=TS) out of 8. The PS score is a six 
score system 0= no stain, 1=≤0.1% of the cells stained, 2=≤10% of the cells 
stained, 3=≤33% of the cells stained, 4=≤67% of the cells stained and 5= all the 
cells stained. The IS score depends on the four categories 0=no stain, 1= weak, 
2= moderate and 3= high stain. This scoring is applied for both the nucleus and 
the cytoplasm. The assessment of this scoring system was by three independent 
scorers (MA, AA) and overview by KS, which show a good agreement for the 
outcome. Finally, all data were analysed using non-parametric one-way 
ANNOVA with SEM by GraphPad Prism (Version 8.0) software as a statistical 
calculation for the scoring of the analysed tissue.  
4.2.4.2 FOXQ1 protein expression  
The FOXQ1 protein is mainly expressed in the nucleus. Thus, the IHC was used 
to assess the FOXQ1 protein expression in 80 UM tissue sections. The control 
used to evaluate the protein expression of FOXQ1 was normal kidney tissue. 
This showed that there was staining in the renal tubules which varies between 
moderate and strong, in comparison with the negative normal kidney tissue 
control (Figure 4.5 A and B).  
The 80 UM FFPE tissue sections were stained with FOXQ1 antibody with the 
extent of staining varying from one tissue to another, regardless to their groups. 
Some UM tissue samples showed low nuclear staining for FOXQ1 protein, as 
seen in Figure 4.5 C. In addition, some of the UM samples had a high FOXQ1 
staining in both the cytoplasm and the nucleus (Figure 4.5 D) while other UM 
samples showed a mixed staining from cell to cell between low to moderate, as 
appeared in Figure 4.5 E. The UM samples showed more staining of the nucleus 





Figure 4.5: The expression of FOXQ1 protein in UM tissue sections using 
IHC. 
(A) Negative control of normal kidney FFPE tissue section without any FOXQ1 primary 
antibody and only haematoxylin counter staining. (B) Same normal kidney FFPE tissue 
section with FOXQ1 primary antibody, immune staining mainly in the renal tubules 
(brown) rather than the nucleus (blue), varying between moderate to strong, as 
recommended by the manufacturer. (C) The staining of FOXQ1 was mainly low for both 
the cytoplasm and nucleus with exception of a few cells. (D) In contrast, the staining of 
FOXQ1 was high in the cytoplasm encompassing the area of nucleus. (E) Represents 
the moderate nucleus staining of FOXQ1 that appears to vary between cells. All images 
were taken using Qupath software (v 0.1.0).  
 
The analysis of FOXQ1 protein expression using Allred scoring system resulted 
in all groups having the staining in the nucleus more than cytoplasm (Figure 4.6 
A). Based on the Allred scoring system, there was no significant difference 
between groups 1, 3 and 4 of chromosome 6 aberrations which their intensity for 
the nucleus is 5, except for the group 2 that showed a slight increase for the 




the p value of 0.003, which is significant in respect to the outcome for FOXQ1 
protein.  
In addition, the survival analysis was done to compare the protein expression of 
FOXQ1 with UM patients’ survival. Therefore, the expression of FOXQ1 been 
grouped into three groups based on the TS of the nucleus (Figure 4.6 B). This is 
because, as mentioned before, the expected expression of FOXQ1 is in the 
nucleus, which is similar to the outcome of this study. The TS score for the low 
expression group is between (0-2), the moderate expression group is between 
(3-5) and the high expression group us between (5-8). Therefore, the survival 
analysis showed no significant difference between the expression of FOXQ1 and 





Figure 4.6: Allred scoring and Kaplan-Meier analysis of FOXQ1 protein 
expression. 
(A) Based on the chromosome 6 groups, and the amount of TS for each nucleus (N) and 
cytoplasm (C) was calculated based on the Allred scoring system. It shows the staining 
is more in the nucleus than the cytoplasm. The results seemed broadly equal among in 
groups 1, 3 and 4 (5 for nucleus and 3 for cytoplasm) except a slight increase in group 
2 (isochromosome 6p), around 6 for the nucleus and around 5 for cytoplasm. The P 
value is 0.003. (B) The Kaplan-Meier survival analysis for FOXQ1 shows that the X-axis 
represents the survival time in months and the Y-axis represents the percentage of 
survival among UM patients. The high, moderate and low nuclear protein expression for 
FOXQ1 shows no significant difference for survival.  





4.2.4.3 FARS2 protein expression 
IHC was used to assess the expression of FARS2 protein in 80 UM tissue 
sections. The FARS2 protein is usually expressed in the cytoplasm. The control 
used to evaluate the protein expression of FARS2 was human colon carcinoma. 
This showed that the staining was mainly in the cytoplasm with a slight nuclear 
staining, in comparison to the negative human colon carcinoma tissue control 
(Figure 4.7 A and B).  
The 80 UM FFPE tissue sections were stained with FARS2 antibody with the 
staining varying from tissue to another, regardless to their groups. For example, 
there was a low cytoplasmic and nucleus staining for FARS2 protein among 
some of the UM tissue samples (Figure 4.7 C). Additionally, some of the UM 
samples showed a strong FARS2 protein expression, as seen in Figure 4.7 D, 
while there was a mix cytoplasmic staining for some UM tissue sections for 
FARS2 that varies between low to moderate from cell to cell, as appeared in 
Figure 4.7 E. Thus, these UM samples showed more staining of the cytoplasm 





Figure 4.7: The expression of FARS2 protein in UM tissue sections using 
IHC. 
(A) Negative control of human colon carcinoma FFPE tissue section without any FARS2 
primary antibody and only haematoxylin counter staining. (B) Same human colon 
carcinoma FFPE tissue section with FARS2 primary antibody, showing some staining 
was in the cytoplasm (brown), while some of the immune staining in the nucleus varying 
between low and moderate. (C) The staining of FARS2 was low and neither the 
cytoplasm nor nucleus were strongly stained. In contrast, (D) the staining of FARS2 was 
high in the cytoplasm (brown) also encompassed the area of the nucleus. (E) Shows the 
mix staining for FRAS2 from one cell to another. All images were taken using Qupath 








The analysis of FARS2 protein expression using the Allred scoring system 
revealed that the staining to be more in the cytoplasm than nucleus, as 
mentioned before, although there were broadly low among all chromosome 6 
groups (Figure 4.8 A). The UM samples showed that there was no significant 
difference between chromosome 6 aberration groups and their intensity varies 
between the total of 2 to 4, expect for group 4 (no changes in chromosome 6) 
which had a slight increase. The analysis using one-way ANOVA showed a p 
value of <0.0001, indicating significance in the respect of the FARS2 protein.  
Similar to FOXQ1, the survival analysis was done to compare the protein 
expression of FARS2 with patients’ survival (Figure 4.8 B). Therefore, the 
expression of FARS was grouped into three groups based on the TS of the 
cytoplasm, because FARS2 was expected to be expressed in the cytoplasm 
more than nucleus, which similar to the outcome of this study. The TS of the low 
expression group is between (0-2), the moderate expression group is between 
(3-5) and the high expression group is between (5-8). Although the high FARS2 
expression showed a lower survival at early months compared to the low FARS2 
expression, the results showed that there is no significant difference between the 





Figure 4.8: Allred scoring and Kaplan-Meier analysis of FARS2 protein 
expression. 
(A) Based on the chromosome 6 groups, and the amount of TS for each nucleus (N) and 
cytoplasm (C) was calculated based on the Allred scoring system. The cytoplasm 
appeared to have more staining than the nucleus, as estimated before. The results 
between the three groups 1-3 seemed broadly the same (2 for nucleus and around 4 for 
cytoplasm) except for a slight increase in group 4 (no changes in chromosome 6), of 
around 5 for the cytoplasm and around 4 for nucleus. The P value is <0.0001. (B) The 
Kaplan-Meier survival analysis for FARS2 showed that the X-axis represents the survival 
time in months and the Y-axis represents the percentage of survival among UM patients. 
The high, moderate and low protein expression for FARS2 showed no significant 
difference for survival, although the high expression showed a slight lower survival at 
early months compared to the low FARS2 expression.  





4.2.4.4 AMD1 protein expression  
Besides FOXQ1 and FARS2, IHC was used to assess the AMD1 protein 
expression in 80 UM tissue sections. The main site the AMD1 protein expression 
is cytoplasm. The control used to evaluate the protein expression of AMD1 was 
mammary cancer tissue section. Staining was evident in the cytoplasm more than 
the nucleus and it varies between moderate to high, in comparison with the 
negative mammary cancer tissue control (Figure 4.9 A and B).  
The 80 UM FFPE tissue sections were stained with AMD1 antibody and it 
appeared there was a difference in the level of staining intensities among the UM 
tissue sections, regardless to their chromosome 6 groups. For example, there 
was low cytoplasm and nuclear staining for AMD1 protein among some of the 
UM tissue samples (Figure 4.9 C). Additionally, some of the UM sample had a 
high expression of AMD1 in the cytoplasm, as seen in Figure 4.9 D, while other 
UM had a mix of cytoplasm staining that varies between low to moderate from 
cell to cell, as appeared in Figure 4.9 E. Therefore, the expression of AMD1 in 
UM samples overall showed more cytoplasm staining than nucleus, which is 





Figure 4.9: The expression of AMD1 protein in UM tissue sections using 
IHC. 
(A) Negative control of mammary cancer FFPE tissue section without any AMD1 primary 
antibody and only haematoxylin counter staining. (B) Same mammary cancer FFPE 
tissue section with AMD1 primary antibody revealing some immune staining was mainly 
in the cytoplasm (brown) that appears to be between moderate to strong. (C) The 
staining of AMD1 was lower for both the cytoplasm and nucleus, and it showed a small 
amount of melanin pigmentation remaining even after the recommended treatment. In 
contrast, (D) the staining of AMD1 was high in the cytoplasm and nucleus also. (E) Show 
the mix of staining for AMD1 from one cell to another. All images were taken using 








The analysis of AMD1 protein expression using the Allred scoring system 
revealed the cytoplasm is to be more stained than the nucleus amongst all the 
UM samples that were analysed (Figure 4.10 A). Remarkably, there was a 
significant difference between chromosome 6 aberration groups, based on the 
Allred scoring system. In group 1 (gain of chromosome 6p only), there was an 
increase in staining in both the nucleus and cytoplasm between 5 and 6, 
respectively, which is similar to group 4 (no chromosome 6 changes). Groups 2 
(isochromosome 6p) and 3 (different aberrations in chromosome 6), however, 
showed a significant reduction in staining, at between 3 and 4 for both nucleus 
and cytoplasm. The analysis using one-way ANOVA showed p value of <0.0001 
indicating a significance of the outcome in respect to AMD1 protein. 
Moreover, the survival analysis was done to compare the protein expression of 
AMD1 with patients’ survival and it was also grouped into three groups based on 
the TS of the cytoplasm (Figure 4.10 B). The TS of the low expression group is 
between (0-2), the moderate expression group is between (3-5) and the high 
expression group is between (5-8). Therefore, the survival analysis showed no 
significant difference between the expression of AMD1 and the overall survival. 
However, there was a slight difference between high expression and low or 
moderate expression of AMD1 for survival beyond 50 months. Conversely, this 
was the opposite to the survival for groups 2 and 3 where chromosome 6q was 





Figure 4.10: Allred scoring and Kaplan-Meier analysis of AMD1 protein 
expression. 
(A) Based on the chromosome 6 groups, and the amount of TS for each nucleus (N) and 
cytoplasm (C) was calculated based on the Allred scoring system. The cytoplasm 
appeared to have more staining than the nucleus, as described earlier. Interestingly, the 
results for group 1 (gain in chromosome 6p) and group 4 (no changes in chromosome 
6) appeared to be equal with a TS between 5 to 6. There was a decrease in groups 2 
(isochromosome 6p) and group 3 (different changes in chromosome 6), in comparison 
with the other groups, however, with scores of between 3 and 4. The P value is <0.0001. 
(B) The Kaplan-Meier survival analysis for AMD1 showed that the X-axis represents the 
survival time in months and the Y-axis represents the percentage of survival among UM 
patients. The high, moderate and low protein expression for AMD1 showed no significant 
difference for survival, although from this figure the differences between these 
expressions of AMD1 appeared to occur after 50 months. 





4.3 Discussion  
Here array-CGH on 22 UM samples confirmed groupings of chromosome 6 
abnormalities and the previously identified genes (FOXQ1, FARS2 and AMD1) 
were still implicated in different subsets of UM. Expression of target genes was 
investigated in a series of 80 UM samples that could be subdivided similarly on 
the basis of chromosome 6 changes. Based on the clinicopathological data of 
this study, the survival for UM patients were in agreement with a previous reports 
(McLean et al., 1982, Seregard and Kock, 1995, Kujala et al., 2003, Diener-West 
et al., 2005, Shields et al., 2009, Shields et al., 2012). The clinical data of this 
study were collected after the results been done and that indicated there were no 
selection bias toward any type of UM and there were treated anonymously to 
have a clear representation of the UM outcome. 
4.3.1 Chromosome 6 changes and prognosis  
The association of gain chromosome 6p with disomy 3 in UM appears to occur 
early in the progression of some UM (Parrella et al., 1999). The association of 
different chromosome 6 aberrations in UM with survival has recently been 
considered  (Drabarek et al., 2019), which they found that gain of chromosome 
6p and isochromosome 6p are considered as a good and intermediate prognostic 
markers in UM, respectively. Thus, the association in this study was also 
generated to confirm the effect of different chromosome 6 alterations on the 
patient’s overall survival (Figure 4.4 A). Based on the chromosome 6 groups, it 
showed that group 1 (gain of chromosome 6p only) usually have the longest 
survival while group 2 (isochromosome 6p) have a shorter survival than group 1, 
however, group 3 (gain or deletion of whole chromosome 6) and group 4 (disomy 
6) showed the worst prognosis and with a low survival rate. The findings of this 
current study confirm that chromosome 6q indicate a poorer outcome for UM 
patients and also confirmed the initial findings of the previous study undertaken 




4.3.2 Confirmation of target genes 
In the earlier study, Nexus software has been used as opposed to Agilent 
Workbench software used in the present study. The Nexus software uses an 
algorithm called FASST2 (Fast Adaptive States Segmentation Technique 2) for 
the aberration calls. This algorithm uses an approach of calling based on Hidden 
Markov Model (HMM), which estimates the copy number based on many states 
of the probe. Similar to the Nexus software, the algorithm of Agilent Genomic 
Workbench software that been used in this study is ADM-2, which makes the 
calls based on the states of the probes, yet it lacks the statistical tools that 
provided in the Nexus software to identify genes. The statistical tools that are 
available for Nexus software are significance testing for aberrant copy number 
(STAC) (Diskin et al., 2006), and genomic identification of significant targets in 
cancer (GISTIC) (Beroukhim et al., 2007). These statistical tools helped to 
precisely identify FOXQ1, FARS2 and AMD1 genes in the aberrant chromosome 
6 (Alshammari, 2017). Therefore, despite lack of similar statistical tools and 
smaller sample, the results of this study were broadly supportive of the previous 
findings with FARS2 called for group 1 and AMD1 called for group 2; however, 
group 3 cases were not in this small series. This independent confirmation 
suggested that further exploration of these genes was warranted.  
4.3.3 Are target genes potentially relevant to UM? 
UMs are now well characterised by mutations of BAP1 and preferential deletion 
of BAP1 (Harbour et al., 2010), There has however been much debate as to 
whether the mutations of BAP1 confer a poor outcome, as previous studies 
suggest that the expression of BAP1 in the nucleus is more reliable than the 
assessment of the mutations  (Shah et al., 2013, Koopmans et al., 2014b, van 
de Nes et al., 2016, Field et al., 2018).  
In this study, the expression of FOXQ1 did not appear to be predictive of outcome 
for UM patients (Figure 4.6). The FOXQ1 gene on chromosome 6p25.3 consists 
of 2319bp which encode for FOXQ1 protein that has 403 amino acids (Bieller et 
al., 2001). It was first discovered in Drosophila melanogaster and there was little 




Subsequently, It has found that the forkhead box (FOX) family is a transcription 
factor and consists of more than 100 members that been classified into 19 
subfamilies (Kaestner et al., 2000, Benayoun et al., 2011). These subfamilies are 
involved in various human cellular functions such as, cell proliferation, 
differentiation and apoptosis, as reviewed in Carlsson and Mahlapuu (2002). In 
addition to their cellular function, these genes have a role in different human 
health properties, as an example, embryonic development, metabolism of 
glucose and lipid, ageing and immune regulation.  
Thus, FOXQ1 is a key oncogenic transcription factor gene among the Fox family 
of genes and it has an essential role in tumorigenesis (Cao et al., 2004, 
Feuerborn et al., 2011). The overexpression and dysregulation of FOXQ1 
oncogene is also found in other types of cancers including ovarian and breast 
cancers (Gao et al., 2012, Sehrawat et al., 2013), cervical cancer (Fan et al., 
2014), gastric cancer (Xiang et al., 2015), pancreatic cancer (Bao et al., 2014), 
bladder cancer (Zhu et al., 2013), glioma (Sun et al., 2013) and liver cancer (Xia 
et al., 2014).  
The expression of FOXQ1 has a role within the Wnt pathway and the 
transforming growth factor (TGF) pathway, both of which are considered to be 
oncogenic signalling pathways that may transform normal cells into cancerous 
ones (Christensen et al., 2013, Fan et al., 2014). In addition, Peng et al, found 
that FOXQ1 serves as a mediator between Wnt and TGF pathways during the 
tumorigenesis of colorectal cancer (Peng et al., 2015). However, lack of growth 
control in UM that is upregulated by TGF pathway has found to play a role in the 
progression of UM cells to the liver (Myatt et al., 2000, Woodward et al., 2002, 
Woodward et al., 2005). Although the FOXQ1 oncogene implicated in the TGF 
pathway, the expression of FOXQ1 does not appear to be relevant to UM 
outcome. 
Similar to FOXQ1, the expression of FARS2, on chromosome 6p25.1, was not 
significant and did not appear to be predictive of outcome for UM patients (Figure 
4.8). FARS2 gene is a nuclear gene encodes for mitochondrial aminoacyl-
transfer RNA (tRNA) synthetases which use phenylalanine to catalyse and 




linked to several infantile and adult diseases, as reviewed in Konovalova and 
Tyynismaa (2013). A few research studies have reported that mutation of FARS2 
mainly causes neurological autosomal recessive disorders such as combined 
oxidative phosphorylation deficiency 14 (COXPD14) (Elo et al., 2012, 
Shamseldin et al., 2012, Almalki et al., 2014) and spastic paraplegia 77 (SPG77) 
(Vernon et al., 2015, Yang et al., 2016).  No studies however have examined 
whether the FARS2 gene is linked to oncogenesis.  
Based on the outcome of this study, AMD1 is an interesting candidate for UM as 
it is supported by the findings of IHC analysis for AMD1 expression for groups 
that have a deletion in chromosome 6q, as seen in Figure 4.10 A. A common 
feature of tumour suppressor genes in different cancer types is somatic deletion 
that acts as a driver for tumorigenesis.  
The AMD1 gene is found on chromosome 6q21, which it consists of around 22kb 
and contains 9 exons (Maric et al., 1992). It encodes for S-adenosylmethionine 
decarboxylase 1 (AdoMetDC) which is the main enzyme in the biosynthesis of 
polyamines and its product serves as a major donor for the catalytic activity of 
various reactions involving DNA methylation, RNA, proteins and metabolites 
(Maric et al., 1995, Chiang et al., 1996, Roje, 2006, Pegg, 2009b, Lu and Mato, 
2012). Additionally, AdoMetDC appear to have an imperative role for embryonic 
stem cell (ESC) self-renewal and the differentiation of neural precursor cells 
(Zhang et al., 2012). Scuoppo and colleagues identified a number of tumour 
suppressor genes that affect lymphoma, one of which was AMD1 (Scuoppo et 
al., 2012). Beside lymphoma, the reduction in AMD1 expression in prostate 
cancer was associated with the inhibition of the polyamine pathway, leading to 
inhibition of cancer growth (Gerner et al., 2005, Kaul et al., 2010). In a recent 
study by Zabala-Letona et al., identified that when AMD1 is upregulated it 
activates the rapamycin complex 1 (mTORC1) pathway in prostate cancer, which 
regulates the dynamics of polyamine and is essential for tumorigenicity (Zabala-
Letona et al., 2017). Furthermore, the inhibition of the mTOR pathway was also 
found to have a significant delay of the UM growth using cell lines and patient-
derived xenograft (Amirouchene-Angelozzi et al., 2014). Although this current 




for those UM patients with chromosome 6q deletions, which seem to have the 
worse prognosis, the findings of IHC and survival seem to contradict the role of 
AMD1, as seen in Figure 4.10 B. Therefore, the increased expression of AMD1 
correlates with the presence of chromosome 6q, which this study proposed that 
AMD1 has a tumour suppressor role in UM. 
In summary, this study independently confirmed potential genes of interest in the 
targeted regions of chromosome 6 that been previously identified using GISTIC 
and STAC by Alshammari (2017). This study validated these findings using IHC 
to determine the expression of those genes on UM tissue sections. The 
expression of AMD1 is the most interesting and significant, as shown in Figure 
4.10 A. The effect therefore of AMD1 on UM warrants further investigation to 


























Chapter 5: The knockout effect of AMD1 












5.1 Introduction  
In the previous chapter, the assessment for AMD1 expression was significantly 
reduced among groups that have deletion in chromosome 6q (Figure 4.10 A). 
There was some indication that loss of chromosome 6q was associated with a 
poorer outcome (Figure 4.4 A), but the reduced expression of AMD1 did not 
associate with poorer prognosis, if anything the reverse was true. 
As previously mentioned, AMD1 is around 22kb, consists of 9 exons and encodes 
for S-adenosylmethionine decarboxylase (AdoMetDC), which is an essential 
enzyme for the polyamine pathway (Maric et al., 1992, Maric et al., 1995). There 
are three types of polyamines produced in mammals, putrescine, spermidine, 
and spermine, which are naturally found in all types of cells and have an essential 
role in proliferation and various cellular events, as reviewed by Pegg (2009a). 
These polyamines are positively charged and their charge allows them to bind 
with negatively charged molecules such as DNA, RNA and some proteins (Childs 
et al., 2003). Putrescine is formed by ornithine decarboxylase (ODC), which is 
therefore considered to be a rate-limiting factor in the polyamine pathway (Pegg, 
2006). The overexpression of ODC activity has been reported to have a role in 
various types of cancers such as, squamous cell carcinoma, colorectal and 
prostate cancer (Zhang et al., 2006, Shukla-Dave et al., 2016, He et al., 2017).  
The other rate-limiting enzyme in the biosynthesis of polyamine is AdoMetDC, 
which converts the putrescine into higher polyamines such as spermidine and 
spermine, respectively (Pegg et al., 1998). AMD1 has been shown to be essential 
for embryonic development in mice, and indeed the knockout of AMD1 is lethal 
in mice (Nishimura et al., 2002). Besides ODC, AMD1 acts as a tumour 
suppressor gene and has been correlated with a number of cancers, including 
lymphoma, colorectal and prostate cancers (Zhang et al., 2006, Scuoppo et al., 
2012, Zabala-Letona et al., 2017). Targeting AMD1 in polyamine biosynthesis 
pathway therefore offers the potential to understand in-depth its relation to the 




In this current study, an initial exploration of AMD1 function in UM cell was 
undertaken. To achieve this, a relatively recent technology called Clustered 
Regularly Interspaced Short Palindromic Repeat (CRISPR) will be used, which 
was first found in E.coli as a natural defence system against viruses DNA (Ishino 
et al., 1987). The elements of CRISPR and its CRISPR-associated (Cas) proteins 
are linked as an adaptive immunity against viral DNA (Jansen et al., 2002). In 
2013, DNA from mammalian cells was for the first time successfully transfected 
and cleaved using a combination of CRISPR and type II Cas protein from 
Streptococcus pyogenes (SpCas9) or the so-called CRISPR/Cas9 system (Cong 
et al., 2013, Mali et al., 2013).  
The formation of CRISPR system to the target sequence allows the Cas9 to 
unwind the DNA and create a double-strand break (DSB). Consequently, the 
targeted cell will repair that break created using non-homologous end joining 
(NHEJ) that often creates different types of mutations that lead to loss-of-function 
for the targeted gene. Alternatively, the break will be repaired by homology 
directed repair (HDR) that needs a donor DNA strand to repair the break, which 
creates a precise mutation if the donor DNA was already altered, as reviewed in 
Pickar-Oliver and Gersbach (2019).  
In summary, AMD1 is essential in polyamine biosynthesis and its effect on UM is 
still not fully known. This chapter therefore aims to knockout AMD1 using 
CRISPR/Cas9 technology so as to determine its effect on the UM cells. To my 








5.2.1 UM cell lines and chromosomal aberrations 
Four UM cell lines, MEL-577, MEL-585, MEL-627 and MEL-644, chosen to 
represent different aberrations of chromosome 6, were grown in RPMI-1640 
media with supplements, as described in section 2.2.4, and incubated at 37 ºC 
with 5% CO2. These cell lines were maintained and passaged every week 
depending on their confluency. In addition to these cell lines, a hepatocellular 
carcinoma cell line (HepG2) was used as an internal control for ICC and WB, as 
recommended by the antibody manufacturer; this was grown in similar conditions 
to the UM cell lines. These UM cell lines been chosen to represent different 
aberrations in chromosome 6. Chromosomal aberrations among those four UM 
cell lines were determined previously by members of our group using array-CGH. 
The cellular characteristics of the MEL-577 cell line passage 59 showed a mixed 
cell morphology (Figure 5.1 A-B). The chromosomal aberrations of MEL-577 
passage 53 represented typical UM chromosomal aberrations such as 
monosomy 3, gain of 8q and the aberration for chromosome 6 profile was partial 





Figure 5.1: Phase contrast micrographs and array-CGH ideogram of MEL-
577. 
(A) The UM cell line MEL-577 passage 59 shows a mixed cell morphology on 10X 
magnification (B) the cells appear clearly under 20X magnification. (C) An ideogram of 
MEL-577 passage 53 showing  a pseudo-isochromosome 6p, as well as aberrations 
such as gain of 1q, monosomy 3, gain of 8q, monosomy 9, partial loss of chromosome 
11q, loss of chromosome 13, gain of 16p and loss of 16q, loss of 17p and gain of 17q 
and loss of 18p.  
All microscope images were taken using REBEL ECHO (Avantor™). Images output for 
ideograms were taken from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 
algorithm was used to detect all the aberrations. 
 
The cellular characteristics of MEL-585 passage 36 also showed a mixed cell 
morphology, as seen in Figure 5.2 A-B. In addition, the chromosomal profile for 
UM cell line MEL-585 passage 29 showed monosomy 3 and isochromosome 8q 
while the chromosome 6 aberration was pseudo-isochromosome 6p (group 2) 





Figure 5.2: Phase contrast micrographs and array-CGH ideogram of MEL-
585. 
(A) The UM cell line MEL-585 passage 36 shows a mixed cell morphology on 10X 
magnification (B) the cells appear clearly under 20X magnification. (C) An ideogram of 
MEL-585 passage 29 showing a partial gain of chromosome 6p and loss of to the rest 
of chromosome 6 where the cells developed different aberrations such as monosomy 3, 
gain of chromosome 5, loss of 8p and gain of 8q, monosomy 9, partial gain of 
chromosome 12, loss of chromosome 13, gain of 16p and loss of 16q, loss of 
chromosome 17 and partial loss and gain of chromosome 21 and loss of chromosome 
22. 
All microscope images were taken using REBEL ECHO (Avantor™). Images output for 
ideograms were taken from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 







The UM cell line of MEL-627 passage 27 showed an epithelioid cell morphology, 
as seen in Figure 5.3 A-B. The chromosomal aberrations for MEL-627 passage 
25 were disomy 3, trisomy 8 and gain of chromosome 6p only, this representing 
group 1 (Figure 5.3 C).  
 
Figure 5.3: Phase contrast micrographs and array-CGH ideogram of MEL-
627. 
(A) The UM cell line MEL-627 passage 27 shows an epithelioid cell morphology on 10X 
magnification (B) the cells appear clearly under 20X magnification. (C) An ideogram of 
MEL-627 passage 25 showing gain of chromosome 6p where the cells developed 
different aberrations such as partial gain of chromosome 2p, loss of chromosome 4p, 
trisomy 8, loss of 9p, partial gain of chromosome 11q, partial gain of 13q and loss of 17p.  
All microscope images were taken using REBEL ECHO (Avantor™). Images output for 
ideograms were taken from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 





The cellular characteristics for MEL-644 passage 27 showed a spindle cell 
morphology, in contrast to the other three cell lines (Figure 5.4 A-B). The 
chromosomal aberrations for MEL-644 passage 22 exhibited classical UM 
aberrations such as loss of chromosome 1p, monosomy 3 and gain of 8q 
whereas there was no aberration for chromosome 6 (group 4) (Figure 5.4 C). 
 
Figure 5.4: Phase contrast micrographs and array-CGH ideograms of MEL-
644. 
(A) The UM cell line MEL-644 passage 27 shows a spindle cell morphology on 10X 
magnification (B) the cells appeared clearly under 20X magnification. (C) An ideogram 
of MEL-627 passage 22 showing no aberration in chromosome 6 where the cells 
developed different aberrations such as loss of 1p, monosomy 3, gain of 5q, gain of 8q, 
monosomy 9, loss of 11p, partial loss of chromosome 13, loss of 16q, loss of 17p, partial 
loss of 18q, trisomy 21 and partial loss of chromosome 22.  
All microscope images were taken using REBEL ECHO (Avantor™). Images output for 
ideograms were taken from Agilent Genomic Workbench software v7.0.4.0. The ADM-2 





5.2.2 Immunocytochemistry of UM cell lines  
Immunocytochemistry (ICC) was conducted on the UM cell lines mentioned in 
order to determine the protein expression of AMD1. The UM cells were seeded 
on slides as mentioned in section 2.2.5, and fixed for used for the ICC. The AMD1 
antibody that been used in this experiment was optimised based on the 
manufacturer’s recommendation. This experiment was done to confirm the 
expression of AMD1 at a cellular level for those selected UM cell lines similar the 
IHC that was undertaken on UM tissue sections in the previous chapter.  
The results showed that the HepG2 cells have a strong expression of AMD1 in 
the nucleus and cytoplasm compared to the negative control (Figure 5.5 A-B). 
Although it is known that the expression of AMD1 is mainly in the cytoplasm for 
IHC, the expression of AMD1 using ICC showed variation of expression in the 
cytoplasm while nuclear staining was stronger. 
The four UM cell lines exhibited various AMD1 protein expression intensity 
(Figure 5.5 C-F). For instance, the mixed cell morphology of MEL-577 showed a 
moderate staining of AMD1 in the cytoplasm while there was a strong staining in 
the nucleus. Similarly, with MEL-585 the mixed cell morphology also showed a 
moderate staining in the nucleus and low staining in the cytoplasm. The 
epithelioid cell morphology of MEL-627, however, showed a low staining for 
AMD1 in the nucleus and no staining appeared in the cytoplasm. The staining for 
AMD1 on MEL-644, which has a spindle cell morphology, showed a strong 
staining in both nucleus and cytoplasm. Therefore, the increased of AMD1 
expression among spindle cell morphology only may indicate a better prognosis 
for UM. 
These UM cell lines have different chromosome 6 groups, and this explains the 
variation in the expression of AMD1 on these cells, as mentioned in the previous 
section. Although the cell lines (MEL-577 and MEL-585) represent (group 2), 
which is partial gain of chromosome 6p and loss of chromosome 6q, have same 
pattern as IHC analysis by exhibiting a lower expression of AMD1 in the 
cytoplasm, the other cell lines (MEL-627 and MEL-644) did not follow this same 





Figure 5.5: Immunocytochemistry for AMD1 antibody against UM cell lines.  
(A) Negative control of HepG2 cells grown on slides without AMD1 staining and only 
haemoxylin. (B) Positive control for AMD1 using HepG2 cells. (C) Staining of AMD1 on 
MEL-577 cells showing the stronger staining in the nucleus than the cytoplasm. (D) 
Staining of AMD1 on MEL-585 showing a moderate staining in the nucleus than the 
cytoplasm. (E) Staining of AMD1 on MEL-627 showing a low staining in nucleus and no 
staining appeared in the cytoplasm. (F) Staining of AMD1 on MEL-644 showing a high 
staining in nucleus and moderate in the cytoplasm.  





5.2.3 AMD1 knockout using CRISPR/Cas9 
The first step in knockout AMD1 gene is to design an appropriate sgRNA to bind 
with the desired DNA target. The design of AMD1 sgRNA was therefore done by 
using the Thermofisher website to generate a modified synthetic sgRNA. It 
appeared that the most efficient location for to knockout of AMD1 was on exon 1, 
as explained in section 2.2.7. The UM cells were therefore transfected using 
lipofectamine (CRISPRMAX), a lipid transfection agent, that was mixed with the 
sgRNA and Cas9 protein to form ribonucleoprotein (RNP) complex and that 
complex was added to each UM cell line, which was then incubated at 37ºC and 
5% CO2 for 48 hours. The UM cell line MEL-585 was excluded from this 
experiment, however, due to its poor cellular growth which there was insufficient 
time to resolve. The downstream applications to assess the efficiency of the 
AMD1 knockout were done by extracting the DNA and protein from each UM cell 
line. 
5.2.3.1 Assessment of AMD1 knockout efficiency using 
Genomic cleavage detection (GCD) assay 
The DNA that was extracted from UM cell lines were used to calculate the 
efficiency of the AMD1 knockout. The DNA was amplified using PCR around the 
target site, as explained in section 2.2.7. The amplified PCR products were then 
incubated with T7 Endonuclease I, which has the ability to recognize the 
heteroduplex mismatches and cleave them to produce a small two bands shorter 
than the original parental band. After amplifying the target and treating it with T7 
Endonuclease I, the results showed that all transfected UM PCR products had a 
parental band and two shorter cut bands, which was as expected because of the 
cut between 202 bp and 398 bp in comparison with the untreated PCR product 
that only had one band, as seen in Figure 5.6 A. The calculation of the knockout 
efficiency from these bands was done using Image Lab (BioRad) to determine 
the percentage of each cleaved band in comparison with its parental band, based 
on the following equation: 






This equation was applied to all samples so as to calculate the efficiency of AMD1 
knockout (Figure 5.6 B). The positive control showed a 10.11% efficiency and the 
UM cell lines showed knockout efficiencies of 9.67% for MEL-644, 7.16% for 
MEL-577 and 6.94% for MEL-627.  
 
Figure 5.6: The cleavage efficiency for AMD1 knockout in UM cell lines.  
(A) The gel electrophoresis of both undigested and digested UM cell lines showed that 
the amplified product was at 600 bp and the cuts were at 202 bp and 398 bp, as 
previously designed, while the internal positive control was amplified at 500 bp and the 
cut were at 225 bp and 291 bp, per the manufacturer’s instructions. (B) The calculated 
total efficiency of the transfected cells showed that they were between 7 and 10% in 





5.2.3.2 Assessment of AMD1 knockout efficiency using 
Tracking indel by decomposition (TIDE) 
The PCR products that were generated from the knockout and WT UM cell lines 
were sent to the sequencing core facility at the University of Sheffield. The results 
showed that all PCR products from WT UM cell lines and knockout AMD1 
achieved a good sequence trace (Figure 5.7). These sequences were then 
compared with the WT using an online quantifying method called Tracking of 
Indel by Decomposition (TIDE) http://tide.deskgen.com (Brinkman et al., 2014). 
This method is designed to determine the efficiency frequency from cell pools by 
adding the gRNA sequence before the software aligns this sequence with both 
the control and knockout sequence to calculate the percentage of the efficiency 
with the R2 to confirm the findings. The sequence traces were uploaded so as to 
generate the total efficiency percentage by comparing the WT to the knockout. 
The data showed that MEL-644 had the highest total efficiency (7.5%) in 
comparison with the other UM cell lines, which had total efficiencies between 1 






Figure 5.7: Chromatogram of AMD1 for UM cell lines and total efficiency 
calculation. 
The chromatogram shows that UM cell lines sequenced for AMD1 having the area of 
sgRNA including PAM sequence. The total efficiency percentage calculation for UM cell 
lines using Tracking of Indel by Decomposition (TIDE) appeared to have a variation in 
the total efficiency percentage such as MEL-577 which has a total efficiency of 3.3%, 












5.2.3.3 Assessment of AMD1 knockout efficiency using 
Western blot  
The protein in both WT and knockout UM cell lines were extracted in order to 
measure the protein expression of AMD1. The protein was extracted successfully 
from the HepG2 control and all the UM cell lines. 
Numerous technical issues occurred when used the WB experiment to check the 
expression of AMD1 among UM lysates. For instance, when the SDS-PAGE was 
done and the gel was transferred to the PVDF membrane using the semi-dry 
method, no result was achieved. The wet transfer was therefore used, which was 
successful. Another issue was that while bands for beta-tubulin appeared, there 
were none for the AMD1 antibody. Because the first AMD1 antibody from 
Abcam™ did not work with the samples, the AMD1 antibody was changed to 
another company (ProteinTech™) which worked with the samples. In addition, 
the band for AMD1 was very faint and could not be detected. To overcome this 
issue, a long exposure time (two hours) was applied to give sufficient time for the 
membrane to develop the AMD1, and this worked with the lysate.   
The results for AMD1 protein expression showed to have four bands for HepG2 
(150 KDa, 80 KDa, 60 KDa and 30 KDa) (Figure 5.8 A). These bands are for the 
AMD1 at 30 KDa, proAMD1 at 60 KDa and an unspecific band at 80 KDa. In 
addition, the band at 150 KDa is also unspecific, which was only expressed with 
HepG2 cell line. Thus, the UM cell lines for both knockout and WT expressed 
only three bands (80 KDa, 60 KDa and 30 KDa) and these three bands did not 
change for the knockout in comparison with the WT UM cell lines. Remarkably, 
only the knockout MEL-644 showed a shift of the proAMD1 in comparison to the 
WT MEL-644 from 60KDa to 75KDa.  
The experiment was repeated again to confirm the findings in the previous 
experiment and the proAMD1 for the knockout MEL-644 compared to the WT 
MEL-644 this time had only one band at 75 KDa without the unspecific band on 
80 KDa (Figure 5.8 B). The beta-tubulin worked for all the samples, however, 






Figure 5.8: The effect of AMD1 protein expression knockout and WT UM cell 
lines.  
(A) The positive control showed four bands for AMD1 in HepG2 while the UM cell lines 
showed only three bands. The first band at 30 KDa was for the AMD1, the band at 60 
KDa was for the proAMD1 and the bands at 80 KDa and 150 KDa were unspecific band. 
MEL-644-KO, however, showed a shift in the proAMD1 to 75 KDa in comparison with its 
WT. The beta-tubulin appeared at 50 KDa for all samples except MEL-644-KO. (B) The 
experiment was repeated to confirm the findings and MEL-644-KO showed the AMD1 at 
30KDa and only shifted band at 75KDa without the unspecific band at 80KDa. Similar to 






5.2.3.4 Proliferation assay for WT and knockout UM cell lines  
The UM cell lines that were transfected with AMD1 sgRNA and the WT were 
tested to check for any differences in biological growth, as explained in section 
2.2.8. For this, Mr. Ahmad Alshammari kindly performed the MTT for this study 
due to the limit time for this project and his prior experience with this technique. 
The objective of this experiment was to determine the biological effect of AMD1 
knockout UM cell lines in comparison with the WT UM cell lines. 
The results for MTT showed that there was no significant difference between WT 
UM cell lines MEL- 577 and MEL-627 and the AMD1 knockout, as seen in Figure 
5.9 A-B. Interestingly, the WT UM cell line MEL-644 showed a doubling time of 
around 58 hours while the knockout UM cell line appeared to has a lower doubling 
time of around 50 hours (Figure 5.9 C). This experiment was repeated at least 





Figure 5.9: Analysis of UM cell viability using MTT assay after AMD1 
knockout. 
These results show the calculation of MTT on O.D. 570nm with images of each knockout 
cell line. (A) The cell viability for both MEL-577 WT and KO showed no difference and 
the doubling time was almost the same. (B) There was a slight difference of MEL-627 
between the WT and the KO of MEL-627 with the doubling time being 93.1 and 104 
hours, respectively; this may due to the erroneous reading difference after 48 hours 
because at 24, 72 and 96 hours the cell growth rates were the same. (C) However, the 
doubling time for MEL-644 the WT and KO were different (57.85 and 49.53 hours, 
respectively). All microscope images were taken using REBEL ECHO (Avantor™). 





5.3 Discussion  
This current study, for the first time, knocked out AMD1 in UM cell lines with 
various chromosome 6 abnormalities so as determine its effect using genetic and 
protein analysis. Four UM cell lines were chosen, therefore, representing groups 
1, 2 and 4 of different chromosome 6 aberrations to evaluate the knockout of 
AMD1 in UM cell lines. The determination of the AMD1 protein expression among 
UM cell lines using ICC showed that MEL-644, which is spindle cell morphology, 
had the highest AMD1 expression compared to the other UM cell lines. These 
UM cell lines were then transfected by CRISPR/Cas9 to knockout AMD1 exon 1 
using sgRNA to determine the effect of AMD1 expression on UM cell lines.  
This chapter used the CRISPR/Cas9 knockout instead knock-in of AMD1 gene 
because the knock-in is harder to achieve and has a low efficiency rate. This 
depends on the design of the inserted dsDNA and the number of base pairs that 
should be inserted to the target DNA, as reviewed in Carroll (2016). In addition, 
homology-direct repair (HDR) is necessary to insert the desired dsDNA to the 
targeted DNA, however, the occurrences of error-free HDR in the cells are less 
than the error-prone NHEJ. This is because HDR occurs only in S- or G2-phase 
of the cycle where NHEJ occurs in throughout the cell cycle (Soutoglou et al., 
2007, Zierhut and Diffley, 2008). Furthermore, HDR needs a donor DNA template 
to insert the desired dsDNA to the targeted DNA which NHEJ does not need to 
make the DSB. Subsequently, these issues make knock-in for any piece of 
dsDNA harder to achieve than knockout using CRISPR/Cas9.  
Interestingly, AMD1 showed different sites of expression using WB and that may 
be due to unspecific expression sites of AMD1 appearing in the blot, as recently 
argued by Zabala-Letona et al. (2017). They found that after using WB for AMD1 
expression on their prostate cancer cell lines other expression sites were shown 
as being expressed in the WB, rather than just proAMD1 or AMD1. They also 
exposed their membrane for a longer time to determine the presence of the 
proAMD1, which is similar to the presented WB for both proAMD1 and AMD1. 
This shift of proAMD1 may due the effect of the knockout of AMD1 in UM cell 




AMD1 is produced as a proAMD1 which is self-cleaved and resulting in an active 
form of AMD1 (Pegg, 2006). However, the knockout of AMD1 in UM cells may 
disturb the normal cleavage process of the proAMD1 and result in an 
upregulation of the mTOR pathway. 
5.3.1 What is the correlation between AMD1 and 
mTOR pathway? 
As mentioned earlier, it appears that there is a relationship between 
chromosomal aberrations and genetic mutations. For example, prostate cancer 
has a similar loss of chromosome 6q to that of UM cells (Nupponen et al., 1998). 
In that case, Nupponen et al., used CGH technology to determine the 
chromosomal aberrations among their prostate cancer cell lines and found that 
the deletion of chromosome 6q was significant in most of their prostate cancer 
cell lines. The correlation in this study between AMD1 and chromosome 6q in 
UM is therefore similar to the prostate cancer. 
In addition, AMD1 expression is upregulated in prostate cancer cells by activating 
the mTOR pathway (Zabala-Letona et al., 2017). The mTOR pathway is part of 
the PTEN-PI3K pathway and together they sustain the growth and proliferation 
of cancer cells (Zoncu et al., 2011, Efeyan et al., 2015). The inhibition of the 
mTOR pathway in UM cells showed a reduction in the growth for the UM cells 
(Ho et al., 2012, Amirouchene-Angelozzi et al., 2014). It is plausible, therefore, 
that AMD1 act as a tumour suppressor gene because when this gene is mutated, 
it may affect UM cells by upregulating the mTOR pathway.  
5.3.2 The knockout efficiency differences in CRISPR 
The knockout efficiency percentages were determined using both GCD assay 
and TIDE to estimate the effect of AMD1 knockout on UM cell lines. The GCD 
assay used T7 endonuclease I to detect and cleave any structural abnormalities 
in the amplified heteroduplex DNA (Mashal et al., 1995). This assay is considered 
to be a simple and cost-effective technique which is also easy to interpret for 
CRISPR edits. A comparison between GCD assay using both T7 endonuclease 




technique for measuring the editing efficiency of sgRNA (Vouillot et al., 2015). 
Other work has argued that the GCD assay using T7 endonuclease I, however, 
may not be highly sensitive because it is may influenced by various factors such 
as the length of the mismatch, secondary structure, flanking sequence and the 
abundance of mutated sequences (Mashal et al., 1995, Vouillot et al., 2015).  
Sentmanat et al. (2018) evaluated the strategies of different techniques used to 
determine the editing efficiency of CRISPR in comparison to next generation 
sequencing (NGS). They found that the T7 endonuclease I did not accurately 
measure the cells edited by CRISPR in comparison with NGS. On the other hand, 
they also found TIDE has a similar accuracy to that of the. TIDE is an algorithm 
created by Brinkman et al. (2014) which calculates the Sanger sequence traces 
after amplifying the PCR product to detect edited cells created by CRISPR 
compared to the WT cells. Although NGS is more sensitive and reliable more 
than other techniques, it is a high cost and labour intensive approach, and thus 
TIDE was chosen here as a reliable technique for a low number of samples 
(Sentmanat et al., 2018). The results of this study revealed that MEL-644 had the 
highest editing efficiency of the various tested UM cell lines. 
5.3.3 The effect of polyamines on beta-tubulin 
The absence of beta-tubulin expression in the membrane for the knockout UM 
cell line MEL-644, may be due to a relationship between microtubules (alpha- 
and beta-tubulin) and the polyamines (Figure 5.8). Thus, Pohjanpelto et al. (1981) 
found that the starvation of polyamines may cause a disappearance of 
microtubule and actin filaments in the mammalian cells, as reviewed in 
Bouchereau et al. (1999). In addition, Mechulam and colleagues found that there 
was a relation between microtubules and the polyamines such as spermidine and 
spermine both in vitro and in vivo (Mechulam et al., 2009). Therefore, this relation 
between the polyamines and tubulin may have an effect on the edited MEL-644 
which showed a shift in proAMD1 from 60 KDa to 75 KDa compared to the WT, 
while there was no expression for beta-tubulin in that edited sample (Figure 5.8).  
In addition, this relation may also affect the proliferation of the knockout of AMD1 
in MEL-644 which showed an increase in the growth rate compared to the WT 




between one of the polyamines regulators (AMD1) and beta-tubulin that leads to 
a diffusion of beta-tubulin in the knockout UM cell line in comparison to its WT. 
Although there are a correlation AMD1 and beta-tubulin, the diffusion in beta-
tubulin may have resulted from unexpected off-target effect from CRISPR 
technology. 
In summary, this chapter used CRISPR as a new technology to knockout AMD1 
so as to determine its effect on UM cell lines. The knockout of AMD1 was 
achieved in the UM cell line (MEL-644) with normal chromosome 6 and the 
efficiency was determined to be effective. Although it is known in this study that 
spindle cell morphology is correlated with good prognosis, this UM cell line 
exhibits chromosomal aberrations such as monosomy 3 and gain of chromosome 
8q, which indicates a poor prognosis. In addition, this study also showed that the 
results effectively produce less of the AMD1 and therefore it has a tumour 
suppressor gene role in UM. Although the result of this study found a shift of 
proAMD1 to a higher molecular weight, this outcome needs to be repeated to 
confirm this effect of AMD1 on knockout UM cells. However, due to the limited 
time of this PhD, the repeat of knocking out AMD1 in UM cell line was not 
achievable and that will be done in the future to confirm this outcome. Accordingly, 
further exploration of AMD1 in UM may help in understanding how changes of 





































6.1 Overview of this study 
The clinical, histopathological and genetic prognostic factors for UM have been  
well characterised in numerous previous research studies (Mooy and De Jong, 
1996, Sisley et al., 1997, Singh et al., 2001, Coupland et al., 2013). Although the 
chromosomal aberrations in UM have previously been correlated with prognosis 
(Sisley et al., 1990, Prescher et al., 1996, Sisley et al., 1997), these chromosomal 
aberrations have not been explored in detail to identify the relevant drivers of UM 
and its metastasis. Furthermore, although genes may be implicated, such as 
BAP1, the relationship between its mutation, expression and prognosis is unclear 
(Harbour et al., 2010, Koopmans et al., 2014b, Van Beek et al., 2015). The role 
of chromosome 6 has not been fully as extensively studied as other common 
chromosomes changes found in UM, such as chromosomes 3 and 8 (Sisley et 
al., 1997, Cross et al., 2006, van de Nes et al., 2016, Dogrusoz et al., 2017). 
Therefore, the aim of this current thesis was to evaluate in-depth chromosome 6 
aberrations and identify driver genes that may help understand the progression 
of UM, as summarised in Figure 6.1. 
This study started with a comparison between the common chromosome 6 
aberrations in UM along with their relationship to other known genetic biomarkers 
such as SF3B1, EIF1AX and TERTp (Furney et al., 2013, Harbour et al., 2013, 
Martin et al., 2013, Dono et al., 2014, Yavuzyigitoglu et al., 2016b). The outcome 
of chapter 3 proposed an alternative sequence of events in UM considering 
disomy 3 with isochromosome 6p followed by mutations in SF3B1 and then gain 
of chromosome 8q as one of the events that affect the prognosis of UM (Figures 
3.9).  
Moreover, this study broadly confirmed the target genes of interest on 
chromosome 6 (FOXQ1, FARS2 and AMD1) using a small number of cases, 
which been identified previously by Alshammari (2017). This study also evaluated 
the protein expression of those targeted genes using IHC and found that there 
was a significant reduction of AMD1 expression among groups with chromosome 




Furthermore, in chapter 5, the AMD1 gene was knocked out in UM cell lines using 
CRISPR/Cas9 technology, for the first time, in order to evaluate the efficiency 
and determine its effect on UM cell lines. In addition, the findings from the specific 
targeting of AMD1 raised a number of questions specifically a depletion beta-
tubulin (Figure 5.8). It was also found that specific targeting of AMD1 raised a 
number of questions, specifically a depletion of beta-tubulin, as seen in Figure 
5.8. 
6.1.1 Can the importance of AMD1 to UM be 
independently validated? 
The Cancer Genome Atlas (TCGA), which is a project supported by the National 
Institute of Health (NIH), aims to provide an extensive genetic analysis for 
different types of cancers, correlated with their clinical outcomes. Robertson and 
colleagues analysed 80 primary UM samples together with their clinico-
pathological profiles, genomic alterations and mutational status and NGS, and  
published their data on TCGA (Robertson et al., 2017). They classified the 
genetic mutations of EIF1AX and SF3B1 similarly to the classification used in 
Chapter 3 of this thesis. In addition, the SCNA of UM were categorised into four 
categories based on monosomy 3, gain of chromosome 8q and gain of 
chromosome 6p. Therefore, TCGA is a good approach to correlate our outcome 
on AMD1 and confirm this gene in a published database.  
The University of California Santa Cruz (UCSC) developed an online analysis 
tool called Xena to explore the TCGA data and analyse them directly from their 
website (www.xenabrowser.net). This online tool allows the users to explore 
genomic data and correlate them with genomic or phenotypic data. This study 
used Xena to explore AMD1 with the outcome of UM TCGA of 80 UM samples 
and generate a correlation between the gene and the published data on UM. It 
was found that AMD1 is lost in 22 out of 80 samples (27.5%) and gained in 6 
samples only (7.5%). Loss of AMD1 was correlated with the isochromosome 6p 
while the gain of AMD1 appeared to be correlated with a gain of whole 
chromosome 6, as appears in Figure 6.2 column C and D. Similarly, loss of AMD1 




different high and low gene expressions for the gain of chromosome 6, as shown 
in Figure 6.2 column E.  
 
 
Figure 6.2: Analysis using UCSC Xena for AMD1. 
The figure shows that in column (A) the sample ID and (B) the copy number of gene 
level of AMD1; (C) similar to column B but without the germline mutations. (D) The copy 
number segregation of chromosome 6; (E) showed the gene expression profile of AMD1.   
 
 
The Kaplan-Meier analysis for chromosome 6 alterations with AMD1 showed that 
patients have a poor overall survival with loss of AMD1 than with its gain (Figure 
6.3). Indeed, the loss of AMD1 in UM patients have a lower overall survival, 




overall survival. This is because the overall survival for both AMD1 gain and loss 
have decreased at about three and half years. This suggests that the loss of 
AMD1 has particularly striking early effect on overall survival in comparison with 
the AMD1 gain. Therefore, the outcome from TCGA is interesting and indicates 
that AMD1 may have a role in the development of UM and subsequent prognosis, 
which is supporting the findings of this study. 
 
 
Figure 6.3: The Kaplan-Meier analysis of AMD1 gain and loss.  
The analysis of AMD1 in TCGA using Xena showed that the loss of AMD1 in UM cells 





6.2 Study limitations  
Although this study found an interesting gene (AMD1) that may have a 
relationship to the development and metastasis of UM that has not been reported, 
there were limitations. Technical challenges towards the end of the project did 
not allow in-depth analysis of the functional impact of AMD1 on UM development 
and were limited by the remaining time of the study. In addition, another important 
constrain is that Nexus software licence was not available for analysis in chapter 
4 and some of the clinical follow-up information was limited. In chapter 5, the 
transfection of AMD1 using CRISPR/Cas9 needs to be repeated to confirm the 
findings in UM cell lines and the protein expression of UM among those cell lines. 
Moreover, the gene expression should be measured after the transfection to 
determine any differences in the expression of AMD1 when it was knocked out 
in comparison with its normal status.  
6.3 Future direction 
This thesis used a novel approached to identify AMD1 as a plausible target for 
the future research. Based on this finding, CRISPR/Cas9 knockout for AMD1 
should be done again and including a control cell line such as human embryonic 
kidney (HEK293) to compare the efficiency between the UM cell line and the 
control cell line. It would be advisable to increase the number of UM cell lines in 
order to compare the effect of transfection and thus potentially of generate a 
higher knockout efficiency. Furthermore, although the relationship between 
AMD1 and beta-tubulin showed that there may be an off-target effect resulted 
from CRISPR, it is still an acceptable approach for further exploration which 
needs to be considered for future research.  
In addition, a single cell colony should be achieved after the transfection using 
fluorescence activated cell sorting (FACS) because the cells were in mixed cell 
pools post CRISPR transfection, i.e. some of them were transfected and others 
not, and the single cell colony technique will generate a unified knockout AMD1 




approaches to validate the AMD1 gene expression in vitro such as gene 
expression, genetic analysis and protein expression. In addition, the use of NGS 
for the UM knockout cells may give a detailed information about other genes that 
may be mutated. After validating the knockout cell line, it would be interesting to 
check the effect of knockout AMD1 on an UM cell line in vivo by transfecting 
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Appendix 1: Mapping for genes used in this study and 
mutations hotspots 
GNAQ exon 4 codon R183 
Forward primer: TCTTTTTCTCCCACCCCTTGC 
Reverse primer: TTGTTTTGAAGCCTACACATGATTCC 











Mutation hotspot, primers and sequencing area  
GNAQ exon 5 codon Q209 
Forward primer: AGAAGTAAGTTCACTCCATTCCC 
Reverse primer: TTCCCTAAGTTTGTAAGTAGTGC 













GNA11 exon 4 codon R183 
Forward primer: GTGCTGTGTCCCTGTCCTG 
Reverse primer: GGCAAATGAGCCTCTCAGTG 







Mutation hotspot, primers and sequencing area  
 
GNA11 exon 5 codon Q209  
Forward primer: CGCTGTGTCCTTTCAGGATG 
Reverse primer: CCTCGTTGTCCGACT 















EIF1AX exon 1   
Forward primer: GAAAAGCGACGCAAAGAGTC 
Reverse primer: CTGGGTGACCTGCAATCTAC 








Mutation hotspot, primers and sequencing area  
 
EIF1AX exon 2 codon K3 
Forward primer: GGGTAGGGAGGTGATAATGTG 
Reverse primer: CTGTAATCGTGCCACCACAC 
















SF3B1 exon 14  
Forward primer: TGATTATGGAAAGAAATGGTTGAAG 
Reverse primer: CATGTTCAATGATTTCAACTAAACTTC 







Mutation hotspot, primers and sequencing area  
 
TERT promoter  
Forward primer: GTCCTGCCCCTTCACCTT 
Reverse primer: GCTTCCCACGTGCGCA 










Appendix 2: Samples clinical data  
Sample No. Sex Age Location* Cell Type Mean Diameter (mm) Survival 
157 Male 71 C Epithelioid 22.15 Died from liver metastasis 14 months 
158 Male 54 C Spindle 17 Alive 187 months 
161 Female 68 CB/C Mixed 14 Died 81 months from unrelated death 
166 Female 74 C Spindle 15 Died from liver metastasis 17 months 
167 Female 88 CB Mixed 15 Died from liver metastasis 16 months 
169 Female 76 C Spindle 12 Died from unrelated 142 months 
170 Male 56 CB Mixed 17 Died from liver metastasis 30 months 
171 Female 75 CB Spindle NA Died from liver metastasis 23 months 
209 Female 64 C Mixed 14.5 Died from liver metastasis 12 months 
218 Male 42 C Mixed 12 Died from liver metastasis 38 months 
235 Female 71 CB/C Mixed 14 Died from metastasis 32 months 
244 Female 54 CB Spindle 7.58 Alive 102 months 
255 Female 63 C/CB Spindle 16 Died from liver metastasis 35 months 
284 Male 61 C Spindle 13.5 Died from liver metastasis 30 months 
300 Male 52 C Spindle 14 Alive 154 months 
301 Male 27 C Mixed NA Alive 49 months but lost follow up 
304 Female 45 C Spindle 16.72 Died from metastasis 65 months 
305 Male 67 CB Spindle 15.01 Died from liver metastasis 32 months 
306 Male 78 C Mixed 11.55 Died from unrelated 27 months 
308 Male 71 C Spindle NA Alive 64 months but lost follow up 
316 Male 75 C NA NA Died from liver metastasis 36 months 




Sample No. Sex Age Location* Cell Type Mean Diameter (mm) Survival 
312 NA NA NA NA NA Died from metastasis 15 months 
323 Female 56 C Spindle 12.1 Alive 169 months 
324 Female 41 CB Spindle 9.6 Alive 18 months but follow up 
325 Male 71 C Spindle 11.05 Alive 118 months 
327 Male 68 C Epithelioid 20.2 Died from liver metastasis 24 months 
328 Male 81 C Spindle 15.2 Died from unrelated 54 months 
330 Male 27 C Spindle 14.4 Died from metastasis 118 months 
335 Female 60 C NA 12.6 Died from metastasis 11 months 
341 Female 63 C Mixed 15 Died from liver metastasis 7 months 
342 Male 53 C Spindle 13.15 Alive 110 months 
343 Female 77 C Spindle 9.7 Alive 111 months 
344 Female 54 C Spindle 12.5 Died 111 months cause not confirmed 
345 Female 55 C NA 21.2 Alive 108 months 
346 Male 62 C Mixed 13.45 Alive 110 months 
352 NA NA NA NA NA Died from metastasis 18 months 
353 Female 65 CB/C Epithelioid 16.7 Died 92 months cause unknown 
355 Male 59 C Spindle 14.05 Alive 104 months 
375 Female 30 CB/C NA 13.7 Alive 84 months 
392 Male 58 CB Spindle 20 Died from liver metastasis 131 months 
401 Male 52 CB Mixed 12.59 Died from liver metastasis 32 months 
408 Male 57 C Spindle 12.5 Died from liver metastasis 18 months 
409 Male 50 C Epithelioid 14.7 Died from liver metastasis 32 months 
410 Female 57 CB Spindle 19.55 Died 73 months cause not confirmed 




Sample No. Sex Age Location* Cell Type Mean Diameter (mm) Survival 
412 Female 13 C Spindle 14.65 Died from liver metastasis 103 months 
429 Male 46 CB Epithelioid 10.1 Died from liver metastasis 12 months 
432 Female 77 C Spindle 11.74 Alive 81 months 
442 Female 47 C Spindle NA Died from metastases 123 months 
450 Male 73 CB Mixed 19.75 Died from metastases 15 months 
454 Male 60 C Spindle 12.7 Alive 100 months 
456 Male 69 C Spindle 13.6 Alive 134 months 
457 Female 79 C Mixed 14.95 Died from metastasis 18 months 
463 Male 76 C Mixed NA Died from liver metastasis 14 months 
467 Female 56 C Spindle 9.8 Died 128 months cause unknown 
472 Male 54 C Mixed 20.75 Died from metastasis 11 months 
485 NA NA NA NA NA Alive 55 months 
486 NA NA NA NA NA Alive 61 months 
489 NA NA NA NA NA Alive 63 months 
491 NA NA NA NA NA Alive 50 months 
492 NA NA NA NA NA Alive 50 months 
497 Male 63 C Mixed 15.3 Died 31 months cause unknown 
498 Male 80 CB Spindle 13.2 Died from liver metastasis 28 months 
520 Female 21 CB Spindle 10.16 Alive 120 months 
521 NA NA NA NA NA Died from metastasis 10 months 
522 NA NA NA NA NA Died from metastasis 2 months 
523 NA NA NA NA NA Died from metastasis 38 months 
524 NA NA NA NA NA Died from metastasis 11 months 




Sample No. Sex Age Location* Cell Type Mean Diameter (mm) Survival 
529 NA NA NA NA NA Alive 36 months 
530 NA NA NA NA NA Alive 38 months 
532 Male 45 C Mixed 13 Alive 70 months 
547 Male 48 C Mixed 15.3 Died from liver metastasis 80 months 
551 Female 31 C Spindle NA Alive 6 months 
578 Male 83 CB/C Mixed 16.35 Died 17 months cause unknown 
579 Male 72 CB Mixed 11.6 Died from liver metastasis 43 months 
580 Male 23 CB Mixed NA Alive 55 months 
581 Female 40 C Spindle 13.4 Alive 13 months 
582 Male 58 CB/C  Mixed NA Alive 12 months 
583 Female 87 CB/C Mixed 12 Died 14 months cause unknown 
584 Male 76 I/CB/C Mixed 9.26 Alive 34 months 
585 Male 59 C Mixed 16.36 Alive 26 months 
586 Female 89 CB/C Epithelioid 11.1 Died from liver metastasis 16 months 
587 Female 64 CB/C Mixed NA Alive 30 months 
588 Male 54 C Mixed 13.53 Alive 18 months 
589 NA 62 CB/C Mixed NA Alive 20 months 
590 Male 74 C Spindle 13.66 Alive 7 months 
591 Female 69 C NA NA Died 52 months cause not confirmed 
592 Male 70 C Spindle 12.605 Alive 51 months 
593 Female 61 C Spindle 13.37 Alive 6 months 
594 Male 54 C Mixed 13.835 Died from liver metastasis 29 months 
595 Female 84 C NA 15.44 Died 47 months cause unknown 




Sample No. Sex Age Location* Cell Type Mean Diameter (mm) Survival 
598 Female 61 CB/C Mixed 15.785 Died from liver metastasis 24 months 
599 Female 69 CB/C Epithelioid 13.54 Alive 48 months 
601 Female 54 CB/C NA 14.125 Alive 46 months 
604 Male 50 C Mixed 16.17 Alive 42 months 
605 Male 81 C Mixed 15.48 Alive 23 months 
611 Male 68 C Epithelioid 14.655 Alive 37 months 
652 NA NA NA NA NA NA 
654 NA NA NA NA NA NA 
655 NA NA NA NA NA NA 
656 NA NA NA NA NA NA 
657 NA NA NA NA NA NA 
658 NA NA NA NA NA NA 
659 NA NA NA NA NA NA 
660 NA NA NA NA NA NA 
661 NA NA NA NA NA NA 
663 NA NA NA NA NA NA 
664 NA NA NA NA NA NA 
665 NA NA NA NA NA NA 
667 NA NA NA NA NA NA 
670 NA NA NA NA NA NA 
671 NA NA NA NA NA NA 
672 NA NA NA NA NA NA 




Appendix 3: Western blot images 
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